description,drugbank-id,name,reagent-id
The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.,BIOD00024,Azficel-T,DB11051
Cyclophosphamide may increase the cardiotoxic activities of Cetuximab.,BIOD00071,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Denileukin diftitox.,BIOD00084,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Etanercept is combined with Pitolisant.,BIOD00052,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Bivalirudin is combined with Azficel-T.,DB02351,Azficel-T,DB11051
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Leuprolide.",BIOD00009,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine.,BIOD00043,Zidovudine,DB00495
The risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.,BIOD00050,Treprostinil,DB00374
The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.,DB00084,Zidovudine,DB00495
Darbepoetin alfa may increase the thrombogenic activities of Thalidomide.,BIOD00032,Thalidomide,DB01041
The risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.,BIOD00030,Treprostinil,DB00374
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Goserelin.",BIOD00113,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.,BIOD00013,Treprostinil,DB00374
Erythropoietin may increase the thrombogenic activities of Thalidomide.,DB08923,Thalidomide,DB01041
The serum concentration of Lithium can be decreased when it is combined with Salmon Calcitonin.,BIOD00025,Lithium,DB01356
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Zidovudine.,BIOD00023,Zidovudine,DB00495
The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Pegloticase.,BIOD00094,Pegloticase,DB09208
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.,BIOD00035,Cyclophosphamide,DB00531
The therapeutic efficacy of Secretin can be decreased when used in combination with Methscopolamine.,BIOD00039,Methscopolamine,DB11315
The serum concentration of Zotepine can be increased when it is combined with Peginterferon alfa-2b.,BIOD00048,Zotepine,DB09225
The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Escherichia coli.,BIOD00011,Dexamethasone,DB01234
"The risk or severity of hypercoagulability can be increased when Emicizumab is combined with Antihemophilic factor, human recombinant.",DBSALT002413,Emicizumab,DB13923
Trastuzumab may increase the neutropenic activities of Anakinra.,BIOD00060,Trastuzumab,DB00072
The serum concentration of Brentuximab vedotin can be increased when it is combined with Gramicidin D.,BIOD00036,Brentuximab vedotin,DB08870
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Immune Globulin Human.,BIOD00091,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.,BIOD00102,Treprostinil,DB00374
Trolamine salicylate may increase the hypoglycemic activities of Insulin Human.,DB08914,Trolamine salicylate,DB11079
The risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.,BIOD00019,Treprostinil,DB00374
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Zidovudine.,BIOD00017,Zidovudine,DB00495
"The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Zidovudine.",DB00037,Zidovudine,DB00495
The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.,BIOD00061,Lithium,DB01356
Cyclophosphamide may increase the cardiotoxic activities of Oprelvekin.,BIOD00021,Cyclophosphamide,DB00531
The serum concentration of Palifermin can be increased when it is combined with Heparin.,BIOD00042,Heparin,DB01109
Glucagon recombinant may increase the anticoagulant activities of Tioclomarol.,BIOD00057,Tioclomarol,DB13451
Aldesleukin may increase the hypotensive activities of Risperidone.,BIOD00082,Risperidone,DB00734
Bekanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.,BIOD00070,Bekanamycin,DB13673
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Omalizumab.,BIOD00081,Hepatitis B Vaccine (Recombinant),DB11627
Trolamine salicylate may increase the hypoglycemic activities of Insulin Lispro.,DB01310,Trolamine salicylate,DB11079
Trolamine salicylate may increase the hypoglycemic activities of Insulin Glargine.,DB01308,Trolamine salicylate,DB11079
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Collagenase clostridium histolyticum.,DB11249,Ticagrelor,DB08816
Sarilumab may increase the immunosuppressive activities of Rasburicase.,BIOD00090,Sarilumab,DB11767
The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.,BIOD00049,Cyclosporine,DB00091
The therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Somatotropin.,DB06417,Cortisone acetate,DB01380
The risk or severity of adverse effects can be increased when Abciximab is combined with Azficel-T.,BIOD00041,Azficel-T,DB11051
The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.,BIOD00068,Treprostinil,DB00374
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.,BIOD00077,Sipuleucel-T,DB06688
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Indium In-111 satumomab pendetide.,BIOD00108,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Zidovudine can be decreased when it is combined with Alpha-1-proteinase inhibitor.,BIOD00002,Zidovudine,DB00495
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.,BIOD00079,Sipuleucel-T,DB06688
The risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Zidovudine.,BIOD00093,Zidovudine,DB00495
The therapeutic efficacy of Pegademase bovine can be decreased when used in combination with Pegloticase.,BIOD00100,Pegloticase,DB09208
Vitamin E may increase the antiplatelet activities of Eptifibatide.,BIOD00063,Vitamin E,DB00163
Trastuzumab may increase the neutropenic activities of Infliximab.,BIOD00004,Trastuzumab,DB00072
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Patent Blue.,DB09392,Patent Blue,DB13967
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.,BIOD00078,Zidovudine,DB00495
The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine.,BIOD00062,Zidovudine,DB00495
The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Metabutethamine.,BIOD00022,Metabutethamine,DB13578
Insulin Pork may increase the hypoglycemic activities of Insulin Glulisine.,BIOD00031,Insulin Glulisine,DB01309
Trastuzumab may increase the neutropenic activities of Wortmannin.,BIOD00098,Wortmannin,DB08059
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.,BIOD00014,Sipuleucel-T,DB06688
Trastuzumab may increase the neutropenic activities of Basiliximab.,BIOD00073,Trastuzumab,DB00072
Trastuzumab may increase the neutropenic activities of Muromonab.,BIOD00005,Trastuzumab,DB00072
The risk or severity of adverse effects can be increased when Licorice is combined with Digoxin Immune Fab (Ovine).,BIOD00027,Licorice,DB10675
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan.,BIOD00069,Ticagrelor,DB08816
The risk or severity of adverse effects can be increased when Mevastatin is combined with Daptomycin.,BIOD00111,Mevastatin,DB06693
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab.,DB09557,Ticagrelor,DB08816
Pegvisomant may increase the hypoglycemic activities of Sulfisoxazole.,BIOD00044,Sulfisoxazole,DB00263
Bekanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.,BIOD00092,Bekanamycin,DB13673
Pancrelipase can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB05356,Ferric pyrophosphate,DB09147
The risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.,BIOD00028,Treprostinil,DB00374
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.,BIOD00109,Sipuleucel-T,DB06688
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Capromab pendetide.,BIOD00080,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.,BIOD00003,Dasatinib,DB01254
Trastuzumab may increase the neutropenic activities of Alefacept.,BIOD00055,Trastuzumab,DB00072
The therapeutic efficacy of Felypressin can be decreased when used in combination with Patent Blue.,BIOD00114,Patent Blue,DB13967
Trastuzumab may increase the neutropenic activities of Efalizumab.,BIOD00074,Trastuzumab,DB00072
Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).,BIOD00040,Trastuzumab,DB00072
The risk or severity of adverse effects can be increased when Filgrastim is combined with Cyclophosphamide.,DB09560,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Coagulation Factor IX (Recombinant).,BIOD00038,Aminocaproic Acid,DB00513
The risk or severity of adverse effects can be increased when Becaplermin is combined with Azficel-T.,BIOD00053,Azficel-T,DB11051
The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.,BIOD00075,Amiodarone,DB01118
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Octreotide.",BIOD00088,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
"The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Zidovudine.",DB05600,Zidovudine,DB00495
Oxytocin may increase the QTc-prolonging activities of Lenvatinib.,BIOD00016,Lenvatinib,DB09078
Trastuzumab may increase the neutropenic activities of Natalizumab.,BIOD00083,Trastuzumab,DB00072
The metabolism of Enfuvirtide can be decreased when combined with Nicotine.,BIOD00106,Nicotine,DB00184
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Palivizumab.,BIOD00097,Hepatitis B Vaccine (Recombinant),DB11627
Trastuzumab may increase the neutropenic activities of Daclizumab.,BIOD00007,Trastuzumab,DB00072
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.,BIOD00087,Sorafenib,DB00398
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Technetium Tc-99m arcitumomab.,BIOD00107,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Cyanocobalamin can be decreased when it is combined with Colchicine.,EXPT00965,Colchicine,DB01394
Trastuzumab may increase the neutropenic activities of L-Phenylalanine.,NUTR00044,Trastuzumab,DB00072
The serum concentration of Choline can be increased when it is combined with Bupropion.,NUTR00020,Bupropion,DB01156
The serum concentration of Bazedoxifene can be increased when it is combined with Vitamin C.,DB11317,Bazedoxifene,DB06401
The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine.,NUTR00026,Lactulose,DB00581
The therapeutic efficacy of Levodopa can be decreased when used in combination with Methionine.,NUTR00038,Levodopa,DB01235
The serum concentration of Calcitriol can be increased when it is combined with Dasatinib.,DB05314,Dasatinib,DB01254
Riboflavin may increase the photosensitizing activities of Verteporfin.,DB09358,Verteporfin,DB00460
"The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Glutamic Acid.",NUTR00027,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The risk or severity of adverse effects can be increased when Glycine is combined with Memantine.,NUTR00028,Memantine,DB01043
Calcidiol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).,APRD00428,Digoxin Immune Fab (Ovine),DB00076
L-Tryptophan may increase the serotonergic activities of Vilazodone.,EXPT02064,Vilazodone,DB06684
The serum concentration of Ergocalciferol can be increased when it is combined with Dasatinib.,APRD00426,Dasatinib,DB01254
The serum concentration of Folic Acid can be increased when it is combined with Teriflunomide.,NUTR00025,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Fluticasone is combined with Icosapent.,NUTR00024,Fluticasone,DB13867
Cyclophosphamide may increase the cardiotoxic activities of Vitamin A.,APRD00486,Cyclophosphamide,DB00531
Vitamin E may increase the antiplatelet activities of Ramatroban.,EXPT03227,Ramatroban,DB13036
The metabolism of Phenytoin can be increased when combined with Pyridoxine.,APRD00204,Phenytoin,DB00252
The therapeutic efficacy of Cisplatin can be decreased when used in combination with Lipoic Acid.,NUTR00035,Cisplatin,DB00515
The serum concentration of Cholecalciferol can be increased when it is combined with Dasatinib.,APRD00506,Dasatinib,DB01254
The serum concentration of Menadione can be decreased when it is combined with Osimertinib.,NUTR00062,Osimertinib,DB09330
"The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Adenine.",EXPT00520,Irinotecan,DB00762
The serum concentration of Pravastatin can be increased when it is combined with Dasatinib.,APRD00328,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.,APRD00425,Doxylamine,DB00366
The serum concentration of Valsartan can be decreased when it is combined with Apalutamide.,APRD00133,Apalutamide,DB11901
Trimethoprim may increase the hyperkalemic activities of Ramipril.,APRD00009,Trimethoprim,DB00440
The risk or severity of adverse effects can be increased when Masoprocol is combined with Pitolisant.,DB05900,Pitolisant,DB11642
The serum concentration of Flunisolide can be increased when it is combined with Dasatinib.,APRD00976,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.,APRD00551,Doxylamine,DB00366
Amphetamine may increase the hypertensive activities of Norepinephrine.,APRD00480,Norepinephrine,DB00368
The serum concentration of Nicotine can be increased when it is combined with Dasatinib.,DB11303,Dasatinib,DB01254
The serum concentration of Cevimeline can be increased when it is combined with Dasatinib.,APRD00224,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.,APRD00116,Doxylamine,DB00366
Esmolol may increase the hypoglycemic activities of Metahexamide.,APRD00954,Metahexamide,DB13675
The serum concentration of Bortezomib can be increased when it is combined with Dasatinib.,DB07475,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.,APRD00958,Doxylamine,DB00366
The therapeutic efficacy of Droxidopa can be decreased when used in combination with Carbidopa.,APRD00160,Droxidopa,DB06262
The risk or severity of adverse effects can be increased when Ethanol is combined with Phentermine.,APRD00093,Ethanol,DB00898
Tramadol may increase the constipating activities of Ramosetron.,APRD00028,Ramosetron,DB09290
Vidarabine may increase the myelosuppressive activities of Lipegfilgrastim.,EXPT02753,Lipegfilgrastim,DB13200
The serum concentration of Brexpiprazole can be increased when it is combined with Betaxolol.,APRD00245,Brexpiprazole,DB09128
Fluconazole may increase the QTc-prolonging activities of Delamanid.,APRD00327,Delamanid,DB11637
The serum concentration of Troglitazone can be increased when it is combined with Dasatinib.,APRD00488,Dasatinib,DB01254
The serum concentration of the active metabolites of Oseltamivir can be increased when Oseltamivir is used in combination with Probenecid.,APRD01148,Probenecid,DB01032
The serum concentration of Erythromycin can be increased when it is combined with Dasatinib.,APRD00953,Dasatinib,DB01254
The serum concentration of Caffeine can be increased when it is combined with Dasatinib.,APRD00673,Dasatinib,DB01254
Vancomycin may increase the neuromuscular blocking activities of Succinylcholine.,APRD00159,Vancomycin,DB00512
The serum concentration of Sildenafil can be increased when it is combined with Dasatinib.,APRD00556,Dasatinib,DB01254
The serum concentration of Dofetilide can be increased when it is combined with Dasatinib.,APRD00367,Dasatinib,DB01254
The metabolism of Avatrombopag can be decreased when combined with Pyrimethamine.,APRD00599,Avatrombopag,DB11995
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.,APRD00472,Doxylamine,DB00366
The serum concentration of Azithromycin can be increased when it is combined with Dasatinib.,APRD00397,Dasatinib,DB01254
The serum concentration of Bupropion can be increased when it is combined with Ticlopidine.,APRD01257,Bupropion,DB01156
The risk or severity of adverse effects can be increased when Trospium is combined with Nicomorphine.,APRD00393,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Adapalene is combined with Pitolisant.,APRD00780,Pitolisant,DB11642
Nabilone may increase the tachycardic activities of Midodrine.,APRD01116,Nabilone,DB00486
The serum concentration of Zidovudine can be decreased when it is combined with Remikiren.,APRD00163,Zidovudine,DB00495
The serum concentration of Brentuximab vedotin can be increased when it is combined with Pantoprazole.,APRD00073,Brentuximab vedotin,DB08870
The serum concentration of Torasemide can be decreased when it is combined with Apalutamide.,APRD00217,Apalutamide,DB11901
The serum concentration of Citalopram can be increased when it is combined with Dasatinib.,APRD00147,Dasatinib,DB01254
The serum concentration of Eletriptan can be increased when it is combined with Dasatinib.,APRD00945,Dasatinib,DB01254
Iloprost may increase the hypotensive activities of Bethanidine.,APRD00825,Iloprost,DB01088
Moxifloxacin may increase the QTc-prolonging activities of Delamanid.,APRD00281,Delamanid,DB11637
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Nicomorphine.,APRD00189,Nicomorphine,DB13454
Nelfinavir may increase the QTc-prolonging activities of Delamanid.,APRD00003,Delamanid,DB11637
Racepinephrine may decrease the vasoconstricting activities of Isoetarine.,APRD00750,Racepinephrine,DB11124
The serum concentration of Glimepiride can be increased when it is combined with Voriconazole.,APRD00381,Voriconazole,DB00582
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Diflorasone.,APRD00921,Corticorelin ovine triflutate,DB09067
Indinavir may increase the QTc-prolonging activities of Delamanid.,APRD00069,Delamanid,DB11637
Iloprost may increase the hypotensive activities of Guanadrel.,APRD01006,Iloprost,DB01088
The serum concentration of Lovastatin can be increased when it is combined with Dasatinib.,APRD00370,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Enflurane.,APRD00234,Doxylamine,DB00366
The serum concentration of Cefotiam can be increased when it is combined with Probenecid.,APRD00855,Probenecid,DB01032
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.,APRD01198,Doxylamine,DB00366
The serum concentration of Temazepam can be increased when it is combined with Dasatinib.,APRD00676,Dasatinib,DB01254
Alaproclate may increase the hyponatremic activities of Methyclothiazide.,APRD01104,Alaproclate,DB13233
The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Deflazacort.,DB09367,Deflazacort,DB11921
The serum concentration of Reboxetine can be increased when it is combined with Dasatinib.,APRD00198,Dasatinib,DB01254
Milrinone may increase the antiplatelet activities of Relcovaptan.,APRD00010,Relcovaptan,DB13929
Cyclophosphamide may increase the cardiotoxic activities of Pipobroman.,APRD00693,Cyclophosphamide,DB00531
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.,APRD00752,Doxylamine,DB00366
The serum concentration of Agomelatine can be increased when it is combined with Nevirapine.,DB08311,Agomelatine,DB06594
The therapeutic efficacy of Oxiconazole can be increased when used in combination with Menthol.,APRD01154,Menthol,DB00825
The serum concentration of Alclometasone can be increased when it is combined with Dasatinib.,APRD00783,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.,APRD00266,Doxylamine,DB00366
The serum concentration of Cladribine can be increased when it is combined with Teriflunomide.,APRD00260,Teriflunomide,DB08880
The serum concentration of Vindesine can be increased when it is combined with Ranolazine.,APRD01300,Vindesine,DB00309
The risk or severity of adverse effects can be increased when Mesalazine is combined with Pitolisant.,DB06396,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Benzatropine is combined with Nicomorphine.,APRD00748,Nicomorphine,DB13454
The serum concentration of Ziprasidone can be increased when it is combined with Dasatinib.,APRD00540,Dasatinib,DB01254
The metabolism of Methysergide can be decreased when combined with Procarbazine.,APRD00463,Procarbazine,DB01168
The serum concentration of Cabergoline can be increased when it is combined with Dasatinib.,APRD00836,Dasatinib,DB01254
The serum concentration of Dapsone can be increased when it is combined with Dasatinib.,APRD00345,Dasatinib,DB01254
The therapeutic efficacy of Terconazole can be increased when used in combination with Menthol.,APRD00659,Menthol,DB00825
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.,APRD00241,Doxylamine,DB00366
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Medrysone.,APRD01091,Corticorelin ovine triflutate,DB09067
Doxycycline may increase the anticoagulant activities of Tioclomarol.,APRD00597,Tioclomarol,DB13451
The serum concentration of Diethylstilbestrol can be decreased when it is combined with Apalutamide.,EXPT01164,Apalutamide,DB11901
The serum concentration of Medrogestone can be decreased when it is combined with Lymecycline.,EXPT01049,Medrogestone,DB09124
The serum concentration of Bupropion can be increased when it is combined with Clotrimazole.,APRD00244,Bupropion,DB01156
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Acetate.,APRD00839,Menthol,DB00825
The serum concentration of Rilpivirine can be increased when it is combined with Sulfanilamide.,APRD00438,Rilpivirine,DB08864
The risk or severity of adverse effects can be increased when Isoniazid is combined with Cycloserine.,DB03123,Isoniazid,DB00951
Anagrelide may increase the QTc-prolonging activities of Delamanid.,APRD00798,Delamanid,DB11637
The serum concentration of Carmustine can be decreased when it is combined with Osimertinib.,APRD00006,Osimertinib,DB09330
The serum concentration of Sulfisoxazole can be decreased when it is combined with Apalutamide.,APRD00595,Apalutamide,DB11901
The serum concentration of Brexpiprazole can be increased when it is combined with Metoprolol.,APRD00208,Brexpiprazole,DB09128
The risk or severity of adverse effects can be increased when Dicoumarol is combined with Azficel-T.,APRD00761,Azficel-T,DB11051
The serum concentration of Cefmenoxime can be increased when it is combined with Probenecid.,APRD00851,Probenecid,DB01032
The serum concentration of Ropinirole can be increased when it is combined with Dasatinib.,APRD00302,Dasatinib,DB01254
Chlorotrianisene may increase the thrombogenic activities of Conestat alfa.,APRD00715,Conestat alfa,DB09228
The serum concentration of Isradipine can be increased when it is combined with Dasatinib.,APRD00298,Dasatinib,DB01254
The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.,APRD00913,Aldesleukin,DB00041
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.,APRD00237,Doxylamine,DB00366
The serum concentration of Cefmetazole can be increased when it is combined with Probenecid.,APRD00852,Probenecid,DB01032
The serum concentration of Olmesartan can be decreased when it is combined with Apalutamide.,APRD00223,Apalutamide,DB11901
The serum concentration of Brentuximab vedotin can be increased when it is combined with Amsacrine.,APRD00064,Brentuximab vedotin,DB08870
The serum concentration of Theophylline can be increased when it is combined with Dasatinib.,DB09359,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Argatroban is combined with Azficel-T.,APRD00105,Azficel-T,DB11051
The serum concentration of Liothyronine can be decreased when it is combined with Apalutamide.,APRD01074,Apalutamide,DB11901
The serum concentration of Disopyramide can be increased when it is combined with Dasatinib.,APRD00507,Dasatinib,DB01254
The serum concentration of Lidocaine can be increased when it is combined with Dasatinib.,DB05291,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Palmidrol is combined with Pamidronate.,APRD01161,Palmidrol,DB14043
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.,APRD00875,Doxylamine,DB00366
Trolamine salicylate may increase the hypoglycemic activities of Acarbose.,APRD00656,Trolamine salicylate,DB11079
The serum concentration of Bupropion can be increased when it is combined with Venlafaxine.,APRD00125,Bupropion,DB01156
The serum concentration of Conjugated estrogens can be increased when it is combined with Dasatinib.,APRD00396,Dasatinib,DB01254
Iloprost may increase the hypotensive activities of Travoprost.,APRD01271,Iloprost,DB01088
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Amcinonide.,APRD00788,Corticorelin ovine triflutate,DB09067
The serum concentration of Rilpivirine can be increased when it is combined with Atomoxetine.,APRD00614,Rilpivirine,DB08864
The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin.,EXPT00718,Sargramostim,DB00020
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Chlorambucil.,APRD00115,Sipuleucel-T,DB06688
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.,APRD00965,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Raltitrexed.,EXPT01092,Cyclophosphamide,DB00531
The serum concentration of Etonogestrel can be increased when it is combined with Dasatinib.,APRD00766,Dasatinib,DB01254
Morphine may increase the constipating activities of Ramosetron.,DB05354,Ramosetron,DB09290
The serum concentration of Ropivacaine can be increased when it is combined with Dasatinib.,APRD00492,Dasatinib,DB01254
The serum concentration of Bupivacaine can be increased when it is combined with Dasatinib.,APRD00247,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.,APRD00902,Doxylamine,DB00366
The serum concentration of Agomelatine can be increased when it is combined with Tenofovir disoproxil.,DB13426,Agomelatine,DB06594
The serum concentration of Methotrexate can be increased when it is combined with Flucloxacillin.,APRD00609,Methotrexate,DB00563
Tretinoin may increase the thrombogenic activities of Tranexamic Acid.,EXPT00508,Tretinoin,DB00755
The serum concentration of Ertapenem can be increased when it is combined with Probenecid.,APRD00952,Probenecid,DB01032
Desogestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,APRD00762,Lamotrigine,DB00555
The serum concentration of Brentuximab vedotin can be increased when it is combined with Mitomycin.,APRD00284,Brentuximab vedotin,DB08870
The risk or severity of sedation and somnolence can be increased when Talbutal is combined with Deutetrabenazine.,APRD01333,Deutetrabenazine,DB12161
The serum concentration of Bexarotene can be increased when it is combined with Dasatinib.,APRD00114,Dasatinib,DB01254
Ibutilide may increase the QTc-prolonging activities of Delamanid.,APRD01025,Delamanid,DB11637
The serum concentration of Vindesine can be increased when it is combined with Dasatinib.,APRD00392,Dasatinib,DB01254
Yohimbine may decrease the antihypertensive activities of Chlorthalidone.,APRD00127,Yohimbine,DB01392
The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Phenytoin.,DB07727,Phenytoin,DB00252
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.,APRD01174,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.,APRD00066,Doxylamine,DB00366
Capreomycin may increase the neuromuscular blocking activities of Colistimethate.,APRD00844,Colistimethate,DB01111
The serum concentration of Zolmitriptan can be increased when it is combined with Propranolol.,APRD00376,Propranolol,DB00571
Acetaminophen may increase the hepatotoxic activities of Mipomersen.,APRD00252,Mipomersen,DB05528
The serum concentration of Gefitinib can be increased when it is combined with Dasatinib.,DB07998,Dasatinib,DB01254
Codeine may increase the constipating activities of Ramosetron.,DB09471,Ramosetron,DB09290
The serum concentration of Methotrexate can be increased when it is combined with Piperacillin.,APRD00325,Methotrexate,DB00563
The serum concentration of Dihydroergotamine can be increased when it is combined with Dasatinib.,DB05743,Dasatinib,DB01254
The serum concentration of Amitriptyline can be increased when it is combined with Dasatinib.,APRD00227,Dasatinib,DB01254
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Floxuridine.,APRD00692,Sipuleucel-T,DB06688
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.,APRD00445,Doxylamine,DB00366
The serum concentration of Fluorometholone can be increased when it is combined with Dasatinib.,APRD00980,Dasatinib,DB01254
Yohimbine may decrease the antihypertensive activities of Nitroprusside.,APRD01143,Yohimbine,DB01392
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Gluceptate.,APRD00841,Menthol,DB00825
Hydromorphone may increase the constipating activities of Ramosetron.,APRD01021,Ramosetron,DB09290
The risk or severity of adverse effects can be increased when Indomethacin is combined with Dibotermin alfa.,APRD00109,Dibotermin alfa,DB11639
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ethambutol.,APRD00957,Picosulfuric acid,DB09268
The serum concentration of Dofetilide can be increased when it is combined with Metformin.,APRD01099,Dofetilide,DB00204
The serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.,APRD00537,Dasatinib,DB01254
Methadone may increase the constipating activities of Ramosetron.,APRD00485,Ramosetron,DB09290
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.,APRD00138,Doxylamine,DB00366
Atenolol may increase the hypoglycemic activities of Metahexamide.,APRD00172,Metahexamide,DB13675
The serum concentration of Nitrofural can be decreased when it is combined with Peginterferon alfa-2b.,APRD00050,Peginterferon alfa-2b,DB00022
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dibotermin alfa.,APRD01182,Dibotermin alfa,DB11639
The serum concentration of Brentuximab vedotin can be increased when it is combined with Omeprazole.,APRD00446,Brentuximab vedotin,DB08870
The serum concentration of Pyrazinamide can be increased when it is combined with Dasatinib.,APRD01206,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Metixene is combined with Nicomorphine.,APRD01101,Nicomorphine,DB13454
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.,APRD00630,Doxylamine,DB00366
The serum concentration of Terfenadine can be increased when it is combined with Dasatinib.,APRD00606,Dasatinib,DB01254
The serum concentration of Diltiazem can be increased when it is combined with Dasatinib.,APRD00473,Dasatinib,DB01254
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Protriptyline.,APRD00441,Pitolisant,DB11642
The serum concentration of Brentuximab vedotin can be increased when it is combined with Aminohippuric acid.,APRD00792,Brentuximab vedotin,DB08870
The serum concentration of Alfuzosin can be increased when it is combined with Dasatinib.,APRD00490,Dasatinib,DB01254
The serum concentration of Trimethadione can be increased when it is combined with Dasatinib.,APRD00315,Dasatinib,DB01254
The serum concentration of Clobazam can be increased when it is combined with Dasatinib.,APRD00307,Dasatinib,DB01254
Yohimbine may decrease the antihypertensive activities of Minoxidil.,DB08225,Yohimbine,DB01392
The serum concentration of Brentuximab vedotin can be increased when it is combined with Megestrol acetate.,APRD01092,Brentuximab vedotin,DB08870
The metabolism of Tioguanine can be decreased when combined with Sulfasalazine.,APRD00290,Sulfasalazine,DB00795
The serum concentration of Rilpivirine can be increased when it is combined with Methylergometrine.,APRD00739,Rilpivirine,DB08864
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Buclizine.",APRD00723,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aztreonam.,EXPT00605,Picosulfuric acid,DB09268
The serum concentration of Chlorzoxazone can be increased when it is combined with Dasatinib.,APRD00308,Dasatinib,DB01254
The serum concentration of Saxagliptin can be decreased when it is combined with Aminoglutethimide.,APRD00592,Saxagliptin,DB06335
The serum concentration of Mefloquine can be increased when it is combined with Dasatinib.,APRD00300,Dasatinib,DB01254
The serum concentration of Sulfadiazine can be increased when it is combined with Dasatinib.,APRD00190,Dasatinib,DB01254
The serum concentration of Sapropterin can be decreased when it is combined with Pralatrexate.,DB02692,Pralatrexate,DB06813
The serum concentration of Vinorelbine can be increased when it is combined with Dasatinib.,APRD00101,Dasatinib,DB01254
The therapeutic efficacy of Anidulafungin can be increased when used in combination with Menthol.,APRD01301,Menthol,DB00825
The serum concentration of Brexpiprazole can be increased when it is combined with Clozapine.,APRD00470,Brexpiprazole,DB09128
The serum concentration of Levothyroxine can be decreased when it is combined with Sucralfate.,APRD01238,Levothyroxine,DB00451
The serum concentration of Grepafloxacin can be increased when it is combined with Dasatinib.,APRD01003,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nordazepam.,APRD00937,Nordazepam,DB14028
The serum concentration of Levonorgestrel can be increased when it is combined with Dasatinib.,APRD00106,Dasatinib,DB01254
Procarbazine may increase the hypertensive activities of Norepinephrine.,APRD01299,Procarbazine,DB01168
Cidofovir may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.,APRD00148,Tenofovir disoproxil,DB00300
The serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.,APRD00685,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.,APRD01095,Doxylamine,DB00366
Thiethylperazine may increase the hypotensive activities of Nicomorphine.,APRD00323,Nicomorphine,DB13454
Timolol may increase the hypoglycemic activities of Metahexamide.,DB08625,Metahexamide,DB13675
The serum concentration of Treprostinil can be decreased when it is combined with Apalutamide.,APRD01272,Apalutamide,DB11901
Colestipol can cause a decrease in the absorption of Fluticasone resulting in a reduced serum concentration and potentially a decrease in efficacy.,APRD00884,Fluticasone,DB13867
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Nicomorphine.,APRD00070,Nicomorphine,DB13454
The serum concentration of Palonosetron can be increased when it is combined with Dasatinib.,APRD00351,Dasatinib,DB01254
Dydrogesterone may increase the thrombogenic activities of Conestat alfa.,APRD00941,Conestat alfa,DB09228
The serum concentration of Mexiletine can be increased when it is combined with Dasatinib.,APRD00242,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Dexrazoxane.,DB02444,Cyclophosphamide,DB00531
The serum concentration of Amlodipine can be increased when it is combined with Dasatinib.,APRD00520,Dasatinib,DB01254
The serum concentration of Brentuximab vedotin can be increased when it is combined with Tacrine.,APRD00690,Brentuximab vedotin,DB08870
Palmidrol may decrease the antihypertensive activities of Triamterene.,APRD00079,Palmidrol,DB14043
Cyclophosphamide may increase the cardiotoxic activities of Valrubicin.,APRD00662,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Procyclidine is combined with Nicomorphine.,APRD00383,Nicomorphine,DB13454
The serum concentration of Phenylephrine can be increased when it is combined with Propacetamol.,APRD00365,Propacetamol,DB09288
The serum concentration of Aminophylline can be increased when it is combined with Carbimazole.,APRD00503,Aminophylline,DB01223
The serum concentration of Digoxin can be decreased when it is combined with St. John's Wort.,APRD00098,St. John's Wort,DB01323
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.,APRD00032,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Nicomorphine.,APRD00729,Nicomorphine,DB13454
The serum concentration of Nimodipine can be increased when it is combined with Dasatinib.,APRD00612,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Beclomethasone dipropionate.,DB11897,Corticorelin ovine triflutate,DB09067
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.,APRD00417,Doxylamine,DB00366
The serum concentration of Progesterone can be increased when it is combined with Dasatinib.,APRD00700,Dasatinib,DB01254
Nabilone may increase the tachycardic activities of Phenylpropanolamine.,DB09441,Nabilone,DB00486
The serum concentration of Bupropion can be increased when it is combined with Sorafenib.,DB07438,Bupropion,DB01156
The risk or severity of adverse effects can be increased when Palmidrol is combined with Zoledronic acid.,DB06286,Palmidrol,DB14043
The therapeutic efficacy of Griseofulvin can be increased when used in combination with Menthol.,APRD01004,Menthol,DB00825
The serum concentration of Nisoldipine can be increased when it is combined with Dasatinib.,APRD00635,Dasatinib,DB01254
The serum concentration of Eszopiclone can be increased when it is combined with Dasatinib.,APRD00431,Dasatinib,DB01254
The serum concentration of Alprazolam can be increased when it is combined with Dasatinib.,DB05925,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.,APRD00770,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Ardeparin is combined with Azficel-T.,APRD00803,Azficel-T,DB11051
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.,APRD00574,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.,APRD00316,Doxylamine,DB00366
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin.,APRD00162,Picosulfuric acid,DB09268
Carbachol may decrease the anticholinergic activities of Cimetropium.,DB02487,Cimetropium,DB09271
The risk or severity of adverse effects can be increased when Trolnitrate is combined with Rosiglitazone.,APRD00403,Trolnitrate,DB13719
Pramipexole may increase the orthostatic hypotensive activities of Levodopa.,APRD00156,Levodopa,DB01235
The serum concentration of Acetohexamide can be increased when it is combined with Voriconazole.,APRD00773,Voriconazole,DB00582
The serum concentration of Methotrexate can be increased when it is combined with Ampicillin.,APRD00320,Methotrexate,DB00563
Vancomycin may increase the neuromuscular blocking activities of Metocurine Iodide.,APRD01318,Vancomycin,DB00512
The serum concentration of Methotrexate can be increased when it is combined with Phenoxymethylpenicillin.,DB08415,Methotrexate,DB00563
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.,APRD00497,Doxylamine,DB00366
Miglustat may increase the hypoglycemic activities of Insulin Glulisine.,APRD01118,Insulin Glulisine,DB01309
The serum concentration of Promazine can be increased when it is combined with Dasatinib.,APRD00358,Dasatinib,DB01254
Palmidrol may decrease the antihypertensive activities of Spironolactone.,APRD01234,Palmidrol,DB14043
Methylphenidate may decrease the antihypertensive activities of Guanoclor.,APRD00657,Guanoclor,DB13779
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.,APRD01102,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Nicomorphine.,APRD00607,Nicomorphine,DB13454
The serum concentration of Zolpidem can be increased when it is combined with Dasatinib.,APRD00095,Dasatinib,DB01254
The serum concentration of Famciclovir can be increased when it is combined with Dasatinib.,APRD00600,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.,APRD00306,Doxylamine,DB00366
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Streptozocin.,APRD00209,Sipuleucel-T,DB06688
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Palmidrol.,APRD00847,Palmidrol,DB14043
Cefpiramide may increase the nephrotoxic activities of Bekanamycin.,APRD00856,Bekanamycin,DB13673
Cyclophosphamide may increase the cardiotoxic activities of Trifluridine.,APRD01275,Cyclophosphamide,DB00531
The serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.,APRD00624,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.,APRD00033,Doxylamine,DB00366
The serum concentration of Nitric Oxide can be decreased when it is combined with Osimertinib.,APRD01142,Osimertinib,DB09330
Yohimbine may decrease the antihypertensive activities of Bendroflumethiazide.,APRD00666,Yohimbine,DB01392
The serum concentration of Aminophylline can be increased when it is combined with Allopurinol.,DB03027,Aminophylline,DB01223
The serum concentration of Ceftazidime can be increased when it is combined with Probenecid.,APRD00857,Probenecid,DB01032
The serum concentration of Cerivastatin can be increased when it is combined with Dasatinib.,APRD00102,Dasatinib,DB01254
The serum concentration of Trimethoprim can be increased when it is combined with Dasatinib.,APRD00103,Dasatinib,DB01254
The serum concentration of Gemcitabine can be decreased when it is combined with Apalutamide.,APRD00201,Apalutamide,DB11901
Ribavirin may increase the hepatotoxic activities of Entecavir.,APRD00948,Ribavirin,DB00811
The risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.,APRD00513,Deferasirox,DB01609
The serum concentration of Teniposide can be increased when it is combined with Dasatinib.,APRD00649,Dasatinib,DB01254
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Epirubicin.,APRD00361,Sipuleucel-T,DB06688
The metabolism of Metahexamide can be decreased when combined with Chloramphenicol.,EXPT00942,Metahexamide,DB13675
Loracarbef may increase the nephrotoxic activities of Bekanamycin.,APRD01077,Bekanamycin,DB13673
The serum concentration of Brentuximab vedotin can be increased when it is combined with Lansoprazole.,APRD00077,Brentuximab vedotin,DB08870
The risk or severity of adverse effects can be increased when Dipivefrin is combined with Epibatidine.,APRD00930,Epibatidine,DB07720
Droperidol may increase the QTc-prolonging activities of Delamanid.,APRD00939,Delamanid,DB11637
The serum concentration of Levothyroxine can be increased when it is combined with Dasatinib.,EXPT02993,Dasatinib,DB01254
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Framycetin.,APRD00618,Digoxin Immune Fab (Ovine),DB00076
The serum concentration of Medrogestone can be decreased when it is combined with Clomocycline.,APRD00343,Medrogestone,DB09124
Pethidine may increase the constipating activities of Ramosetron.,APRD00074,Ramosetron,DB09290
The serum concentration of Loratadine can be increased when it is combined with Dasatinib.,APRD00384,Dasatinib,DB01254
The serum concentration of Cefalotin can be increased when it is combined with Probenecid.,EXPT00946,Probenecid,DB01032
The serum concentration of Prazosin can be increased when it is combined with Teriflunomide.,APRD00020,Teriflunomide,DB08880
The serum concentration of Imipramine can be increased when it is combined with Dasatinib.,DB08002,Dasatinib,DB01254
The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Acitretin.,APRD00778,Estradiol cypionate,DB13954
Cyclophosphamide may increase the cardiotoxic activities of Verteporfin.,APRD01290,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Nabumetone is combined with Pitolisant.,APRD01128,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Nicomorphine.,APRD00314,Nicomorphine,DB13454
The serum concentration of Metharbital can be decreased when it is combined with Orlistat.,APRD00757,Orlistat,DB01083
The risk or severity of adverse effects can be increased when Ketorolac is combined with Pitolisant.,APRD01060,Pitolisant,DB11642
Enoxacin may increase the QTc-prolonging activities of Delamanid.,APRD00947,Delamanid,DB11637
The serum concentration of Quinine can be increased when it is combined with Dasatinib.,APRD00563,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Pitolisant.,APRD00011,Pitolisant,DB11642
The serum concentration of Dronabinol can be increased when it is combined with Dasatinib.,APRD00571,Dasatinib,DB01254
The serum concentration of Montelukast can be increased when it is combined with Dasatinib.,APRD00434,Dasatinib,DB01254
The serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.,APRD00530,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.,APRD00058,Doxylamine,DB00366
The serum concentration of Chlordiazepoxide can be increased when it is combined with Dasatinib.,APRD00682,Dasatinib,DB01254
The serum concentration of Brexpiprazole can be increased when it is combined with Duloxetine.,APRD00060,Brexpiprazole,DB09128
The serum concentration of Chlorpromazine can be increased when it is combined with Dasatinib.,APRD00482,Dasatinib,DB01254
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Amikacin.,APRD00550,Digoxin Immune Fab (Ovine),DB00076
The serum concentration of Lenalidomide can be decreased when it is combined with Apalutamide.,APRD01303,Apalutamide,DB11901
The serum concentration of Raloxifene can be increased when it is combined with Dasatinib.,APRD00400,Dasatinib,DB01254
The serum concentration of Celecoxib can be increased when it is combined with Dasatinib.,APRD00373,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Nicomorphine.,APRD00712,Nicomorphine,DB13454
Brimonidine may increase the bradycardic activities of Digoxin.,APRD00034,Digoxin,DB00390
The serum concentration of Methotrexate can be increased when it is combined with Dicloxacillin.,APRD00916,Methotrexate,DB00563
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.,APRD01127,Doxylamine,DB00366
Pefloxacin may increase the QTc-prolonging activities of Delamanid.,APRD00108,Delamanid,DB11637
Altretamine may increase the orthostatic hypotensive activities of Procarbazine.,APRD00652,Procarbazine,DB01168
Sotalol may increase the QTc-prolonging activities of Delamanid.,APRD01230,Delamanid,DB11637
The serum concentration of Buspirone can be increased when it is combined with Dasatinib.,APRD00222,Dasatinib,DB01254
Trolamine salicylate may increase the hypoglycemic activities of Miglitol.,APRD01117,Trolamine salicylate,DB11079
Trimethoprim may increase the hyperkalemic activities of Fosinopril.,APRD00526,Trimethoprim,DB00440
Cefotaxime may increase the nephrotoxic activities of Bekanamycin.,APRD00854,Bekanamycin,DB13673
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.,APRD00416,Doxylamine,DB00366
The serum concentration of Zidovudine can be increased when it is combined with Dasatinib.,APRD00449,Dasatinib,DB01254
The serum concentration of Darifenacin can be increased when it is combined with Dasatinib.,APRD00903,Dasatinib,DB01254
Oxycodone may increase the constipating activities of Ramosetron.,APRD00387,Ramosetron,DB09290
The risk or severity of adverse effects can be increased when Phenindione is combined with Azficel-T.,APRD00166,Azficel-T,DB11051
The serum concentration of Flutamide can be increased when it is combined with Dasatinib.,APRD00984,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Tolmetin is combined with Pitolisant.,APRD01268,Pitolisant,DB11642
The serum concentration of Brexpiprazole can be increased when it is combined with Cimetidine.,APRD00568,Brexpiprazole,DB09128
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Haloperidol.,APRD00538,Phenylacetic acid,DB09269
The serum concentration of Ritonavir can be increased when it is combined with Dasatinib.,APRD00312,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Levallorphan is combined with Naloxegol.,APRD00733,Naloxegol,DB09049
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.,APRD00465,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Dextrothyroxine is combined with Piracetam.,APRD00911,Piracetam,DB09210
The risk or severity of adverse effects can be increased when Licorice is combined with Acetyldigitoxin.,APRD01334,Licorice,DB10675
Vancomycin may increase the neuromuscular blocking activities of Alcuronium.,EXPT03217,Alcuronium,DB13648
The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Factor IX Complex (Human).,DB04134,Factor IX Complex (Human),DB11330
The serum concentration of Dextromethorphan can be increased when it is combined with Dasatinib.,APRD00655,Dasatinib,DB01254
The serum concentration of Cisplatin can be increased when it is combined with Teriflunomide.,APRD00359,Teriflunomide,DB08880
The serum concentration of Dolutegravir can be decreased when it is combined with Bentoquatam.,APRD00819,Dolutegravir,DB08930
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Nicomorphine.,APRD00800,Nicomorphine,DB13454
The serum concentration of Albendazole can be increased when it is combined with Dasatinib.,APRD00782,Dasatinib,DB01254
Trimethoprim may increase the hyperkalemic activities of Trandolapril.,APRD01269,Trimethoprim,DB00440
The serum concentration of Brentuximab vedotin can be increased when it is combined with Caspofungin.,APRD00199,Brentuximab vedotin,DB08870
Carteolol may increase the hypoglycemic activities of Metahexamide.,APRD00195,Metahexamide,DB13675
The serum concentration of Alitretinoin can be decreased when it is combined with Apalutamide.,APRD00017,Apalutamide,DB11901
Yohimbine may decrease the antihypertensive activities of Metolazone.,APRD01109,Yohimbine,DB01392
The therapeutic efficacy of Tolnaftate can be increased when used in combination with Menthol.,APRD01607,Menthol,DB00825
The serum concentration of Oxaliplatin can be increased when it is combined with Eltrombopag.,APRD00186,Eltrombopag,DB06210
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.,APRD00915,Doxylamine,DB00366
The serum concentration of Lercanidipine can be increased when it is combined with Dasatinib.,APRD00193,Dasatinib,DB01254
Foscarnet may increase the QTc-prolonging activities of Lenvatinib.,APRD00669,Lenvatinib,DB09078
The serum concentration of Erlotinib can be increased when it is combined with Dasatinib.,APRD00951,Dasatinib,DB01254
Cyclophosphamide may increase the immunosuppressive activities of Cyclosporine.,APRD00408,Cyclosporine,DB00091
The serum concentration of Mephenytoin can be decreased when it is combined with Osimertinib.,APRD00512,Osimertinib,DB09330
The serum concentration of Rofecoxib can be increased when it is combined with Dasatinib.,APRD00151,Dasatinib,DB01254
The serum concentration of Cefdinir can be increased when it is combined with Probenecid.,APRD00644,Probenecid,DB01032
Ciprofloxacin may increase the QTc-prolonging activities of Delamanid.,EXPT00999,Delamanid,DB11637
The serum concentration of Toremifene can be increased when it is combined with Dasatinib.,APRD00391,Dasatinib,DB01254
The serum concentration of Nortriptyline can be increased when it is combined with Dasatinib.,APRD00602,Dasatinib,DB01254
The serum concentration of Vincristine can be increased when it is combined with Dasatinib.,APRD00495,Dasatinib,DB01254
Trimethoprim may increase the hyperkalemic activities of Benazepril.,APRD00063,Trimethoprim,DB00440
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Amoxapine.,APRD00142,Pitolisant,DB11642
The serum concentration of Fluorouracil can be increased when it is combined with Eltrombopag.,EXPT03204,Eltrombopag,DB06210
The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Epibatidine.,APRD00380,Epibatidine,DB07720
The serum concentration of Adinazolam can be increased when it is combined with Dasatinib.,APRD00724,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desoximetasone.,APRD00910,Corticorelin ovine triflutate,DB09067
Cyclophosphamide may increase the cardiotoxic activities of Azelaic Acid.,EXPT00598,Cyclophosphamide,DB00531
The serum concentration of Zafirlukast can be increased when it is combined with Dasatinib.,APRD00377,Dasatinib,DB01254
The serum concentration of Aminophylline can be increased when it is combined with Propylthiouracil.,APRD00297,Aminophylline,DB01223
The risk or severity of adverse effects can be increased when Ethanol is combined with Acetohydroxamic Acid.,EXPT01688,Ethanol,DB00898
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pentostatin.,APRD00202,Sipuleucel-T,DB06688
The serum concentration of Methoxsalen can be increased when it is combined with Dasatinib.,APRD00157,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Piroxicam is combined with Pitolisant.,APRD01187,Pitolisant,DB11642
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.,APRD00570,Doxylamine,DB00366
Vilanterol may increase the QTc-prolonging activities of Perflutren.,APRD01177,Vilanterol,DB09082
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Hydroxyzine.",APRD00688,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Iloprost may increase the hypotensive activities of Bosentan.,APRD00829,Iloprost,DB01088
The serum concentration of Medrogestone can be decreased when it is combined with Tigecycline.,APRD01307,Medrogestone,DB09124
Procarbazine may increase the hypertensive activities of Doxapram.,APRD00935,Procarbazine,DB01168
Alaproclate may increase the hyponatremic activities of Benzthiazide.,APRD00728,Alaproclate,DB13233
The serum concentration of Methotrexate can be increased when it is combined with Metampicillin.,APRD00353,Metampicillin,DB13836
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.,APRD00337,Doxylamine,DB00366
Vancomycin may increase the neuromuscular blocking activities of Cisatracurium.,APRD00874,Vancomycin,DB00512
Succimer can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,APRD01236,Technetium Tc-99m oxidronate,DB09139
The serum concentration of Cephalexin can be increased when it is combined with Dasatinib.,APRD00250,Dasatinib,DB01254
The serum concentration of Cinnarizine can be decreased when it is combined with Apalutamide.,APRD00332,Apalutamide,DB11901
The risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Azficel-T.,DB11728,Azficel-T,DB11051
The serum concentration of Vinblastine can be increased when it is combined with Dasatinib.,APRD00708,Dasatinib,DB01254
The serum concentration of Propranolol can be increased when it is combined with Dasatinib.,APRD00194,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Atropine is combined with Nicomorphine.,EXPT02427,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Pitolisant.,APRD00970,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Thioproperazine is combined with Fenfluramine.,APRD00319,Thioproperazine,DB01622
The serum concentration of Clonidine can be increased when it is combined with Dasatinib.,DB07566,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamethizole.,APRD00684,Dexketoprofen,DB09214
The serum concentration of Mycophenolic acid can be increased when it is combined with Valaciclovir.,APRD00697,Mycophenolic acid,DB01024
The serum concentration of Methotrexate can be increased when it is combined with Carbenicillin.,APRD00846,Methotrexate,DB00563
The serum concentration of Valdecoxib can be increased when it is combined with Dasatinib.,DB07576,Dasatinib,DB01254
The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine.,APRD01063,L-Glutamine,DB00130
Voriconazole may increase the QTc-prolonging activities of Delamanid.,APRD00543,Delamanid,DB11637
L-Carnitine may increase the anticoagulant activities of Tioclomarol.,APRD01070,Tioclomarol,DB13451
The serum concentration of Enalapril can be increased when it is combined with Dasatinib.,APRD00510,Dasatinib,DB01254
The serum concentration of Nizatidine can be decreased when it is combined with Apalutamide.,APRD00706,Apalutamide,DB11901
The serum concentration of Diclofenac can be increased when it is combined with Dasatinib.,APRD00527,Dasatinib,DB01254
The serum concentration of Fluticasone propionate can be increased when it is combined with Dasatinib.,APRD00065,Dasatinib,DB01254
The serum concentration of Lisuride can be increased when it is combined with Dasatinib.,APRD00636,Dasatinib,DB01254
The serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.,APRD00474,Brentuximab vedotin,DB08870
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinolone Acetonide.,APRD00977,Corticorelin ovine triflutate,DB09067
The serum concentration of Piperazine can be decreased when it is combined with Tafenoquine.,DB11514,Tafenoquine,DB06608
The serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.,APRD00318,Dasatinib,DB01254
Palmidrol may decrease the antihypertensive activities of Amiloride.,EXPT00514,Palmidrol,DB14043
Oxytetracycline may increase the anticoagulant activities of Tioclomarol.,APRD00019,Tioclomarol,DB13451
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Ulobetasol.,APRD01010,Corticorelin ovine triflutate,DB09067
Labetalol may increase the hypoglycemic activities of Metahexamide.,APRD01062,Metahexamide,DB13675
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.,APRD00660,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Linezolid is combined with Mosapramine.,DB08769,Mosapramine,DB13676
The serum concentration of Ivermectin can be increased when it is combined with Dasatinib.,APRD01058,Dasatinib,DB01254
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.,APRD00627,Dasatinib,DB01254
The serum concentration of Cisapride can be increased when it is combined with Dasatinib.,APRD00454,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Sulindac is combined with Pitolisant.,APRD01243,Pitolisant,DB11642
Iloprost may increase the hypotensive activities of Cyclothiazide.,EXPT01082,Iloprost,DB01088
The serum concentration of Methotrexate can be increased when it is combined with Nafcillin.,DB08269,Methotrexate,DB00563
The serum concentration of Chloroquine can be increased when it is combined with Dasatinib.,APRD00468,Dasatinib,DB01254
The serum concentration of Isoniazid can be increased when it is combined with Ethionamide.,APRD00961,Isoniazid,DB00951
Nabilone may increase the tachycardic activities of Metaraminol.,APRD00555,Nabilone,DB00486
Butorphanol may increase the constipating activities of Ramosetron.,APRD00835,Ramosetron,DB09290
The serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.,APRD00257,Dasatinib,DB01254
The serum concentration of Ivermectin can be decreased when it is combined with Amodiaquine.,APRD00796,Ivermectin,DB00602
Furazolidone may increase the hypertensive activities of Norepinephrine.,APRD00988,Norepinephrine,DB00368
The metabolism of Barbexaclone can be increased when combined with Rifabutin.,APRD00094,Barbexaclone,DB09001
Trimethoprim may increase the hyperkalemic activities of Candoxatril.,APRD00027,Trimethoprim,DB00440
The serum concentration of Paramethadione can be increased when it is combined with Dasatinib.,APRD00236,Dasatinib,DB01254
Demeclocycline may increase the anticoagulant activities of Tioclomarol.,APRD00272,Tioclomarol,DB13451
The serum concentration of Imatinib can be increased when it is combined with Dasatinib.,DB03261,Dasatinib,DB01254
The serum concentration of Triamcinolone can be increased when it is combined with Dasatinib.,APRD00422,Dasatinib,DB01254
Fluticasone may increase the fluid retaining activities of Oxandrolone.,APRD01151,Fluticasone,DB13867
The serum concentration of Nicardipine can be increased when it is combined with Dasatinib.,APRD00088,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.,APRD00633,Doxylamine,DB00366
The serum concentration of Testosterone can be increased when it is combined with Dasatinib.,DB05275,Dasatinib,DB01254
The serum concentration of Efavirenz can be increased when it is combined with Dasatinib.,DB07709,Dasatinib,DB01254
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bacitracin.,APRD00816,Picosulfuric acid,DB09268
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Niacin.",APRD00536,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The serum concentration of Clorazepate can be increased when it is combined with Dasatinib.,APRD00881,Dasatinib,DB01254
Iloprost may increase the hypotensive activities of Guanabenz.,APRD00487,Iloprost,DB01088
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.,APRD00561,Acetylsalicylic acid,DB00945
The serum concentration of Clofarabine can be increased when it is combined with Teriflunomide.,DB06189,Teriflunomide,DB08880
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.,APRD00578,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfacetamide.,APRD00452,Dexketoprofen,DB09214
The serum concentration of Prednisone can be increased when it is combined with Dasatinib.,APRD00340,Dasatinib,DB01254
The serum concentration of Clofibrate can be increased when it is combined with Dasatinib.,APRD00879,Dasatinib,DB01254
The serum concentration of Astemizole can be increased when it is combined with Dasatinib.,APRD00585,Dasatinib,DB01254
The therapeutic efficacy of Butoconazole can be increased when used in combination with Menthol.,APRD00834,Menthol,DB00825
The risk or severity of adverse effects can be increased when Digoxin is combined with Adenosine.,DB06639,Digoxin,DB00390
The serum concentration of Simvastatin can be increased when it is combined with Dasatinib.,APRD00104,Dasatinib,DB01254
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed.,EXPT02075,Sipuleucel-T,DB06688
The serum concentration of Mebendazole can be increased when it is combined with Dasatinib.,APRD01086,Dasatinib,DB01254
The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Gonadorelin.,APRD01001,Choline C 11,DB09277
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.,APRD00940,Doxylamine,DB00366
The therapeutic efficacy of Nystatin can be increased when used in combination with Menthol.,APRD01146,Menthol,DB00825
Dextropropoxyphene may increase the constipating activities of Ramosetron.,APRD00548,Ramosetron,DB09290
Bevacizumab may increase the cardiotoxic activities of Mitotane.,APRD00494,Bevacizumab,DB00112
The serum concentration of Stavudine can be increased when it is combined with Teriflunomide.,APRD00440,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Leucovorin is combined with Tegafur.,APRD00698,Tegafur,DB09256
"The serum concentration of Dyphylline can be decreased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.",APRD00769,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
Pentazocine may increase the constipating activities of Ramosetron.,APRD01173,Ramosetron,DB09290
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate.,APRD01080,Doxylamine,DB00366
Iloprost may increase the hypotensive activities of Latanoprost.,APRD01065,Iloprost,DB01088
The serum concentration of Estrone can be increased when it is combined with Dasatinib.,APRD00588,Dasatinib,DB01254
The serum concentration of Trazodone can be increased when it is combined with Dasatinib.,APRD00533,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Nicomorphine.,APRD00458,Nicomorphine,DB13454
The serum concentration of Tacrolimus can be decreased when it is combined with Sevelamer.,APRD01226,Tacrolimus,DB00864
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.,APRD00514,Doxylamine,DB00366
The serum concentration of Verapamil can be increased when it is combined with Dasatinib.,APRD00335,Dasatinib,DB01254
Ethanol may increase the central nervous system depressant (CNS depressant) activities of Trimethobenzamide.,APRD01277,Ethanol,DB00898
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flumethasone.,APRD00975,Corticorelin ovine triflutate,DB09067
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfametopyrazine.,APRD00517,Dexketoprofen,DB09214
The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Nilutamide.,APRD00150,Choline C 11,DB09277
The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Nafarelin.,APRD01129,Choline C 11,DB09277
Nabilone may increase the tachycardic activities of Epinephrine.,EXPT00496,Nabilone,DB00486
The serum concentration of Sumatriptan can be decreased when it is combined with Apalutamide.,APRD00379,Apalutamide,DB11901
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Nicomorphine.,APRD00515,Nicomorphine,DB13454
The serum concentration of Cefixime can be increased when it is combined with Probenecid.,APRD00583,Probenecid,DB01032
The serum concentration of Chlorpropamide can be increased when it is combined with Voriconazole.,APRD00029,Voriconazole,DB00582
The serum concentration of Avatrombopag can be increased when it is combined with Aprepitant.,APRD00100,Avatrombopag,DB11995
The serum concentration of Galantamine can be increased when it is combined with Dasatinib.,EXPT01628,Dasatinib,DB01254
The serum concentration of Tamoxifen can be increased when it is combined with Dasatinib.,APRD00123,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Isoflurophate is combined with Epibatidine.,APRD00763,Epibatidine,DB07720
The serum concentration of Losartan can be increased when it is combined with Dasatinib.,APRD00052,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.,APRD00596,Doxylamine,DB00366
Moricizine may increase the hypotensive activities of Nicomorphine.,APRD01124,Nicomorphine,DB13454
Betamethasone may increase the hypokalemic activities of Amphotericin B.,APRD00797,Betamethasone,DB00443
The serum concentration of Warfarin can be decreased when it is combined with Ritonavir.,APRD00341,Ritonavir,DB00503
The serum concentration of Midazolam can be increased when it is combined with Dasatinib.,APRD00680,Dasatinib,DB01254
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Tobramycin.,APRD00582,Digoxin Immune Fab (Ovine),DB00076
Trovafloxacin may increase the QTc-prolonging activities of Delamanid.,APRD01281,Delamanid,DB11637
The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Azficel-T.,APRD01175,Azficel-T,DB11051
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fludrocortisone.,DB02478,Corticorelin ovine triflutate,DB09067
The serum concentration of Mycophenolate mofetil can be increased when it is combined with Dasatinib.,APRD01602,Dasatinib,DB01254
The serum concentration of Cephaloglycin can be increased when it is combined with Probenecid.,APRD00858,Probenecid,DB01032
The serum concentration of Flurazepam can be increased when it is combined with Dasatinib.,APRD00983,Dasatinib,DB01254
Trimethoprim may increase the hyperkalemic activities of Moexipril.,APRD01120,Trimethoprim,DB00440
The risk or severity of hypotension can be increased when Phentolamine is combined with Menthol.,APRD00615,Menthol,DB00825
The serum concentration of Daunorubicin can be increased when it is combined with Dasatinib.,APRD00521,Dasatinib,DB01254
The therapeutic efficacy of Furosemide can be decreased when used in combination with Trolamine salicylate.,DB07799,Trolamine salicylate,DB11079
The serum concentration of Ergotamine can be increased when it is combined with Dasatinib.,APRD00677,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.,APRD00128,Doxylamine,DB00366
The serum concentration of Nitrofurantoin can be increased when it is combined with Teriflunomide.,APRD00191,Teriflunomide,DB08880
The risk or severity of hypotension can be increased when Nicergoline is combined with Menthol.,APRD00617,Menthol,DB00825
The serum concentration of Eplerenone can be increased when it is combined with Dasatinib.,APRD00707,Dasatinib,DB01254
The serum concentration of Amprenavir can be increased when it is combined with Dasatinib.,APRD00605,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Methazolamide is combined with Phenytoin.,APRD00740,Phenytoin,DB00252
The serum concentration of Brentuximab vedotin can be increased when it is combined with Naltrexone.,DB05067,Brentuximab vedotin,DB08870
The serum concentration of Delavirdine can be increased when it is combined with Dasatinib.,DB08563,Dasatinib,DB01254
The serum concentration of Tamsulosin can be increased when it is combined with Dasatinib.,APRD00036,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Porfimer sodium.,APRD00078,Cyclophosphamide,DB00531
Sufentanil may increase the constipating activities of Ramosetron.,DB05563,Ramosetron,DB09290
The serum concentration of Lamivudine can be increased when it is combined with Eltrombopag.,APRD00681,Eltrombopag,DB06210
The risk or severity of adverse effects can be increased when Palmidrol is combined with Ibandronate.,DB04635,Palmidrol,DB14043
The serum concentration of Diethylcarbamazine can be decreased when it is combined with Tafenoquine.,APRD00918,Tafenoquine,DB06608
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pitolisant.,APRD00753,Pitolisant,DB11642
The serum concentration of Methotrexate can be increased when it is combined with Oxacillin.,APRD01149,Methotrexate,DB00563
Racepinephrine may decrease the vasoconstricting activities of Apomorphine.,DB05816,Racepinephrine,DB11124
The serum concentration of Brentuximab vedotin can be increased when it is combined with Paroxetine.,DB00715,Brentuximab vedotin,DB08870
The serum concentration of Norethisterone can be increased when it is combined with Dasatinib.,APRD00679,Dasatinib,DB01254
The serum concentration of Adefovir Dipivoxil can be increased when it is combined with Teriflunomide.,APRD00781,Teriflunomide,DB08880
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Azatadine.",APRD00810,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Estramustine can be increased when it is combined with Clodronic Acid.,APRD00639,Estramustine,DB01196
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Procaine.,DB05342,Doxylamine,DB00366
Trimethoprim may increase the hyperkalemic activities of Lisinopril.,APRD00560,Trimethoprim,DB00440
Nabilone may increase the tachycardic activities of Methoxamine.,APRD00062,Nabilone,DB00486
The serum concentration of Imiquimod can be increased when it is combined with Dasatinib.,APRD01030,Dasatinib,DB01254
The serum concentration of Trimipramine can be increased when it is combined with Dasatinib.,APRD00498,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rosiglitazone.,APRD00153,Rosiglitazone,DB00412
Vancomycin may increase the neuromuscular blocking activities of Rocuronium.,APRD01221,Vancomycin,DB00512
The serum concentration of Thiabendazole can be decreased when it is combined with Tafenoquine.,DB08630,Tafenoquine,DB06608
The serum concentration of Nateglinide can be increased when it is combined with Dasatinib.,APRD00593,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nicomorphine.,APRD00806,Nicomorphine,DB13454
The serum concentration of Risperidone can be increased when it is combined with Dasatinib.,APRD00187,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Naftifine is combined with Pitolisant.,APRD01131,Pitolisant,DB11642
The serum concentration of Esomeprazole can be increased when it is combined with Aprepitant.,APRD00363,Aprepitant,DB00673
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.,APRD00354,Doxylamine,DB00366
The serum concentration of Pentamidine can be increased when it is combined with Dasatinib.,EXPT02625,Dasatinib,DB01254
The serum concentration of Riluzole can be increased when it is combined with Eltrombopag.,APRD00145,Eltrombopag,DB06210
The serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.,DB07886,Dasatinib,DB01254
The serum concentration of Mannitol can be decreased when it is combined with Apalutamide.,EXPT02246,Apalutamide,DB11901
Vilanterol may increase the QTc-prolonging activities of Gadobenic acid.,APRD00989,Vilanterol,DB09082
The serum concentration of Zileuton can be increased when it is combined with Dasatinib.,APRD00265,Dasatinib,DB01254
The serum concentration of Modafinil can be increased when it is combined with Dasatinib.,APRD00534,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Vitamin C is combined with Deferoxamine.,APRD00904,Vitamin C,DB00126
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.,APRD00616,Doxylamine,DB00366
The serum concentration of Carbinoxamine can be increased when it is combined with Dasatinib.,APRD00765,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Etodolac is combined with Pitolisant.,APRD00067,Pitolisant,DB11642
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.,APRD00180,Doxylamine,DB00366
Epinastine may increase the antiplatelet activities of Relcovaptan.,APRD00043,Relcovaptan,DB13929
Tranylcypromine may increase the hypertensive activities of Norepinephrine.,APRD00645,Norepinephrine,DB00368
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.,APRD00212,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.,APRD00962,Doxylamine,DB00366
The serum concentration of Tretinoin can be increased when it is combined with Dasatinib.,APRD00362,Dasatinib,DB01254
The serum concentration of Dolasetron can be increased when it is combined with Dasatinib.,APRD00518,Dasatinib,DB01254
The serum concentration of Bupropion can be increased when it is combined with Clopidogrel.,APRD00444,Bupropion,DB01156
The serum concentration of Tetracycline can be increased when it is combined with Dasatinib.,APRD00572,Dasatinib,DB01254
The serum concentration of Valproic Acid can be decreased when it is combined with Meropenem.,EXPT02153,Valproic Acid,DB00313
Potassium Chloride may increase the hyperkalemic activities of Candoxatril.,APRD01322,Candoxatril,DB00616
The serum concentration of Irinotecan can be increased when it is combined with Dasatinib.,APRD00579,Dasatinib,DB01254
The serum concentration of Aminophylline can be increased when it is combined with Methimazole.,APRD00002,Aminophylline,DB01223
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Mometasone.,APRD00289,Corticorelin ovine triflutate,DB09067
Iloprost may increase the hypotensive activities of Metyrosine.,APRD01112,Iloprost,DB01088
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clavulanate.,APRD00049,Picosulfuric acid,DB09268
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Benzquinamide.",APRD00820,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Olopatadine can be increased when it is combined with Dasatinib.,APRD00310,Dasatinib,DB01254
The serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortamate.,APRD01018,Saxagliptin,DB06335
Alprostadil may increase the antiplatelet activities of Relcovaptan.,APRD00785,Relcovaptan,DB13929
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.,APRD00737,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Malathion is combined with Epibatidine.,APRD01081,Epibatidine,DB07720
The serum concentration of Etoposide can be increased when it is combined with Dasatinib.,APRD00239,Dasatinib,DB01254
Yohimbine may decrease the antihypertensive activities of Hydroflumethiazide.,APRD01020,Yohimbine,DB01392
Vitamin E may increase the antiplatelet activities of Tirofiban.,APRD00304,Vitamin E,DB00163
The serum concentration of Oxcarbazepine can be decreased when it is combined with Valproic Acid.,APRD01308,Valproic Acid,DB00313
The risk or severity of hypotension can be increased when Propiomazine is combined with Menthol.,APRD00339,Menthol,DB00825
The serum concentration of Roxithromycin can be increased when it is combined with Dasatinib.,APRD01305,Dasatinib,DB01254
Nalidixic Acid may increase the hypoglycemic activities of Sulfisoxazole.,APRD01133,Sulfisoxazole,DB00263
Phenelzine may increase the hypertensive activities of Norepinephrine.,APRD00099,Norepinephrine,DB00368
Polymyxin B Sulfate may increase the neuromuscular blocking activities of Colistimethate.,APRD01190,Colistimethate,DB01111
The risk or severity of adverse effects can be increased when Propantheline is combined with Nicomorphine.,APRD00177,Nicomorphine,DB13454
The serum concentration of Estradiol can be increased when it is combined with Dasatinib.,APRD00311,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pitolisant.,APRD00730,Pitolisant,DB11642
Iloprost may increase the hypotensive activities of Cryptenamine.,APRD00890,Iloprost,DB01088
The serum concentration of Acyclovir can be increased when it is combined with Teriflunomide.,DB05347,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Naproxen is combined with Pitolisant.,DB08298,Pitolisant,DB11642
Trimethoprim may increase the hyperkalemic activities of Perindopril.,APRD01178,Trimethoprim,DB00440
Cyclophosphamide may increase the cardiotoxic activities of Uracil mustard.,APRD00130,Cyclophosphamide,DB00531
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Tripelennamine.",APRD00689,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Haloprogin can be increased when used in combination with Menthol.,APRD01011,Menthol,DB00825
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Primidone.,APRD00549,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pitolisant.,DB08518,Pitolisant,DB11642
The serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan cilexetil.,APRD00420,Brentuximab vedotin,DB08870
The risk or severity of hypotension can be increased when Tolazoline is combined with Menthol.,APRD00170,Menthol,DB00825
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Gentamicin.,APRD00214,Digoxin Immune Fab (Ovine),DB00076
The metabolism of Tazarotene can be decreased when combined with Nabilone.,APRD01246,Nabilone,DB00486
Yohimbine may decrease the antihypertensive activities of Fenoldopam.,APRD00969,Yohimbine,DB01392
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Halazepam.,APRD01009,Doxylamine,DB00366
Alfentanil may increase the constipating activities of Ramosetron.,APRD00726,Ramosetron,DB09290
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Colistin.,APRD00886,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Nicomorphine.,APRD00113,Nicomorphine,DB13454
Minaprine may increase the hypertensive activities of Norepinephrine.,APRD00735,Norepinephrine,DB00368
Pentoxifylline may increase the hypotensive activities of Guanoclor.,APRD00121,Guanoclor,DB13779
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.,APRD00522,Doxylamine,DB00366
The serum concentration of Indapamide can be increased when it is combined with Dasatinib.,APRD01031,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Tropicamide is combined with Nicomorphine.,APRD00287,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Biperiden is combined with Nicomorphine.,APRD00725,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ribavirin.,DB01693,Peginterferon alfa-2b,DB00022
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pitolisant.,DB08343,Pitolisant,DB11642
Fentanyl may increase the constipating activities of Ramosetron.,DB05564,Ramosetron,DB09290
The serum concentration of Meloxicam can be increased when it is combined with Dasatinib.,APRD00529,Dasatinib,DB01254
Nabilone may increase the tachycardic activities of Orciprenaline.,APRD00210,Nabilone,DB00486
Rosoxacin may increase the hypoglycemic activities of Sulfisoxazole.,APRD00369,Sulfisoxazole,DB00263
The serum concentration of Propofol can be increased when it is combined with Dasatinib.,DB05893,Dasatinib,DB01254
The serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.,EXPT00604,Cyclosporine,DB00091
The serum concentration of Tadalafil can be increased when it is combined with Dasatinib.,APRD00071,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Carprofen is combined with Pitolisant.,APRD00849,Pitolisant,DB11642
The serum concentration of Disulfiram can be increased when it is combined with Dasatinib.,APRD00767,Dasatinib,DB01254
Ethynodiol diacetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,APRD00760,Lamotrigine,DB00555
The risk or severity of hypotension can be increased when Racepinephrine is combined with Menthol.,APRD01604,Racepinephrine,DB11124
The therapeutic efficacy of Natamycin can be increased when used in combination with Menthol.,APRD01136,Menthol,DB00825
Cinoxacin may increase the hypoglycemic activities of Sulfisoxazole.,APRD00873,Sulfisoxazole,DB00263
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fosfomycin.,APRD00987,Picosulfuric acid,DB09268
The serum concentration of Diazepam can be increased when it is combined with Dasatinib.,DB07699,Dasatinib,DB01254
Nabilone may increase the tachycardic activities of Phenmetrazine.,APRD00262,Nabilone,DB00486
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.,DB08616,Doxylamine,DB00366
The serum concentration of Phensuximide can be decreased when it is combined with Orlistat.,APRD00496,Orlistat,DB01083
The serum concentration of Cefaclor can be increased when it is combined with Probenecid.,APRD00243,Probenecid,DB01032
The serum concentration of Digoxin can be increased when it is combined with Mifepristone.,APRD00432,Digoxin,DB00390
The serum concentration of Brompheniramine can be increased when it is combined with Dasatinib.,APRD00832,Dasatinib,DB01254
The serum concentration of Loperamide can be increased when it is combined with Dasatinib.,APRD00275,Dasatinib,DB01254
The serum concentration of Progabide can be decreased when it is combined with Orlistat.,APRD00072,Orlistat,DB01083
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clocortolone.,APRD00877,Corticorelin ovine triflutate,DB09067
The serum concentration of Tolazamide can be increased when it is combined with Voriconazole.,APRD01267,Voriconazole,DB00582
Nabilone may increase the tachycardic activities of Dobutamine.,APRD00122,Nabilone,DB00486
The serum concentration of Oxazepam can be increased when it is combined with Dasatinib.,APRD01152,Dasatinib,DB01254
The serum concentration of Donepezil can be increased when it is combined with Dasatinib.,APRD00039,Dasatinib,DB01254
Nalbuphine may increase the constipating activities of Ramosetron.,APRD01132,Ramosetron,DB09290
The serum concentration of Clofazimine can be increased when it is combined with Dasatinib.,APRD00278,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flurandrenolide.,APRD00982,Corticorelin ovine triflutate,DB09067
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium carbonate.,APRD00896,Magnesium carbonate,DB09481
The serum concentration of Levamisole can be decreased when it is combined with Tafenoquine.,APRD01067,Tafenoquine,DB06608
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.,APRD00047,Doxylamine,DB00366
The serum concentration of Perphenazine can be increased when it is combined with Dasatinib.,APRD00429,Dasatinib,DB01254
The serum concentration of Dacarbazine can be decreased when it is combined with Osimertinib.,APRD00331,Osimertinib,DB09330
The serum concentration of Pseudoephedrine can be decreased when it is combined with Methenamine.,APRD00634,Methenamine,DB06799
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Temozolomide.,APRD00557,Valproic Acid,DB00313
Levorphanol may increase the constipating activities of Ramosetron.,APRD00764,Ramosetron,DB09290
Cyclophosphamide may increase the cardiotoxic activities of Aminolevulinic acid.,DB05277,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Fluticasone is combined with Chlorphenesin.,APRD00867,Fluticasone,DB13867
The serum concentration of Terbinafine can be increased when it is combined with Dasatinib.,APRD00508,Dasatinib,DB01254
The serum concentration of Penicillamine can be decreased when it is combined with Apalutamide.,APRD01171,Apalutamide,DB11901
The serum concentration of Prednisolone can be increased when it is combined with Dasatinib.,APRD00197,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Diflunisal is combined with Pitolisant.,DB06895,Pitolisant,DB11642
The serum concentration of Vardenafil can be increased when it is combined with Dasatinib.,APRD00699,Dasatinib,DB01254
The serum concentration of Metahexamide can be increased when it is combined with Ranitidine.,APRD00254,Metahexamide,DB13675
The serum concentration of Tacrolimus can be increased when it is combined with Aprepitant.,EXPT01437,Aprepitant,DB00673
The serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.,APRD00759,Dasatinib,DB01254
Alprenolol may increase the hypoglycemic activities of Metahexamide.,APRD00736,Metahexamide,DB13675
Nabilone may increase the tachycardic activities of Ritodrine.,APRD00541,Nabilone,DB00486
The serum concentration of Dorzolamide can be increased when it is combined with Dasatinib.,DB04507,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Suprofen is combined with Pitolisant.,APRD00230,Pitolisant,DB11642
Terbutaline may increase the hypoglycemic activities of Metahexamide.,APRD00589,Metahexamide,DB13675
The serum concentration of Digoxin can be increased when it is combined with Conivaptan.,APRD01302,Digoxin,DB00390
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Loteprednol.,APRD01078,Corticorelin ovine triflutate,DB09067
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.,APRD00388,Doxylamine,DB00366
Yohimbine may decrease the antihypertensive activities of Eprosartan.,APRD00950,Yohimbine,DB01392
The serum concentration of Sirolimus can be increased when it is combined with Dasatinib.,DB02439,Dasatinib,DB01254
Ribavirin may increase the hepatotoxic activities of Emtricitabine.,APRD00226,Ribavirin,DB00811
Yohimbine may decrease the antihypertensive activities of Chlorothiazide.,APRD00721,Yohimbine,DB01392
Trimethoprim may increase the hyperkalemic activities of Quinapril.,APRD00523,Trimethoprim,DB00440
The serum concentration of Clomifene can be decreased when it is combined with Apalutamide.,APRD00880,Apalutamide,DB11901
The serum concentration of Isosorbide Dinitrate can be increased when it is combined with Dasatinib.,APRD00455,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Palmidrol is combined with Risedronate.,DB02782,Palmidrol,DB14043
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Pemirolast.",APRD00394,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Trimethoprim may increase the hyperkalemic activities of Omapatrilat.,APRD00443,Trimethoprim,DB00440
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Trolamine salicylate.,APRD00294,Trolamine salicylate,DB11079
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mechlorethamine.,APRD00249,Sipuleucel-T,DB06688
The serum concentration of Granisetron can be increased when it is combined with Dasatinib.,APRD01002,Dasatinib,DB01254
Dienestrol may increase the thrombogenic activities of Conestat alfa.,APRD00917,Conestat alfa,DB09228
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine.,APRD00491,Dexketoprofen,DB09214
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.,APRD00817,Doxylamine,DB00366
Promethazine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.,APRD01053,Promethazine,DB01069
Cyclophosphamide may increase the cardiotoxic activities of Testolactone.,APRD00640,Cyclophosphamide,DB00531
The serum concentration of Methotrexate can be increased when it is combined with Benzylpenicilloyl Polylysine.,APRD00822,Methotrexate,DB00563
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Rimexolone.,APRD01220,Corticorelin ovine triflutate,DB09067
The serum concentration of Triazolam can be increased when it is combined with Dasatinib.,APRD00313,Dasatinib,DB01254
The serum concentration of Ethanol can be increased when it is combined with Dasatinib.,APRD00738,Dasatinib,DB01254
Remifentanil may increase the constipating activities of Ramosetron.,APRD01216,Ramosetron,DB09290
The serum concentration of Didanosine can be increased when it is combined with Teriflunomide.,DB02392,Teriflunomide,DB08880
Racepinephrine may decrease the vasoconstricting activities of Bitolterol.,APRD00827,Racepinephrine,DB11124
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Methdilazine.",APRD00713,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Trolamine salicylate.,APRD00251,Trolamine salicylate,DB11079
The serum concentration of Ondansetron can be increased when it is combined with Dasatinib.,APRD00481,Dasatinib,DB01254
Iloprost may increase the hypotensive activities of Bimatoprost.,DB06863,Iloprost,DB01088
The serum concentration of Tiagabine can be increased when it is combined with Dasatinib.,APRD00344,Dasatinib,DB01254
The serum concentration of Cocaine can be increased when it is combined with Dasatinib.,APRD00080,Dasatinib,DB01254
The serum concentration of Quinidine can be increased when it is combined with Dasatinib.,APRD00136,Dasatinib,DB01254
The serum concentration of Zonisamide can be increased when it is combined with Dasatinib.,APRD00004,Dasatinib,DB01254
The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib.,APRD01165,Dasatinib,DB01254
The serum concentration of Tinidazole can be increased when it is combined with Dasatinib.,APRD01260,Dasatinib,DB01254
The serum concentration of Repaglinide can be increased when it is combined with Dasatinib.,APRD00439,Dasatinib,DB01254
The serum concentration of Phenformin can be decreased when it is combined with Peginterferon alfa-2b.,APRD00511,Peginterferon alfa-2b,DB00022
The risk or severity of adverse effects can be increased when Amantadine is combined with Memantine.,APRD00787,Memantine,DB01043
The serum concentration of Metronidazole can be increased when it is combined with Dasatinib.,APRD00631,Dasatinib,DB01254
The serum concentration of Dinoprostone can be decreased when it is combined with Apalutamide.,APRD00927,Apalutamide,DB11901
The serum concentration of Almotriptan can be increased when it is combined with Dasatinib.,APRD00169,Dasatinib,DB01254
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Spectinomycin.,APRD01232,Picosulfuric acid,DB09268
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ketotifen.",APRD01061,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Buprenorphine may increase the constipating activities of Ramosetron.,APRD00670,Ramosetron,DB09290
Levosimendan may increase the hypotensive activities of Risperidone.,APRD01296,Risperidone,DB00734
The serum concentration of Ceforanide can be increased when it is combined with Probenecid.,APRD00853,Probenecid,DB01032
The serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.,APRD00213,Dasatinib,DB01254
The serum concentration of Phenoxybenzamine can be increased when it is combined with Dasatinib.,APRD00651,Dasatinib,DB01254
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Famotidine.",APRD00296,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Azacitidine.,APRD00809,Sipuleucel-T,DB06688
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Palmidrol.,DB05379,Palmidrol,DB14043
Colesevelam can cause a decrease in the absorption of Fluticasone resulting in a reduced serum concentration and potentially a decrease in efficacy.,APRD00883,Fluticasone,DB13867
The serum concentration of Medrogestone can be decreased when it is combined with Methacycline.,APRD00137,Medrogestone,DB09124
The serum concentration of Tipranavir can be increased when it is combined with Dasatinib.,APRD01306,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.,APRD00610,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.,APRD00747,Doxylamine,DB00366
Nabilone may increase the tachycardic activities of Oxymetazoline.,APRD01158,Nabilone,DB00486
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Dibotermin alfa.,DB01398,Dibotermin alfa,DB11639
Amoxapine may increase the stimulatory activities of Diethylpropion.,APRD00919,Amoxapine,DB00543
The serum concentration of Salmeterol can be increased when it is combined with Dasatinib.,APRD00277,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pitolisant.,APRD01090,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Methantheline is combined with Nicomorphine.,APRD00751,Nicomorphine,DB13454
The therapeutic efficacy of Hexafluronium can be increased when used in combination with Lorpiprazole.,APRD01013,Lorpiprazole,DB09195
The serum concentration of Zalcitabine can be increased when it is combined with Dasatinib.,APRD00562,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Demecarium is combined with Epibatidine.,APRD00905,Epibatidine,DB07720
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dibotermin alfa.,EXPT00475,Dibotermin alfa,DB11639
The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Azficel-T.,APRD00228,Azficel-T,DB11051
The serum concentration of Fulvestrant can be increased when it is combined with Dasatinib.,APRD00654,Dasatinib,DB01254
The serum concentration of Methotrexate can be increased when it is combined with Mezlocillin.,APRD01113,Methotrexate,DB00563
The serum concentration of Felbamate can be increased when it is combined with Dasatinib.,APRD00505,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.,APRD00349,Doxylamine,DB00366
The serum concentration of Brexpiprazole can be increased when it is combined with Isoniazid.,EXPT01940,Brexpiprazole,DB09128
The risk or severity of adverse effects can be increased when Naratriptan is combined with Mosapramine.,APRD00220,Mosapramine,DB13676
The serum concentration of Rizatriptan can be decreased when it is combined with Osimertinib.,APRD00008,Osimertinib,DB09330
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dirithromycin.,APRD00931,Picosulfuric acid,DB09268
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Netilmicin.,APRD00232,Digoxin Immune Fab (Ovine),DB00076
Hydrocodone may increase the constipating activities of Ramosetron.,DB09475,Ramosetron,DB09290
Norgestimate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,APRD00569,Lamotrigine,DB00555
The serum concentration of Carboplatin can be increased when it is combined with Teriflunomide.,APRD00466,Teriflunomide,DB08880
The serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib.,APRD00342,Dasatinib,DB01254
Pindolol may increase the hypoglycemic activities of Metahexamide.,APRD00678,Metahexamide,DB13675
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.,APRD01094,Doxylamine,DB00366
The serum concentration of Zaleplon can be increased when it is combined with Dasatinib.,APRD00411,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Bromfenac is combined with Pitolisant.,APRD00831,Pitolisant,DB11642
Bucindolol may decrease the vasoconstricting activities of Apraclonidine.,APRD00012,Bucindolol,DB12752
Cyclophosphamide may increase the cardiotoxic activities of Ethiodized oil.,APRD00960,Cyclophosphamide,DB00531
The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Telmisartan.,APRD01247,Digoxin Immune Fab (Ovine),DB00076
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.,APRD00324,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.,APRD01106,Lithium,DB01356
The serum concentration of Alosetron can be increased when it is combined with Dasatinib.,APRD00580,Dasatinib,DB01254
The serum concentration of Dactinomycin can be increased when it is combined with Teriflunomide.,APRD00124,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Azelastine is combined with Dibotermin alfa.,APRD00813,Dibotermin alfa,DB11639
The serum concentration of Ezetimibe can be decreased when it is combined with Apalutamide.,APRD00619,Apalutamide,DB11901
The risk or severity of adverse effects can be increased when Edetic Acid is combined with Azficel-T.,APRD01327,Azficel-T,DB11051
The serum concentration of Dipyridamole can be decreased when it is combined with Apalutamide.,APRD00360,Apalutamide,DB11901
Telithromycin may increase the QTc-prolonging activities of Delamanid.,APRD00483,Delamanid,DB11637
The serum concentration of Ethinyl Estradiol can be increased when it is combined with Dasatinib.,APRD00691,Dasatinib,DB01254
Lomefloxacin may increase the QTc-prolonging activities of Delamanid.,APRD01076,Delamanid,DB11637
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Nicomorphine.,APRD00893,Nicomorphine,DB13454
The serum concentration of Ramelteon can be increased when it is combined with Dasatinib.,APRD01213,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Physostigmine is combined with Epibatidine.,APRD00406,Epibatidine,DB07720
The risk or severity of adverse effects can be increased when Ethanol is combined with Isotretinoin.,APRD00140,Ethanol,DB00898
The metabolism of Formoterol can be decreased when combined with Nicotine.,APRD00641,Nicotine,DB00184
Nandrolone phenpropionate may increase the stimulatory activities of Methoxy polyethylene glycol-epoetin beta.,APRD00134,Methoxy polyethylene glycol-epoetin beta,DB09107
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.,APRD00924,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Nicomorphine.,DB06583,Nicomorphine,DB13454
The serum concentration of Cytarabine can be increased when it is combined with Dasatinib.,APRD00499,Dasatinib,DB01254
Nabilone may increase the tachycardic activities of Dopamine.,APRD00085,Nabilone,DB00486
The risk or severity of adverse effects can be increased when Rivastigmine is combined with Epibatidine.,APRD00321,Epibatidine,DB07720
The serum concentration of Exemestane can be increased when it is combined with Dasatinib.,APRD00144,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Pitolisant.,APRD00030,Pitolisant,DB11642
Cyclophosphamide may increase the cardiotoxic activities of Methyl aminolevulinate.,APRD01105,Cyclophosphamide,DB00531
The metabolism of Azathioprine can be decreased when combined with Sulfasalazine.,APRD00811,Sulfasalazine,DB00795
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Neomycin.,APRD00013,Digoxin Immune Fab (Ovine),DB00076
Sarilumab may increase the immunosuppressive activities of Auranofin.,APRD00808,Sarilumab,DB11767
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.,APRD00015,Doxylamine,DB00366
The serum concentration of Doxorubicin can be increased when it is combined with Teriflunomide.,DB05847,Teriflunomide,DB08880
The serum concentration of Frovatriptan can be decreased when it is combined with Osimertinib.,APRD00270,Osimertinib,DB09330
Yohimbine may decrease the antihypertensive activities of Hydrochlorothiazide.,APRD00092,Yohimbine,DB01392
The serum concentration of Methotrexate can be increased when it is combined with Cyclacillin.,APRD00892,Methotrexate,DB00563
Racepinephrine may decrease the vasoconstricting activities of Salbutamol.,APRD00553,Racepinephrine,DB11124
The serum concentration of Levobupivacaine can be increased when it is combined with Dasatinib.,APRD00110,Dasatinib,DB01254
The serum concentration of Ganciclovir can be increased when it is combined with Mycophenolic acid.,EXPT01540,Mycophenolic acid,DB01024
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydroxyurea.,APRD00023,Sipuleucel-T,DB06688
The serum concentration of Letrozole can be increased when it is combined with Dasatinib.,APRD01066,Dasatinib,DB01254
The therapeutic efficacy of Tioconazole can be increased when used in combination with Menthol.,APRD01262,Menthol,DB00825
The serum concentration of Busulfan can be increased when it is combined with Dasatinib.,APRD00664,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pitolisant.,DB05335,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Edrophonium is combined with Epibatidine.,APRD00944,Epibatidine,DB07720
The serum concentration of Acetaminophen can be increased when it is combined with Metyrapone.,EXPT02271,Acetaminophen,DB00316
The serum concentration of Cinacalcet can be increased when it is combined with Dasatinib.,APRD00872,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clobetasol propionate.,APRD00876,Corticorelin ovine triflutate,DB09067
The risk or severity of adverse effects can be increased when Balsalazide is combined with Pitolisant.,APRD00141,Pitolisant,DB11642
The serum concentration of Sulfamethoxazole can be increased when it is combined with Dasatinib.,APRD00076,Dasatinib,DB01254
The serum concentration of Glyburide can be increased when it is combined with Dasatinib.,APRD00233,Dasatinib,DB01254
Minocycline may increase the neuromuscular blocking activities of Alcuronium.,APRD00547,Alcuronium,DB13648
The serum concentration of Guanfacine can be increased when it is combined with Dasatinib.,APRD00075,Dasatinib,DB01254
Bethanechol may decrease the anticholinergic activities of Cimetropium.,APRD00051,Cimetropium,DB09271
The serum concentration of Isosorbide Mononitrate can be increased when it is combined with Dasatinib.,APRD00528,Dasatinib,DB01254
Iloprost may increase the hypotensive activities of Trichlormethiazide.,APRD00031,Iloprost,DB01088
The serum concentration of Phylloquinone can be decreased when it is combined with Mineral oil.,DB09528,Mineral oil,DB11057
The serum concentration of Felodipine can be increased when it is combined with Dasatinib.,APRD00374,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pitolisant.,EXPT02208,Pitolisant,DB11642
The serum concentration of Fimasartan can be increased when it is combined with Ketoconazole.,APRD00401,Fimasartan,DB09279
The serum concentration of Methoxyflurane can be increased when it is combined with Dasatinib.,APRD00744,Dasatinib,DB01254
The serum concentration of Irbesartan can be decreased when it is combined with Apalutamide.,APRD00413,Apalutamide,DB11901
The serum concentration of Topotecan can be increased when it is combined with Teriflunomide.,APRD00687,Teriflunomide,DB08880
The serum concentration of Dexketoprofen can be increased when it is combined with Probenecid.,APRD00167,Dexketoprofen,DB09214
The metabolism of Mercaptopurine can be decreased when combined with Sulfasalazine.,APRD01096,Sulfasalazine,DB00795
The therapeutic efficacy of Cerulenin can be increased when used in combination with Menthol.,APRD00703,Menthol,DB00825
Procainamide may increase the QTc-prolonging activities of Delamanid.,APRD00509,Delamanid,DB11637
The serum concentration of Tolterodine can be increased when it is combined with Dasatinib.,APRD00146,Dasatinib,DB01254
The serum concentration of Selegiline can be increased when it is combined with Dasatinib.,APRD00525,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Carphenazine is combined with Deutetrabenazine.,APRD00848,Deutetrabenazine,DB12161
The serum concentration of Fenofibrate can be increased when it is combined with Dasatinib.,DB09545,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Thalidomide is combined with Alaproclate.,APRD01251,Alaproclate,DB13233
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Melphalan.,APRD00118,Sipuleucel-T,DB06688
The risk or severity of adverse effects can be increased when Glycine is combined with Memantine.,APRD00221,Glycine,DB00145
Gatifloxacin may increase the QTc-prolonging activities of Delamanid.,APRD00996,Delamanid,DB11637
The metabolism of Barbexaclone can be increased when combined with Rifampicin.,EXPT02777,Barbexaclone,DB09001
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Palmidrol.,APRD01298,Palmidrol,DB14043
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinonide.,APRD00978,Corticorelin ovine triflutate,DB09067
"The serum concentration of Abacavir can be decreased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.",APRD00216,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.,DB01287,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Dibotermin alfa.,APRD00372,Dibotermin alfa,DB11639
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Novobiocin.,APRD00694,Picosulfuric acid,DB09268
The serum concentration of Methotrexate can be increased when it is combined with Benzylpenicillin.,DB11612,Methotrexate,DB00563
The serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.,APRD00421,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Echothiophate is combined with Epibatidine.,APRD00942,Epibatidine,DB07720
The serum concentration of Praziquantel can be increased when it is combined with Dasatinib.,EXPT02728,Dasatinib,DB01254
Norfloxacin may increase the QTc-prolonging activities of Delamanid.,APRD00469,Delamanid,DB11637
The serum concentration of Methotrexate can be increased when it is combined with Amoxicillin.,APRD00248,Methotrexate,DB00563
The serum concentration of Methotrexate can be increased when it is combined with Azlocillin.,APRD00814,Methotrexate,DB00563
The serum concentration of Oxybutynin can be increased when it is combined with Dasatinib.,APRD00427,Dasatinib,DB01254
"Acetophenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.",APRD00462,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Nabilone may increase the tachycardic activities of Isoprenaline.,APRD00182,Nabilone,DB00486
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Melatonin.,DB08189,Doxylamine,DB00366
The serum concentration of Cefditoren can be increased when it is combined with Probenecid.,APRD00850,Probenecid,DB01032
The serum concentration of Glipizide can be increased when it is combined with Dasatinib.,APRD00436,Dasatinib,DB01254
The serum concentration of Clonazepam can be increased when it is combined with Dasatinib.,APRD00054,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.,APRD00601,Doxylamine,DB00366
Dihydrotachysterol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).,APRD00143,Digoxin Immune Fab (Ovine),DB00076
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mequitazine.",APRD00386,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Atazanavir may increase the QTc-prolonging activities of Delamanid.,APRD00804,Delamanid,DB11637
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludarabine.,APRD00594,Sipuleucel-T,DB06688
The serum concentration of Perhexiline can be increased when it is combined with Dasatinib.,APRD00107,Dasatinib,DB01254
The serum concentration of Brexpiprazole can be increased when it is combined with Diphenhydramine.,DB06975,Brexpiprazole,DB09128
The serum concentration of Atorvastatin can be increased when it is combined with Azithromycin.,APRD00055,Azithromycin,DB00207
The risk or severity of adverse effects can be increased when Palmidrol is combined with Etidronic acid.,APRD00964,Palmidrol,DB14043
The risk or severity of adverse effects can be increased when Licorice is combined with Deslanoside.,APRD00909,Licorice,DB10675
The serum concentration of Tegaserod can be decreased when it is combined with Peginterferon alfa-2b.,APRD00096,Peginterferon alfa-2b,DB00022
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.,APRD00282,Doxylamine,DB00366
Diphenoxylate may increase the constipating activities of Ramosetron.,APRD00366,Ramosetron,DB09290
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Streptomycin.,APRD00412,Digoxin Immune Fab (Ovine),DB00076
The serum concentration of Propafenone can be decreased when it is combined with Orlistat.,APRD00255,Propafenone,DB01182
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Emedastine.",APRD00946,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Pilocarpine can be increased when it is combined with Dasatinib.,APRD00382,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.,APRD00539,Doxylamine,DB00366
The serum concentration of Primaquine can be increased when it is combined with Dasatinib.,APRD00604,Dasatinib,DB01254
Iloprost may increase the hypotensive activities of Guanoclor.,APRD01027,Guanoclor,DB13779
Iloprost may increase the hypotensive activities of Deserpidine.,APRD00906,Iloprost,DB01088
The risk or severity of adverse effects can be increased when Pentolinium is combined with Nicomorphine.,APRD00038,Nicomorphine,DB13454
The therapeutic efficacy of Butenafine can be increased when used in combination with Menthol.,APRD00833,Menthol,DB00825
The risk or severity of adverse effects can be increased when Licorice is combined with Ouabain.,APRD00135,Licorice,DB10675
The serum concentration of Rilpivirine can be increased when it is combined with Dimethyl sulfoxide.,EXPT01231,Rilpivirine,DB08864
The serum concentration of Hesperetin can be decreased when it is combined with Osimertinib.,APRD00117,Osimertinib,DB09330
The serum concentration of Fluvastatin can be increased when it is combined with Dasatinib.,APRD00346,Dasatinib,DB01254
The serum concentration of Oxamniquine can be decreased when it is combined with Tafenoquine.,APRD01150,Tafenoquine,DB06608
The risk or severity of adverse effects can be increased when Leflunomide is combined with Pitolisant.,APRD00205,Pitolisant,DB11642
The serum concentration of Rosuvastatin can be increased when it is combined with Dasatinib.,APRD00546,Dasatinib,DB01254
The therapeutic efficacy of Flucytosine can be increased when used in combination with Menthol.,APRD00299,Menthol,DB00825
The serum concentration of Pimozide can be increased when it is combined with Dasatinib.,APRD00218,Dasatinib,DB01254
The serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Metronidazole.,APRD00203,Metronidazole,DB00916
Racepinephrine may decrease the vasoconstricting activities of Arbutamine.,APRD00802,Racepinephrine,DB11124
The serum concentration of Quinacrine can be increased when it is combined with Dasatinib.,APRD00317,Dasatinib,DB01254
The serum concentration of Bupropion can be increased when it is combined with Sertraline.,DB08567,Bupropion,DB01156
The serum concentration of Sibutramine can be increased when it is combined with Dasatinib.,APRD00456,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.,APRD01069,Doxylamine,DB00366
The serum concentration of Methyprylon can be decreased when it is combined with Peginterferon alfa-2b.,APRD00734,Peginterferon alfa-2b,DB00022
Cyclophosphamide may increase the cardiotoxic activities of Trilostane.,APRD01276,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Heparin is combined with Azficel-T.,APRD00056,Azficel-T,DB11051
The serum concentration of Miconazole can be increased when it is combined with Dasatinib.,APRD01115,Dasatinib,DB01254
Capreomycin may increase the neuromuscular blocking activities of Colistimethate.,APRD00885,Capreomycin,DB00314
Promethazine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.,APRD00285,Promethazine,DB01069
Papaverine may increase the QTc-prolonging activities of Delamanid.,DB07725,Delamanid,DB11637
The serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib.,DB09440,Dasatinib,DB01254
The serum concentration of Nifedipine can be increased when it is combined with Dasatinib.,APRD00590,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Trimethaphan is combined with Nicomorphine.,APRD00044,Nicomorphine,DB13454
The serum concentration of Thioproperazine can be increased when it is combined with Atovaquone.,APRD00805,Thioproperazine,DB01622
Amiodarone may increase the QTc-prolonging activities of Delamanid.,APRD00288,Delamanid,DB11637
Iloprost may increase the hypotensive activities of Diazoxide.,APRD00914,Iloprost,DB01088
The serum concentration of Gliclazide can be increased when it is combined with Voriconazole.,APRD00460,Voriconazole,DB00582
The serum concentration of Phenacemide can be decreased when it is combined with Orlistat.,APRD00089,Orlistat,DB01083
The risk or severity of adverse effects can be increased when Ambenonium is combined with Epibatidine.,APRD00771,Epibatidine,DB07720
The serum concentration of Tolbutamide can be increased when it is combined with Voriconazole.,APRD00267,Voriconazole,DB00582
The serum concentration of Dutasteride can be increased when it is combined with Dasatinib.,APRD00385,Dasatinib,DB01254
The therapeutic efficacy of Econazole can be increased when used in combination with Menthol.,APRD00943,Menthol,DB00825
The serum concentration of Bicalutamide can be increased when it is combined with Dasatinib.,DB06284,Dasatinib,DB01254
The serum concentration of Rabeprazole can be increased when it is combined with Aprepitant.,APRD01212,Aprepitant,DB00673
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednicarbate.,APRD01197,Corticorelin ovine triflutate,DB09067
The serum concentration of Proguanil can be increased when it is combined with Dasatinib.,APRD00188,Dasatinib,DB01254
The serum concentration of Pioglitazone can be increased when it is combined with Dasatinib.,APRD00653,Dasatinib,DB01254
The serum concentration of Tiludronic acid can be decreased when it is combined with Acetylsalicylic acid.,APRD01259,Acetylsalicylic acid,DB00945
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desoxycorticosterone Pivalate.,APRD00709,Corticorelin ovine triflutate,DB09067
Vancomycin may increase the neuromuscular blocking activities of Doxacurium chloride.,DB01334,Vancomycin,DB00512
The serum concentration of Carvedilol can be increased when it is combined with Dasatinib.,APRD00091,Dasatinib,DB01254
Levofloxacin may increase the QTc-prolonging activities of Delamanid.,DB06085,Delamanid,DB11637
The serum concentration of Sulfinpyrazone can be increased when it is combined with Dasatinib.,APRD00620,Dasatinib,DB01254
The serum concentration of Cefapirin can be increased when it is combined with Probenecid.,APRD00860,Probenecid,DB01032
The serum concentration of Cefadroxil can be increased when it is combined with Probenecid.,APRD00196,Probenecid,DB01032
The therapeutic efficacy of Micafungin can be increased when used in combination with Menthol.,APRD01114,Menthol,DB00825
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.,APRD00398,Doxylamine,DB00366
Amifostine may increase the hypotensive activities of Risperidone.,APRD00021,Risperidone,DB00734
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Phenytoin.,DB07948,Phenytoin,DB00252
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Diphenylpyraline.",APRD00719,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Methotrexate can be increased when it is combined with Cloxacillin.,EXPT01068,Methotrexate,DB00563
The risk or severity of adverse effects can be increased when Flavoxate is combined with Nicomorphine.,APRD00972,Nicomorphine,DB13454
Nefazodone may increase the QTc-prolonging activities of Delamanid.,APRD00402,Delamanid,DB11637
The serum concentration of Cefprozil can be increased when it is combined with Probenecid.,APRD00461,Probenecid,DB01032
The serum concentration of Brexpiprazole can be increased when it is combined with Desipramine.,DB07682,Brexpiprazole,DB09128
The therapeutic efficacy of Candicidin can be increased when used in combination with Menthol.,APRD00843,Menthol,DB00825
The therapeutic efficacy of Sertaconazole can be increased when used in combination with Menthol.,APRD00305,Menthol,DB00825
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.,APRD00154,Doxylamine,DB00366
Gemifloxacin may increase the QTc-prolonging activities of Delamanid.,APRD00053,Delamanid,DB11637
The serum concentration of Bupropion can be increased when it is combined with Curcumin.,APRD00621,Curcumin,DB11672
The therapeutic efficacy of Trimetrexate can be increased when used in combination with Menthol.,APRD00268,Menthol,DB00825
Yohimbine may decrease the antihypertensive activities of Bretylium.,APRD00830,Yohimbine,DB01392
The serum concentration of Halothane can be increased when it is combined with Dasatinib.,DB02330,Dasatinib,DB01254
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Palmidrol.,APRD00926,Palmidrol,DB14043
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.,APRD00404,Doxylamine,DB00366
The serum concentration of Brentuximab vedotin can be increased when it is combined with Terazosin.,APRD00667,Brentuximab vedotin,DB08870
The serum concentration of Methotrexate can be increased when it is combined with Amdinocillin.,APRD00789,Methotrexate,DB00563
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Chloride.,APRD00840,Menthol,DB00825
Ofloxacin may increase the QTc-prolonging activities of Delamanid.,APRD00502,Delamanid,DB11637
Cilostazol may increase the QTc-prolonging activities of Delamanid.,APRD00155,Delamanid,DB11637
Itraconazole may increase the QTc-prolonging activities of Delamanid.,APRD00040,Delamanid,DB11637
Procarbazine may increase the hypertensive activities of Norepinephrine.,APRD00695,Norepinephrine,DB00368
Arsenic trioxide may increase the QTc-prolonging activities of Delamanid.,APRD00171,Delamanid,DB11637
Iloprost may increase the hypotensive activities of Guanethidine.,APRD01007,Iloprost,DB01088
Moclobemide may increase the hypertensive activities of Norepinephrine.,APRD00603,Norepinephrine,DB00368
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Kanamycin.,APRD00026,Digoxin Immune Fab (Ovine),DB00076
The serum concentration of Orphenadrine can be increased when it is combined with Dasatinib.,APRD00097,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.,APRD00184,Doxylamine,DB00366
The serum concentration of Escitalopram can be increased when it is combined with Dasatinib.,APRD00683,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.,APRD00061,Doxylamine,DB00366
The serum concentration of Idarubicin can be decreased when it is combined with Apalutamide.,APRD00126,Apalutamide,DB11901
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.,APRD00865,Doxylamine,DB00366
The serum concentration of Podofilox can be increased when it is combined with Dasatinib.,DB08417,Dasatinib,DB01254
Trimethoprim may increase the hyperkalemic activities of Rescinnamine.,APRD00112,Trimethoprim,DB00440
The serum concentration of Ifosfamide can be increased when it is combined with Dasatinib.,APRD00007,Dasatinib,DB01254
The serum concentration of Propafenone can be increased when it is combined with Dasatinib.,APRD00261,Dasatinib,DB01254
The serum concentration of Naloxone can be increased when it is combined with Dasatinib.,APRD00025,Dasatinib,DB01254
The serum concentration of Domperidone can be increased when it is combined with Dasatinib.,APRD00418,Dasatinib,DB01254
Fluticasone may increase the fluid retaining activities of Fluoxymesterone.,APRD00981,Fluticasone,DB13867
The serum concentration of Pergolide can be increased when it is combined with Dasatinib.,APRD00663,Dasatinib,DB01254
The therapeutic efficacy of Ciclopirox can be increased when used in combination with Menthol.,APRD00871,Menthol,DB00825
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.,APRD00907,Doxylamine,DB00366
The serum concentration of Clindamycin can be increased when it is combined with Dasatinib.,APRD00566,Dasatinib,DB01254
The serum concentration of Dexfenfluramine can be decreased when it is combined with Osimertinib.,APRD00648,Osimertinib,DB09330
Oxymorphone may increase the constipating activities of Ramosetron.,APRD00158,Ramosetron,DB09290
Acebutolol may increase the hypoglycemic activities of Metahexamide.,APRD00772,Metahexamide,DB13675
The serum concentration of Brinzolamide can be increased when it is combined with Dasatinib.,APRD00475,Dasatinib,DB01254
Flecainide may increase the QTc-prolonging activities of Delamanid.,APRD00129,Delamanid,DB11637
The serum concentration of Estramustine can be increased when it is combined with Dasatinib.,APRD00625,Dasatinib,DB01254
Trimethoprim may increase the hyperkalemic activities of Captopril.,APRD00164,Trimethoprim,DB00440
The serum concentration of Zopiclone can be increased when it is combined with Dasatinib.,APRD00356,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Nicomorphine.,APRD00176,Nicomorphine,DB13454
The serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.,APRD00622,Dasatinib,DB01254
The metabolism of Barbexaclone can be increased when combined with Rifapentine.,APRD01217,Barbexaclone,DB09001
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.,APRD01068,Doxylamine,DB00366
Nadolol may increase the hypoglycemic activities of Metahexamide.,APRD00301,Metahexamide,DB13675
The serum concentration of Mitoxantrone can be increased when it is combined with Teriflunomide.,APRD00371,Teriflunomide,DB08880
Flumazenil may decrease the sedative activities of Tasimelteon.,APRD00974,Tasimelteon,DB09071
The serum concentration of Rilpivirine can be increased when it is combined with Lomustine.,APRD00292,Rilpivirine,DB08864
Ridogrel may increase the antiplatelet activities of Relcovaptan.,APRD00271,Relcovaptan,DB13929
Sparfloxacin may increase the QTc-prolonging activities of Delamanid.,APRD01231,Delamanid,DB11637
Dezocine may increase the constipating activities of Ramosetron.,APRD00912,Ramosetron,DB09290
Levobunolol may increase the hypoglycemic activities of Metahexamide.,APRD00165,Metahexamide,DB13675
Clarithromycin may increase the QTc-prolonging activities of Delamanid.,APRD00181,Delamanid,DB11637
The serum concentration of Ceftriaxone can be increased when it is combined with Probenecid.,APRD00395,Probenecid,DB01032
The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Fomepizole resulting in a loss in efficacy.,APRD00985,Artesunate,DB09274
Metipranolol may increase the hypoglycemic activities of Metahexamide.,APRD00668,Metahexamide,DB13675
The serum concentration of Estazolam can be increased when it is combined with Dasatinib.,APRD00955,Dasatinib,DB01254
The serum concentration of Finasteride can be increased when it is combined with Dasatinib.,DB07774,Dasatinib,DB01254
The serum concentration of Rilpivirine can be increased when it is combined with Anastrozole.,APRD00016,Rilpivirine,DB08864
The serum concentration of Halofantrine can be increased when it is combined with Dasatinib.,APRD00419,Dasatinib,DB01254
The serum concentration of Dantrolene can be increased when it is combined with Dasatinib.,APRD00901,Dasatinib,DB01254
The metabolism of Barbexaclone can be increased when combined with Rifaximin.,APRD01218,Barbexaclone,DB09001
The serum concentration of Ketamine can be increased when it is combined with Dasatinib.,APRD00493,Dasatinib,DB01254
The serum concentration of Budesonide can be increased when it is combined with Dasatinib.,APRD00442,Dasatinib,DB01254
The serum concentration of Aminophylline can be increased when it is combined with Dasatinib.,APRD00329,Dasatinib,DB01254
The serum concentration of Quetiapine can be increased when it is combined with Dasatinib.,APRD00675,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Enoxaparin is combined with Azficel-T.,APRD00068,Azficel-T,DB11051
Vancomycin may increase the neuromuscular blocking activities of Mivacurium.,APRD01119,Vancomycin,DB00512
Levomethadyl Acetate may increase the constipating activities of Ramosetron.,APRD00745,Ramosetron,DB09290
The serum concentration of Encainide can be decreased when it is combined with Peginterferon alfa-2b.,APRD00613,Peginterferon alfa-2b,DB00022
The serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.,DB05526,Dasatinib,DB01254
Saquinavir may increase the QTc-prolonging activities of Delamanid.,APRD00623,Delamanid,DB11637
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Epibatidine.,APRD00665,Epibatidine,DB07720
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone.,APRD00674,Corticorelin ovine triflutate,DB09067
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.,EXPT01107,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.,APRD00219,Doxylamine,DB00366
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Bromodiphenhydramine.",APRD00710,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.,APRD00638,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.,APRD00718,Doxylamine,DB00366
The serum concentration of Epoprostenol can be decreased when it is combined with Apalutamide.,APRD00949,Apalutamide,DB11901
The serum concentration of Gemfibrozil can be increased when it is combined with Dasatinib.,APRD00293,Dasatinib,DB01254
The serum concentration of Clomipramine can be increased when it is combined with Dasatinib.,DB07600,Dasatinib,DB01254
The therapeutic efficacy of Chloroxine can be increased when used in combination with Menthol.,APRD00866,Menthol,DB00825
Bepridil may increase the QTc-prolonging activities of Delamanid.,APRD00727,Delamanid,DB11637
The risk or severity of adverse effects can be increased when Decamethonium is combined with Epibatidine.,APRD00696,Epibatidine,DB07720
Alimemazine may increase the hypotensive activities of Nicomorphine.,APRD00258,Nicomorphine,DB13454
Isocarboxazid may increase the hypertensive activities of Norepinephrine.,APRD00701,Norepinephrine,DB00368
The serum concentration of Docetaxel can be increased when it is combined with Dasatinib.,APRD00932,Dasatinib,DB01254
The risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.,DB01249,Aldesleukin,DB00041
The risk or severity of adverse effects can be increased when Olsalazine is combined with Pitolisant.,DB01250,Pitolisant,DB11642
The serum concentration of Gliquidone can be increased when it is combined with Voriconazole.,DB01251,Voriconazole,DB00582
Mitiglinide may increase the hypoglycemic activities of Insulin Glulisine.,DB01252,Insulin Glulisine,DB01309
The serum concentration of Ergonovine can be increased when it is combined with Dasatinib.,DB01253,Dasatinib,DB01254
The serum concentration of Avatrombopag can be increased when it is combined with Dasatinib.,DB01254,Avatrombopag,DB11995
Iprindole may increase the stimulatory activities of Lisdexamfetamine.,DB01255,Iprindole,DB13496
The serum concentration of Retapamulin can be increased when it is combined with Dasatinib.,DB01256,Dasatinib,DB01254
Trastuzumab may increase the neutropenic activities of Eculizumab.,DB01257,Trastuzumab,DB00072
The serum concentration of Lapatinib can be increased when it is combined with Dasatinib.,DB02584,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desonide.,DB01260,Corticorelin ovine triflutate,DB09067
The serum concentration of Sitagliptin can be increased when it is combined with Dasatinib.,DB07214,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Decitabine.,DB01262,Cyclophosphamide,DB00531
Posaconazole may increase the QTc-prolonging activities of Delamanid.,DB01263,Delamanid,DB11637
Darunavir may increase the QTc-prolonging activities of Delamanid.,EXPT00002,Delamanid,DB11637
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.,DB01265,Peginterferon alfa-2b,DB00022
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.,DB01267,Doxylamine,DB00366
The serum concentration of Sunitinib can be increased when it is combined with Dasatinib.,DB07417,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Panitumumab.,DB01269,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Ranibizumab.,DB01270,Cyclophosphamide,DB00531
Varenicline may decrease the anticholinergic activities of Cimetropium.,DB01273,Cimetropium,DB09271
The metabolism of Arformoterol can be decreased when combined with Nicotine.,DB01274,Nicotine,DB00184
Yohimbine may decrease the antihypertensive activities of Hydralazine.,DB01275,Yohimbine,DB01392
Trolamine salicylate may increase the hypoglycemic activities of Exenatide.,DB01276,Trolamine salicylate,DB11079
Trolamine salicylate may increase the hypoglycemic activities of Mecasermin.,DB01277,Trolamine salicylate,DB11079
Trolamine salicylate may increase the hypoglycemic activities of Pramlintide.,DB01278,Trolamine salicylate,DB11079
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nelarabine.,DB01280,Sipuleucel-T,DB06688
Trastuzumab may increase the neutropenic activities of Abatacept.,DB01281,Trastuzumab,DB00072
Carbetocin may increase the hypotensive activities of Risperidone.,DB01282,Risperidone,DB00734
The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pitolisant.,DB01283,Pitolisant,DB11642
Tetracosactide may increase the hepatotoxic activities of Clonazepam.,DB01284,Clonazepam,DB01068
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Corticotropin.",DB09547,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
Nabilone may increase the tachycardic activities of Fenoterol.,DB01288,Nabilone,DB00486
The serum concentration of Glisoxepide can be increased when it is combined with Voriconazole.,DB01289,Voriconazole,DB00582
Racepinephrine may decrease the vasoconstricting activities of Pirbuterol.,DB01291,Racepinephrine,DB11124
The serum concentration of Tetracycline can be decreased when it is combined with Bismuth Subsalicylate.,DB01402,Tetracycline,DB00759
Bevantolol may increase the hypoglycemic activities of Metahexamide.,DB01295,Metahexamide,DB13675
Glucosamine may increase the antiplatelet activities of Ticagrelor.,EXPT01563,Ticagrelor,DB08816
Practolol may increase the hypoglycemic activities of Metahexamide.,DB01297,Metahexamide,DB13675
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfacytine.,DB01298,Dexketoprofen,DB09214
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfadoxine.,DB01299,Dexketoprofen,DB09214
The serum concentration of Rilpivirine can be increased when it is combined with Rolitetracycline.,DB01301,Rilpivirine,DB08864
The serum concentration of Oxtriphylline can be decreased when it is combined with Osimertinib.,DB01303,Osimertinib,DB09330
Trolamine salicylate may increase the hypoglycemic activities of Insulin Aspart.,DB01306,Trolamine salicylate,DB11079
Trolamine salicylate may increase the hypoglycemic activities of Insulin Detemir.,DB01307,Trolamine salicylate,DB11079
Trolamine salicylate may increase the hypoglycemic activities of Insulin Glulisine.,DB01309,Trolamine salicylate,DB11079
The serum concentration of Fosamprenavir can be increased when it is combined with Dasatinib.,DB01319,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.,DB01320,Doxylamine,DB00366
The serum concentration of Rilpivirine can be increased when it is combined with Josamycin.,DB01321,Rilpivirine,DB08864
The serum concentration of Digoxin can be decreased when it is combined with St. John's Wort.,DB01323,Digoxin,DB00390
Iloprost may increase the hypotensive activities of Polythiazide.,DB01324,Iloprost,DB01088
Alaproclate may increase the hyponatremic activities of Quinethazone.,DB01325,Alaproclate,DB13233
The serum concentration of Cefamandole can be increased when it is combined with Probenecid.,DB01326,Probenecid,DB01032
The serum concentration of Cefazolin can be increased when it is combined with Teriflunomide.,DB01327,Teriflunomide,DB08880
The serum concentration of Cefonicid can be increased when it is combined with Probenecid.,DB01328,Probenecid,DB01032
The serum concentration of Cefoperazone can be increased when it is combined with Probenecid.,DB01329,Probenecid,DB01032
The risk or severity of adverse effects can be increased when Cefotetan is combined with Carbocisteine.,DB01330,Carbocisteine,DB04339
The serum concentration of Cefoxitin can be increased when it is combined with Probenecid.,EXPT00897,Probenecid,DB01032
The serum concentration of Ceftizoxime can be increased when it is combined with Probenecid.,DB01332,Probenecid,DB01032
The serum concentration of Saxagliptin can be decreased when it is combined with Cefradine.,DB01333,Saxagliptin,DB06335
Vancomycin may increase the neuromuscular blocking activities of Metocurine.,DB01336,Vancomycin,DB00512
The risk or severity of adverse effects can be increased when Pancuronium is combined with Nicomorphine.,DB01337,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Pipecuronium is combined with Nicomorphine.,DB01338,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Vecuronium is combined with Nicomorphine.,DB01339,Nicomorphine,DB13454
Trimethoprim may increase the hyperkalemic activities of Cilazapril.,DB01340,Trimethoprim,DB00440
Trimethoprim may increase the hyperkalemic activities of Forasartan.,DB01342,Trimethoprim,DB00440
The serum concentration of Lithium can be decreased when it is combined with Tolevamer.,DB06658,Lithium,DB01356
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Potassium.,DB01345,Nicomorphine,DB13454
Iloprost may increase the hypotensive activities of Saprisartan.,DB01347,Iloprost,DB01088
Trimethoprim may increase the hyperkalemic activities of Spirapril.,DB01348,Trimethoprim,DB00440
The serum concentration of Tasosartan can be increased when it is combined with Dasatinib.,DB01349,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.,DB01351,Doxylamine,DB00366
The risk or severity of sedation and somnolence can be increased when Aprobarbital is combined with Deutetrabenazine.,DB01352,Deutetrabenazine,DB12161
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butethal.,DB01353,Doxylamine,DB00366
The risk or severity of sedation and somnolence can be increased when Heptabarbital is combined with Deutetrabenazine.,DB01354,Deutetrabenazine,DB12161
The serum concentration of Hexobarbital can be increased when it is combined with Dasatinib.,EXPT03301,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium.,DB01356,Doxylamine,DB00366
The serum concentration of Mestranol can be decreased when it is combined with Apalutamide.,DB01357,Apalutamide,DB11901
Penbutolol may increase the hypoglycemic activities of Metahexamide.,DB01359,Metahexamide,DB13675
The risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.,DB01362,Aldesleukin,DB00041
Ephedra may increase the hypertensive activities of Droxidopa.,DB01363,Droxidopa,DB06262
Nabilone may increase the tachycardic activities of Ephedrine.,DB01364,Nabilone,DB00486
The serum concentration of Mephentermine can be decreased when it is combined with Methenamine.,DB01365,Methenamine,DB06799
Nabilone may increase the tachycardic activities of Procaterol.,DB01366,Nabilone,DB00486
Rasagiline may increase the hypertensive activities of Norepinephrine.,EXPT02758,Norepinephrine,DB00368
The serum concentration of Rilpivirine can be increased when it is combined with Quinupristin.,DB01369,Rilpivirine,DB08864
The serum concentration of Mevastatin can be decreased when it is combined with Aluminium.,DB11314,Mevastatin,DB06693
The serum concentration of Mevastatin can be decreased when it is combined with Magnesium oxide.,DB01377,Mevastatin,DB06693
The serum concentration of Cortisone acetate can be increased when it is combined with Dasatinib.,DB01380,Dasatinib,DB01254
The serum concentration of Efavirenz can be decreased when it is combined with Ginkgo biloba.,DB01381,Efavirenz,DB00625
The serum concentration of Paramethasone can be increased when it is combined with Dasatinib.,DB01384,Dasatinib,DB01254
The serum concentration of Mibefradil can be increased when it is combined with Dasatinib.,DB01388,Dasatinib,DB01254
The serum concentration of Mevastatin can be decreased when it is combined with Sodium bicarbonate.,DB01390,Mevastatin,DB06693
The serum concentration of Yohimbine can be increased when it is combined with Dasatinib.,DB01392,Dasatinib,DB01254
The serum concentration of Bezafibrate can be increased when it is combined with Dasatinib.,DB08380,Dasatinib,DB01254
The serum concentration of Brentuximab vedotin can be increased when it is combined with Colchicine.,DB01394,Brentuximab vedotin,DB08870
Candoxatril may increase the hyperkalemic activities of Drospirenone.,DB01395,Candoxatril,DB00616
The serum concentration of Digitoxin can be increased when it is combined with Dasatinib.,DB01396,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pitolisant.,DB01397,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Salsalate is combined with Pitolisant.,DB01399,Pitolisant,DB11642
The serum concentration of Brentuximab vedotin can be increased when it is combined with Neostigmine.,DB01400,Brentuximab vedotin,DB08870
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pitolisant.,DB01401,Pitolisant,DB11642
Methotrimeprazine may increase the hypotensive activities of Nicomorphine.,DB01403,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Fluticasone is combined with Ginseng.,DB01404,Fluticasone,DB13867
Temafloxacin may increase the QTc-prolonging activities of Delamanid.,DB01405,Delamanid,DB11637
Fluticasone may increase the fluid retaining activities of Danazol.,DB01406,Fluticasone,DB13867
Nabilone may increase the tachycardic activities of Clenbuterol.,DB01407,Nabilone,DB00486
Racepinephrine may decrease the vasoconstricting activities of Bambuterol.,DB01408,Racepinephrine,DB11124
The serum concentration of Tiotropium can be increased when it is combined with Dasatinib.,DB01409,Dasatinib,DB01254
The serum concentration of Ciclesonide can be increased when it is combined with Dasatinib.,DB01410,Dasatinib,DB01254
The serum concentration of Pranlukast can be increased when it is combined with Curcumin.,DB01411,Curcumin,DB11672
The serum concentration of Theobromine can be decreased when it is combined with Osimertinib.,DB01412,Osimertinib,DB09330
The serum concentration of Cefepime can be increased when it is combined with Probenecid.,DB01413,Probenecid,DB01032
The serum concentration of Cefacetrile can be increased when it is combined with Teriflunomide.,DB01414,Teriflunomide,DB08880
The serum concentration of Ceftibuten can be increased when it is combined with Probenecid.,DB01415,Probenecid,DB01032
Promethazine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB01416,Promethazine,DB01069
The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Azficel-T.,DB01418,Azficel-T,DB11051
The risk or severity of adverse effects can be increased when Fluticasone is combined with Antrafenine.,DB01419,Fluticasone,DB13867
The serum concentration of Testosterone propionate can be increased when it is combined with Dasatinib.,DBSALT001032,Dasatinib,DB01254
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Paromomycin.,DB01421,Digoxin Immune Fab (Ovine),DB00076
The therapeutic efficacy of Nitroxoline can be increased when used in combination with Menthol.,DB01422,Menthol,DB00825
Trastuzumab may increase the neutropenic activities of Stepronin.,DB01423,Trastuzumab,DB00072
The serum concentration of Aminophenazone can be increased when it is combined with Dasatinib.,DB01424,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Alizapride is combined with Deutetrabenazine.,DB01425,Deutetrabenazine,DB12161
The serum concentration of Ajmaline can be decreased when it is combined with Peginterferon alfa-2b.,DB01426,Peginterferon alfa-2b,DB00022
The risk or severity of hypotension can be increased when Racepinephrine is combined with Amrinone.,DB01427,Racepinephrine,DB11124
The serum concentration of Aprindine can be decreased when it is combined with Peginterferon alfa-2b.,DB01429,Peginterferon alfa-2b,DB00022
The serum concentration of Allylestrenol can be increased when it is combined with Dasatinib.,DB01431,Dasatinib,DB01254
Cholestyramine can cause a decrease in the absorption of Fluticasone resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB01432,Fluticasone,DB13867
Methadyl Acetate may increase the constipating activities of Ramosetron.,DB01433,Ramosetron,DB09290
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 19-norandrostenedione.,DB01434,Corticorelin ovine triflutate,DB09067
The serum concentration of Antipyrine can be increased when it is combined with Dasatinib.,DB01435,Dasatinib,DB01254
Alfacalcidol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).,DB01436,Digoxin Immune Fab (Ovine),DB00076
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.,DB01437,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Phenazopyridine is combined with Nitrous acid.,DB01438,Nitrous acid,DB09112
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.,DB01440,Doxylamine,DB00366
Amoxapine may increase the stimulatory activities of MMDA.,DB01442,Amoxapine,DB00543
The therapeutic efficacy of Bufotenine can be increased when used in combination with Isocarboxazid.,DB01445,Isocarboxazid,DB01247
Dihydroetorphine may increase the constipating activities of Ramosetron.,DB01450,Ramosetron,DB09290
Heroin may increase the constipating activities of Ramosetron.,DB01452,Ramosetron,DB09290
Amoxapine may increase the stimulatory activities of Midomafetamine.,DB01454,Amoxapine,DB00543
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 5-androstenedione.,DB01456,Corticorelin ovine triflutate,DB09067
Bezitramide may increase the constipating activities of Ramosetron.,DB01459,Ramosetron,DB09290
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.,DB01463,Doxylamine,DB00366
Ethylmorphine may increase the constipating activities of Ramosetron.,DB01466,Ramosetron,DB09290
"Amoxapine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.",DB01467,Amoxapine,DB00543
The serum concentration of Fentanyl can be decreased when it is combined with 4-Methoxyamphetamine.,EXPT03303,Fentanyl,DB00813
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital.,DB01483,Doxylamine,DB00366
"Amoxapine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.",DB01484,Amoxapine,DB00543
The therapeutic efficacy of Dimethyltryptamine can be increased when used in combination with Isocarboxazid.,DB01488,Isocarboxazid,DB01247
The therapeutic efficacy of Camazepam can be decreased when used in combination with Yohimbine.,DB01489,Yohimbine,DB01392
The risk or severity of sedation and somnolence can be increased when Dichloralphenazone is combined with Deutetrabenazine.,DB01495,Deutetrabenazine,DB12161
Etorphine may increase the constipating activities of Ramosetron.,DB01497,Ramosetron,DB09290
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.,DB01501,Doxylamine,DB00366
"Amoxapine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.",DB01509,Amoxapine,DB00543
The risk or severity of sedation can be increased when Lorpiprazole is combined with Delorazepam.,DB01511,Lorpiprazole,DB09195
The risk or severity of adverse effects can be increased when Tenocyclidine is combined with Memantine.,DB01520,Memantine,DB01043
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.,DB01525,Doxylamine,DB00366
Dextromoramide may increase the constipating activities of Ramosetron.,DB01529,Ramosetron,DB09290
Carfentanil may increase the constipating activities of Ramosetron.,DB01535,Ramosetron,DB09290
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Androstenedione.,DB07386,Corticorelin ovine triflutate,DB09067
The serum concentration of Flunitrazepam can be increased when it is combined with Dasatinib.,DB01544,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.,DB01545,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.,DB01547,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Diprenorphine is combined with Naloxegol.,DB01548,Naloxegol,DB09049
Dihydrocodeine may increase the constipating activities of Ramosetron.,DB01551,Ramosetron,DB09290
The therapeutic efficacy of Cloxazolam can be decreased when used in combination with Yohimbine.,DB01553,Yohimbine,DB01392
Alphacetylmethadol may increase the constipating activities of Ramosetron.,DB01555,Ramosetron,DB09290
Amoxapine may increase the stimulatory activities of Chlorphentermine.,DB01556,Amoxapine,DB00543
The serum concentration of Bromazepam can be increased when it is combined with Dasatinib.,DB01558,Dasatinib,DB01254
The serum concentration of Clotiazepam can be increased when it is combined with Dasatinib.,DB01559,Dasatinib,DB01254
The therapeutic efficacy of Cathinone can be increased when used in combination with Isocarboxazid.,DB01560,Isocarboxazid,DB01247
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.,DB01563,Doxylamine,DB00366
Dihydromorphine may increase the constipating activities of Ramosetron.,DB01565,Ramosetron,DB09290
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.,DB01567,Doxylamine,DB00366
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Kaolin.,DB01575,Digoxin Immune Fab (Ovine),DB00076
Iprindole may increase the stimulatory activities of Dextroamphetamine.,DB01576,Iprindole,DB13496
The serum concentration of Methamphetamine can be decreased when it is combined with Methenamine.,DB01577,Methenamine,DB06799
The serum concentration of Fentanyl can be decreased when it is combined with Phendimetrazine.,DB01579,Fentanyl,DB00813
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.,DB01580,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamerazine.,DB01581,Dexketoprofen,DB09214
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamethazine.,DB01582,Dexketoprofen,DB09214
The serum concentration of Liotrix can be decreased when it is combined with Apalutamide.,DB01583,Apalutamide,DB11901
The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Aluminium clofibrate.,DB01586,Aluminium clofibrate,DB13780
The serum concentration of Ketazolam can be increased when it is combined with Dasatinib.,DB01587,Dasatinib,DB01254
The serum concentration of Prazepam can be increased when it is combined with Dasatinib.,DB01588,Dasatinib,DB01254
The serum concentration of Quazepam can be increased when it is combined with Dasatinib.,DB01589,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Everolimus is combined with Candoxatril.,DB01590,Candoxatril,DB00616
The serum concentration of Solifenacin can be increased when it is combined with Dasatinib.,APRD00168,Dasatinib,DB01254
Promethazine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB01592,Promethazine,DB01069
The serum concentration of Dolutegravir can be decreased when it is combined with Zinc.,DB01593,Dolutegravir,DB08930
The risk or severity of sedation and somnolence can be increased when Cinolazepam is combined with Deutetrabenazine.,DB01594,Deutetrabenazine,DB12161
The serum concentration of Nitrazepam can be increased when it is combined with Dasatinib.,DB01595,Dasatinib,DB01254
The serum concentration of Zidovudine can be decreased when it is combined with Cilastatin.,EXPT00918,Zidovudine,DB00495
The serum concentration of Imipenem can be increased when it is combined with Probenecid.,DB01598,Probenecid,DB01032
Probucol may increase the QTc-prolonging activities of Delamanid.,DB01599,Delamanid,DB11637
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pitolisant.,DB01600,Pitolisant,DB11642
Lopinavir may increase the QTc-prolonging activities of Delamanid.,EXPT00388,Delamanid,DB11637
The serum concentration of Methotrexate can be increased when it is combined with Bacampicillin.,DB01602,Methotrexate,DB00563
The serum concentration of Methotrexate can be increased when it is combined with Meticillin.,DB01603,Methotrexate,DB00563
The serum concentration of Methotrexate can be increased when it is combined with Pivampicillin.,DB01604,Methotrexate,DB00563
The serum concentration of Methotrexate can be increased when it is combined with Pivmecillinam.,DB01605,Methotrexate,DB00563
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tazobactam.,EXPT03012,Picosulfuric acid,DB09268
The serum concentration of Methotrexate can be increased when it is combined with Ticarcillin.,DB01607,Methotrexate,DB00563
Propericiazine may increase the hypotensive activities of Nicomorphine.,DB01608,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.,DB01609,Betamethasone,DB00443
The serum concentration of Valganciclovir can be increased when it is combined with Mycophenolic acid.,DB01610,Mycophenolic acid,DB01024
The serum concentration of Ivermectin can be decreased when it is combined with Hydroxychloroquine.,DB01611,Ivermectin,DB00602
Amyl Nitrite may increase the hypotensive activities of Risperidone.,DB01612,Risperidone,DB00734
The risk or severity of adverse effects can be increased when Erythrityl Tetranitrate is combined with Rosiglitazone.,DB01613,Rosiglitazone,DB00412
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.,DB01614,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.,DB01615,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Molindone.,DB01618,Doxylamine,DB00366
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Phenindamine.",DB01619,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Pheniramine.",DB01620,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Pipotiazine can be increased when it is combined with Dasatinib.,DB01621,Dasatinib,DB01254
Thioproperazine may increase the hypotensive activities of Nicomorphine.,DB01622,Nicomorphine,DB13454
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.,DB01623,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.,DB08920,Doxylamine,DB00366
Pargyline may increase the hypertensive activities of Norepinephrine.,DB01626,Norepinephrine,DB00368
The serum concentration of Doxofylline can be increased when it is combined with Lincomycin.,DB01627,Doxofylline,DB09273
The serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.,DB07166,Dasatinib,DB01254
The serum concentration of Brentuximab vedotin can be increased when it is combined with Genistein.,EXPT01582,Brentuximab vedotin,DB08870
Roflumilast may increase the hypotensive activities of Riociguat.,EXPT02802,Riociguat,DB08931
Cyclophosphamide may increase the cardiotoxic activities of 8-azaguanine.,EXPT00603,Cyclophosphamide,DB00531
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Virginiamycin M1.,EXPT03225,Picosulfuric acid,DB09268
The serum concentration of Zidovudine can be decreased when it is combined with Chymostatin.,EXPT00915,Zidovudine,DB00495
The serum concentration of Rilpivirine can be increased when it is combined with Topiroxostat.,EXPT01517,Rilpivirine,DB08864
The serum concentration of Rilpivirine can be increased when it is combined with Rutin.,EXPT02824,Rilpivirine,DB08864
AICA ribonucleotide may increase the hypoglycemic activities of Insulin Glulisine.,EXPT00407,Insulin Glulisine,DB01309
The serum concentration of Prasterone can be increased when it is combined with Dasatinib.,DB06593,Dasatinib,DB01254
The serum concentration of Rilpivirine can be increased when it is combined with Dalfopristin.,EXPT01246,Rilpivirine,DB08864
The risk or severity of adverse effects can be increased when Castanospermine is combined with Pitolisant.,EXPT01055,Pitolisant,DB11642
The risk or severity of rhabdomyolysis can be increased when Epothilone D is combined with Mevastatin.,EXPT01350,Mevastatin,DB06693
Benzophenone may increase the photosensitizing activities of Verteporfin.,EXPT00794,Verteporfin,DB00460
The therapeutic efficacy of Sinefungin can be increased when used in combination with Menthol.,EXPT02890,Menthol,DB00825
Cyclophosphamide may increase the cardiotoxic activities of 7-Hydroxystaurosporine.,EXPT03167,Cyclophosphamide,DB00531
The therapeutic efficacy of Rolipram can be increased when used in combination with Isocarboxazid.,EXPT02804,Isocarboxazid,DB01247
The serum concentration of Brentuximab vedotin can be increased when it is combined with Staurosporine.,EXPT02972,Brentuximab vedotin,DB08870
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with SU4984.,EXPT02973,Vemurafenib,DB08881
Cyclophosphamide may increase the cardiotoxic activities of Hadacidin.,EXPT01711,Cyclophosphamide,DB00531
The serum concentration of Topotecan can be increased when it is combined with Daidzin.,EXPT01311,Topotecan,DB01030
Glycochenodeoxycholic Acid may decrease the excretion rate of Cholic Acid which could result in a higher serum level.,EXPT00909,Cholic Acid,DB02659
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Phenylacetaldehyde.,EXPT01801,Calcium carbimide,DB09116
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Equilin.,EXPT01355,Corticorelin ovine triflutate,DB09067
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.,EXPT00314,Doxylamine,DB00366
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Maltotetraose.,EXPT02252,Picosulfuric acid,DB09268
The serum concentration of Zidovudine can be decreased when it is combined with GM6001.,EXPT01618,Zidovudine,DB00495
Platelet Activating Factor may increase the hypoglycemic activities of Metahexamide.,EXPT02559,Metahexamide,DB13675
Cyclophosphamide may increase the cardiotoxic activities of Formycin.,EXPT01453,Cyclophosphamide,DB00531
The serum concentration of Thioproperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.,EXPT02241,Thioproperazine,DB01622
Protoporphyrin may increase the photosensitizing activities of Verteporfin.,EXPT02636,Verteporfin,DB00460
The risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcipotriol.,EXPT02131,Calcium Carbonate,DB06724
The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Palmidrol.,EXPT01314,Palmidrol,DB14043
Cyclophosphamide may increase the cardiotoxic activities of 2-Methoxyestradiol.,EXPT01362,Cyclophosphamide,DB00531
"The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Epibatidine.",EXPT02592,Epibatidine,DB07720
The serum concentration of Zidovudine can be decreased when it is combined with Geldanamycin.,EXPT01571,Zidovudine,DB00495
The therapeutic efficacy of Thymol can be increased when used in combination with Menthol.,EXPT01913,Menthol,DB00825
Ditiocarb can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,EXPT01132,Technetium Tc-99m oxidronate,DB09139
The serum concentration of Cyclic Adenosine Monophosphate can be increased when it is combined with Teriflunomide.,EXPT00959,Teriflunomide,DB08880
Valproic Acid may increase the thrombocytopenic activities of Vorinostat.,EXPT02902,Valproic Acid,DB00313
The serum concentration of Zidovudine can be decreased when it is combined with Phosphoramidon.,EXPT02764,Zidovudine,DB00495
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PD173955.,EXPT02468,Vemurafenib,DB08881
The serum concentration of Brentuximab vedotin can be increased when it is combined with Colforsin.,EXPT01467,Brentuximab vedotin,DB08870
Terlipressin may increase the QTc-prolonging activities of Delamanid.,EXPT03310,Delamanid,DB11637
Cyclophosphamide may increase the cardiotoxic activities of Fumagillin.,EXPT01509,Cyclophosphamide,DB00531
The serum concentration of Cholic Acid can be decreased when it is combined with Apalutamide.,EXPT00906,Apalutamide,DB11901
The serum concentration of Rilpivirine can be increased when it is combined with Nicotinamide.,EXPT02307,Rilpivirine,DB08864
The serum concentration of Tioclomarol can be increased when it is combined with Fusidic Acid.,EXPT01507,Tioclomarol,DB13451
The risk or severity of adverse effects can be increased when Resveratrol is combined with Pitolisant.,EXPT02968,Pitolisant,DB11642
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Pregnenolone.,EXPT02608,Corticorelin ovine triflutate,DB09067
Trastuzumab may increase the neutropenic activities of 2-Methoxyethanol.,EXPT02260,Trastuzumab,DB00072
Vancomycin may increase the neuromuscular blocking activities of Domoic Acid.,EXPT01248,Vancomycin,DB00512
The serum concentration of Zidovudine can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.,EXPT00003,Zidovudine,DB00495
The therapeutic efficacy of Calyculin A can be decreased when used in combination with Patent Blue.,EXPT01080,Patent Blue,DB13967
Cyclophosphamide may increase the cardiotoxic activities of Arotinoid acid.,EXPT03128,Cyclophosphamide,DB00531
The serum concentration of Stanolone can be decreased when it is combined with Apalutamide.,EXPT01199,Apalutamide,DB11901
The therapeutic efficacy of Piretanide can be decreased when used in combination with Trolamine salicylate.,EXPT03308,Trolamine salicylate,DB11079
The therapeutic efficacy of Oxitriptan can be increased when used in combination with Isocarboxazid.,EXPT01780,Isocarboxazid,DB01247
The serum concentration of Benzimidazole can be decreased when it is combined with Tafenoquine.,EXPT00791,Tafenoquine,DB06608
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with GE-2270A.,EXPT01578,Picosulfuric acid,DB09268
Cyclophosphamide may increase the cardiotoxic activities of Arsanilic acid.,EXPT00575,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Patupilone.,EXPT01349,Cyclophosphamide,DB00531
Nitrilotriacetic Acid can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,EXPT02390,Technetium Tc-99m oxidronate,DB09139
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Malonaldehyde.,EXPT02141,Calcium carbimide,DB09116
Cyclophosphamide may increase the cardiotoxic activities of 3-Methoxybenzamide.,EXPT00177,Cyclophosphamide,DB00531
The serum concentration of Zidovudine can be decreased when it is combined with Benzamidine.,EXPT00669,Zidovudine,DB00495
Acetylcholine may decrease the anticholinergic activities of Cimetropium.,EXPT00412,Cimetropium,DB09271
Cyclophosphamide may increase the cardiotoxic activities of Tubercidin.,EXPT03017,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Phosphonoacetaldehyde.,EXPT02628,Calcium carbimide,DB09116
The serum concentration of Sphingosine can be decreased when it is combined with Apalutamide.,EXPT02945,Apalutamide,DB11901
Phenol may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.,EXPT01917,Technetium Tc-99m tilmanocept,DB09266
The serum concentration of Zidovudine can be decreased when it is combined with Enalkiren.,EXPT03298,Zidovudine,DB00495
Hemin may increase the anticoagulant activities of Lepirudin.,EXPT01720,Lepirudin,DB00001
The serum concentration of Zidovudine can be decreased when it is combined with Ubenimex.,EXPT00673,Zidovudine,DB00495
Cyclophosphamide may increase the cardiotoxic activities of Sparfosic acid.,EXPT02494,Cyclophosphamide,DB00531
The serum concentration of Brentuximab vedotin can be increased when it is combined with Naringenin.,EXPT02295,Brentuximab vedotin,DB08870
The serum concentration of Alvocidib can be increased when it is combined with Teriflunomide.,EXPT00998,Teriflunomide,DB08880
Cyclophosphamide may increase the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.,EXPT00973,Cyclophosphamide,DB00531
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Equilenin.,EXPT01356,Corticorelin ovine triflutate,DB09067
The serum concentration of Glutaric Acid can be increased when it is combined with Teriflunomide.,EXPT01668,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with P-Hydroxybenzaldehyde.,EXPT01694,Calcium carbimide,DB09116
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Butyric Acid.",EXPT00774,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The risk or severity of adverse effects can be increased when Phencyclidine is combined with Memantine.,EXPT03307,Memantine,DB01043
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pitolisant.,EXPT02440,Pitolisant,DB11642
The therapeutic efficacy of Capric acid can be increased when used in combination with Menthol.,DB03838,Menthol,DB00825
The risk or severity of adverse effects can be increased when Tiratricol is combined with Piracetam.,DB12922,Piracetam,DB09210
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Ribostamycin.,EXPT02786,Digoxin Immune Fab (Ovine),DB00076
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Deoxycholic Acid.,DB07690,Ticagrelor,DB08816
The serum concentration of Vanoxerine can be increased when it is combined with Dasatinib.,EXPT03312,Dasatinib,DB01254
The serum concentration of Mevastatin can be decreased when it is combined with Tromethamine.,EXPT03072,Mevastatin,DB06693
The serum concentration of Doconexent can be decreased when it is combined with Apalutamide.,DB11070,Apalutamide,DB11901
The therapeutic efficacy of Radicicol can be increased when used in combination with Menthol.,EXPT02763,Menthol,DB00825
The serum concentration of Phenacetin can be increased when it is combined with Dasatinib.,DB08243,Dasatinib,DB01254
The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Haloperidol.,EXPT00675,Haloperidol,DB00502
The serum concentration of Brentuximab vedotin can be increased when it is combined with Palmitic Acid.,EXPT02607,Brentuximab vedotin,DB08870
The therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Menthol.,EXPT02900,Menthol,DB00825
Cyclophosphamide may increase the cardiotoxic activities of Rhodamine 6G.,EXPT02782,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Formaldehyde.,EXPT01444,Calcium carbimide,DB09116
The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Palmidrol.,EXPT02577,Palmidrol,DB14043
The serum concentration of Zidovudine can be decreased when it is combined with Batimastat.,EXPT00627,Zidovudine,DB00495
"Cyclophosphamide may increase the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.",EXPT01187,Cyclophosphamide,DB00531
The therapeutic efficacy of para-Coumaric Acid can be decreased when used in combination with Tipiracil.,EXPT01706,Tipiracil,DB09343
The risk or severity of rhabdomyolysis can be increased when 6-Deoxyerythronolide B is combined with Mevastatin.,EXPT01153,Mevastatin,DB06693
Cyclophosphamide may increase the cardiotoxic activities of Fotemustine.,EXPT03300,Cyclophosphamide,DB00531
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aurodox.,EXPT02115,Picosulfuric acid,DB09268
The serum concentration of Valpromide can be decreased when it is combined with Orlistat.,EXPT03231,Orlistat,DB01083
The serum concentration of Anthranilic acid can be decreased when it is combined with Orlistat.,DB04056,Orlistat,DB01083
The serum concentration of Brentuximab vedotin can be increased when it is combined with Quercetin.,EXPT02732,Brentuximab vedotin,DB08870
Cyclophosphamide may increase the cardiotoxic activities of Sparsomycin.,EXPT02949,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Tretazicar.,DB12772,Cyclophosphamide,DB00531
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Seocalcitol.,EXPT01322,Sipuleucel-T,DB06688
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Geneticin.,EXPT01586,Digoxin Immune Fab (Ovine),DB00076
Dipicolinic Acid can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,EXPT02530,Technetium Tc-99m oxidronate,DB09139
The risk or severity of adverse effects can be increased when Citric Acid is combined with Azficel-T.,EXPT00922,Azficel-T,DB11051
The therapeutic efficacy of Phenethylamine can be increased when used in combination with Isocarboxazid.,EXPT02542,Isocarboxazid,DB01247
The risk or severity of adverse effects can be increased when Metahexamide is combined with Carbocisteine.,DB02476,Metahexamide,DB13675
The serum concentration of Taurocholic Acid can be decreased when it is combined with Apalutamide.,EXPT03023,Apalutamide,DB11901
Arecoline may decrease the anticholinergic activities of Cimetropium.,EXPT03296,Cimetropium,DB09271
The serum concentration of Flecainide can be increased when it is combined with Lactic Acid.,DB09294,Flecainide,DB01195
The serum concentration of Brentuximab vedotin can be increased when it is combined with P-Nitrophenol.,EXPT02385,Brentuximab vedotin,DB08870
Cyclophosphamide may increase the cardiotoxic activities of Nebularine.,EXPT02701,Cyclophosphamide,DB00531
"The serum concentration of Zidovudine can be decreased when it is combined with 3,4-Dichloroisocoumarin.",EXPT01202,Zidovudine,DB00495
Cyclophosphamide may increase the cardiotoxic activities of Afimoxifene.,EXPT02425,Cyclophosphamide,DB00531
The therapeutic efficacy of Glyphosate can be increased when used in combination with Menthol.,EXPT01639,Menthol,DB00825
The serum concentration of Cholesterol can be increased when it is combined with Teriflunomide.,EXPT00945,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pitolisant.,EXPT02331,Pitolisant,DB11642
The serum concentration of Arachidonic Acid can be decreased when it is combined with Apalutamide.,EXPT00409,Apalutamide,DB11901
Latamoxef may increase the nephrotoxic activities of Bekanamycin.,DB04570,Bekanamycin,DB13673
Trioxsalen may increase the photosensitizing activities of Verteporfin.,DB04571,Verteporfin,DB00460
The serum concentration of Bupropion can be increased when it is combined with Thiotepa.,DB04572,Bupropion,DB01156
The serum concentration of Estriol can be decreased when it is combined with Apalutamide.,DB05375,Apalutamide,DB11901
The serum concentration of Estrone sulfate can be increased when it is combined with Dasatinib.,DB04574,Dasatinib,DB01254
Quinestrol may increase the thrombogenic activities of Conestat alfa.,DB04575,Conestat alfa,DB09228
Fleroxacin may increase the QTc-prolonging activities of Delamanid.,DB04576,Delamanid,DB11637
The therapeutic efficacy of Aniracetam can be increased when used in combination with Isocarboxazid.,DB04599,Isocarboxazid,DB01247
ACETOPHENONE may increase the photosensitizing activities of Verteporfin.,DB04619,Verteporfin,DB00460
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Apramycin.,DB04626,Digoxin Immune Fab (Ovine),DB00076
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Aldosterone.,DB04630,Corticorelin ovine triflutate,DB09067
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Corticosterone.,DB04652,Corticorelin ovine triflutate,DB09067
Cyclophosphamide may increase the cardiotoxic activities of Metoprine.,DB04655,Cyclophosphamide,DB00531
The therapeutic efficacy of Octylphenoxy polyethoxyethanol can be decreased when used in combination with Tipiracil.,DB04682,Tipiracil,DB09343
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.,DB04688,Doxylamine,DB00366
The serum concentration of Camptothecin can be increased when it is combined with Teriflunomide.,DB04690,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Hydroxyfasudil.,DB04707,Dexketoprofen,DB09214
The risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.,DB04711,Aldesleukin,DB00041
The serum concentration of Licofelone can be decreased when it is combined with Apalutamide.,DB04725,Apalutamide,DB11901
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with GENTAMICIN C1A.,DB04729,Digoxin Immune Fab (Ovine),DB00076
The therapeutic efficacy of Myxothiazol can be increased when used in combination with Menthol.,DB04741,Menthol,DB00825
The risk or severity of adverse effects can be increased when Nimesulide is combined with Pitolisant.,DB04743,Pitolisant,DB11642
"The therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Menthol.",DB04744,Menthol,DB00825
The serum concentration of Suramin can be decreased when it is combined with Tafenoquine.,DB04786,Tafenoquine,DB06608
The therapeutic efficacy of Bifonazole can be increased when used in combination with Menthol.,DB04794,Menthol,DB00825
Thenoyltrifluoroacetone can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB04795,Technetium Tc-99m oxidronate,DB09139
The risk or severity of hyperkalemia can be increased when Inecalcitol is combined with Benzthiazide.,DB04796,Benzthiazide,DB00562
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Neamine.,DB04808,Digoxin Immune Fab (Ovine),DB00076
The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pitolisant.,DB04812,Pitolisant,DB11642
The serum concentration of Bithionol can be decreased when it is combined with Tafenoquine.,DB04813,Tafenoquine,DB06608
The risk or severity of adverse effects can be increased when Metamizole is combined with Pitolisant.,DB04817,Pitolisant,DB11642
Iproniazid may increase the hypertensive activities of Norepinephrine.,DB04818,Norepinephrine,DB00368
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.,DB04819,Doxylamine,DB00366
Nialamide may increase the hypertensive activities of Norepinephrine.,DB04820,Norepinephrine,DB00368
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nomifensine.,DB04821,Vemurafenib,DB08881
The risk or severity of hypotension can be increased when Racepinephrine is combined with Prenylamine.,DB04825,Racepinephrine,DB11124
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.,DB04827,Doxylamine,DB00366
The serum concentration of Zomepirac can be increased when it is combined with Dasatinib.,DB04828,Dasatinib,DB01254
The therapeutic efficacy of Lysergic Acid Diethylamide can be increased when used in combination with Isocarboxazid.,DB04829,Isocarboxazid,DB01247
Buformin may increase the hypoglycemic activities of Insulin Glulisine.,DB04830,Insulin Glulisine,DB01309
Iloprost may increase the hypotensive activities of Ticrynafen.,DB04831,Iloprost,DB01088
The serum concentration of Brentuximab vedotin can be increased when it is combined with Zimelidine.,DB04832,Brentuximab vedotin,DB08870
The serum concentration of Methaqualone can be increased when it is combined with Dasatinib.,DB04833,Dasatinib,DB01254
Vancomycin may increase the neuromuscular blocking activities of Rapacuronium.,DB04834,Vancomycin,DB00512
The serum concentration of Maraviroc can be increased when it is combined with Dasatinib.,DB04835,Dasatinib,DB01254
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Amineptine.,DB04836,Pitolisant,DB11642
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Clofedanol.",DB04837,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The risk or severity of hypotension can be increased when Racepinephrine is combined with Cyclandelate.,DB04838,Racepinephrine,DB11124
Cyproterone acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,DB04839,Lamotrigine,DB00555
The serum concentration of Debrisoquin can be decreased when it is combined with Apalutamide.,DB04840,Apalutamide,DB11901
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.,DB04841,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.,DB04842,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.,DB04844,Doxylamine,DB00366
The serum concentration of Ixabepilone can be increased when it is combined with Dasatinib.,DB04845,Dasatinib,DB01254
The serum concentration of Celiprolol can be increased when it is combined with Dasatinib.,DB04846,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Cediranib.,DB12033,Cyclophosphamide,DB00531
The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat.,DB03786,Aminophylline,DB01223
The serum concentration of Dronedarone can be increased when it is combined with Dasatinib.,DB04855,Dasatinib,DB01254
The metabolism of Tirapazamine can be decreased when combined with Ticlopidine.,DB04858,Ticlopidine,DB00208
Nebivolol may increase the hypoglycemic activities of Metahexamide.,DB04861,Metahexamide,DB13675
The risk or severity of adverse effects can be increased when Huperzine A is combined with Epibatidine.,DB01928,Epibatidine,DB07720
Cyclophosphamide may increase the cardiotoxic activities of Omacetaxine mepesuccinate.,DB04865,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Halofuginone.,DB04866,Cyclophosphamide,DB00531
The serum concentration of Nilotinib can be increased when it is combined with Dasatinib.,DB04868,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Oleoyl-estrone.,DB04870,Corticorelin ovine triflutate,DB09067
The serum concentration of Lorcaserin can be increased when it is combined with Dasatinib.,DB04871,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.,DB04872,Doxylamine,DB00366
The serum concentration of Zidovudine can be decreased when it is combined with Vildagliptin.,DB04876,Zidovudine,DB00495
The serum concentration of Brentuximab vedotin can be increased when it is combined with Voacamine.,DB04877,Brentuximab vedotin,DB08870
Voglibose may increase the hypoglycemic activities of Insulin Glulisine.,DB04878,Insulin Glulisine,DB01309
The serum concentration of Topotecan can be increased when it is combined with Elacridar.,DB04881,Topotecan,DB01030
Dapoxetine may increase the orthostatic hypotensive activities of Trolnitrate.,DB04884,Trolnitrate,DB13719
"Bifeprunox may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.",DB04888,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Bepotastine.",DB04890,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The risk or severity of hyperkalemia can be increased when Becocalcidiol is combined with Benzthiazide.,DB04891,Benzthiazide,DB00562
The risk or severity of adverse effects can be increased when Vapreotide is combined with Pegvisomant.,DB04894,Pegvisomant,DB00082
The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegloticase.,DB04895,Pegloticase,DB09208
The risk or severity of adverse effects can be increased when Nordazepam is combined with Milnacipran.,DB04896,Nordazepam,DB14028
Lucinactant may increase the bradycardic activities of Poractant alfa.,DB04897,Poractant alfa,DB09113
The risk or severity of adverse effects can be increased when Ximelagatran is combined with Azficel-T.,DB04898,Azficel-T,DB11051
Nesiritide may increase the hypotensive activities of Risperidone.,DB04899,Risperidone,DB00734
Cyclophosphamide may increase the cardiotoxic activities of Thymalfasin.,DB04900,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Galiximab.,DB04901,Hepatitis B Vaccine (Recombinant),DB11627
Tesmilifene may increase the antiplatelet activities of Relcovaptan.,DB04905,Relcovaptan,DB13929
Cyclophosphamide may increase the cardiotoxic activities of EG009.,DB04907,Cyclophosphamide,DB00531
The serum concentration of Flibanserin can be increased when it is combined with Dasatinib.,DB04908,Dasatinib,DB01254
The serum concentration of Oxibendazole can be decreased when it is combined with Tafenoquine.,DB04910,Tafenoquine,DB06608
The serum concentration of Tioclomarol can be increased when it is combined with Oritavancin.,DB04911,Tioclomarol,DB13451
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with G17DT.,DB04914,Dimethyl fumarate,DB08908
The serum concentration of Ceftobiprole can be increased when it is combined with Probenecid.,DB04918,Probenecid,DB01032
The risk or severity of hypotension can be increased when Racepinephrine is combined with Clevidipine.,DB04920,Racepinephrine,DB11124
The therapeutic efficacy of Itopride can be decreased when used in combination with Methscopolamine.,DB04924,Methscopolamine,DB11315
The risk or severity of adverse effects can be increased when Desmoteplase is combined with Treprostinil.,DB04925,Treprostinil,DB00374
The serum concentration of Permethrin can be increased when it is combined with Dasatinib.,DB04930,Dasatinib,DB01254
Vitamin E may increase the antiplatelet activities of Defibrotide.,DB04932,Vitamin E,DB00163
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Rifalazil.,DB04934,Picosulfuric acid,DB09268
Tagatose can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB04936,Technetium Tc-99m oxidronate,DB09139
The serum concentration of Ospemifene can be increased when it is combined with Dasatinib.,DB04938,Dasatinib,DB01254
The serum concentration of Iloperidone can be increased when it is combined with Dasatinib.,DB04946,Dasatinib,DB01254
Yohimbine may decrease the antihypertensive activities of Lofexidine.,DB04948,Yohimbine,DB01392
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pexelizumab.,DB04949,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Ranpirnase.,DB04950,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pitolisant.,DB04951,Pitolisant,DB11642
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ramoplanin.,DB04952,Picosulfuric acid,DB09268
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.,DB04953,Doxylamine,DB00366
Trastuzumab may increase the neutropenic activities of Afelimomab.,DB04956,Trastuzumab,DB00072
The risk or severity of hypotension can be increased when Racepinephrine is combined with Azimilide.,DB04957,Racepinephrine,DB11124
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Epratuzumab.,DB04958,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Tipifarnib.,DB04960,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Troxacitabine.,DB04961,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bectumomab.,DB04962,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Oregovomab.,DB04964,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Lucanthone can be decreased when it is combined with Tafenoquine.,DB04967,Tafenoquine,DB06608
The serum concentration of Banoxantrone can be increased when it is combined with Dasatinib.,DB04975,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with IGN311.,DB04988,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Phenytoin can be decreased when it is combined with Satraplatin.,DB04996,Phenytoin,DB00252
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Adecatumumab.,DB05006,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Belinostat can be decreased when it is combined with Apalutamide.,DB05015,Apalutamide,DB11901
Cyclophosphamide may increase the cardiotoxic activities of Amonafide.,DB05022,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Ularitide.,DB05034,Nicomorphine,DB13454
The serum concentration of Indacaterol can be increased when it is combined with Dasatinib.,DB05039,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when SRT501 is combined with Pitolisant.,DB05073,Pitolisant,DB11642
Cyclophosphamide may increase the cardiotoxic activities of Fenretinide.,DB03922,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Tiomolibdate ion.,DB05088,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Fluticasone is combined with Cimicoxib.,DB05095,Fluticasone,DB13867
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Labetuzumab.,DB05097,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Ancrod is combined with Azficel-T.,DB05099,Azficel-T,DB11051
The serum concentration of Zidovudine can be decreased when it is combined with Prinomastat.,DB05100,Zidovudine,DB00495
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Matuzumab.,DB05101,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 16-Bromoepiandrosterone.,DB05107,Corticorelin ovine triflutate,DB09067
The serum concentration of Trabectedin can be increased when it is combined with Dasatinib.,DB05109,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fontolizumab.,DB05111,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Elsamitrucin.,DB05129,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bavituximab.,DB05136,Hepatitis B Vaccine (Recombinant),DB11627
Lobeline may decrease the anticholinergic activities of Cimetropium.,DB05137,Cimetropium,DB09271
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with CR002.,DB05139,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Zidovudine can be decreased when it is combined with Elafin.,DB05161,Zidovudine,DB00495
Cyclophosphamide may increase the cardiotoxic activities of Vintafolide.,DB12503,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when PTC299 is combined with Pitolisant.,DB05173,Pitolisant,DB11642
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with SYM001.,DB05209,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with HE3286.,DB05212,Corticorelin ovine triflutate,DB09067
The metabolism of Apalutamide can be decreased when combined with Crisaborole.,DB05219,Apalutamide,DB11901
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pracinostat.,DB05223,Vemurafenib,DB08881
Vitamin E may increase the antiplatelet activities of Beraprost.,DB05229,Vitamin E,DB00163
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.,DB05232,Doxylamine,DB00366
The serum concentration of Cobimetinib can be increased when it is combined with Teriflunomide.,DB05239,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Silver sulfadiazine.,DB05245,Dexketoprofen,DB09214
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.,DB05246,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Fibrinolysin is combined with Treprostinil.,DB08977,Treprostinil,DB00374
The risk or severity of adverse effects can be increased when Natural alpha interferon is combined with Zidovudine.,DB05258,Zidovudine,DB00495
Trastuzumab may increase the neutropenic activities of Glatiramer Acetate.,APRD00999,Trastuzumab,DB00072
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gallium nitrate.,DB05260,Sipuleucel-T,DB06688
The serum concentration of Zidovudine can be decreased when it is combined with Ecabet.,DB05265,Zidovudine,DB00495
Ibudilast may increase the antiplatelet activities of Relcovaptan.,DB05066,Relcovaptan,DB13929
The serum concentration of Rotigotine can be increased when it is combined with Dasatinib.,DB05271,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with anecortave acetate.,DB05288,Corticorelin ovine triflutate,DB09067
The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pitolisant.,DB12936,Pitolisant,DB11642
The serum concentration of Vandetanib can be increased when it is combined with Dasatinib.,DB08764,Dasatinib,DB01254
The risk or severity of hyperkalemia can be increased when Eldecalcitol is combined with Benzthiazide.,DB05295,Benzthiazide,DB00562
Motexafin lutetium may increase the photosensitizing activities of Verteporfin.,DB05296,Verteporfin,DB00460
The therapeutic efficacy of Rotigotine can be decreased when used in combination with Pimavanserin.,DB05316,Rotigotine,DB05271
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with INGN 201.,DB05322,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with INGN 225.,DB05325,Dimethyl fumarate,DB08908
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Obiltoxaximab.,DB05336,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Dexlansoprazole can be increased when it is combined with Aprepitant.,DB05351,Aprepitant,DB00673
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Rindopepimut.,DB05612,Dimethyl fumarate,DB08908
The serum concentration of Histamine can be increased when it is combined with Dasatinib.,DB00667,Dasatinib,DB01254
The serum concentration of Phenytoin can be decreased when it is combined with NOV-002.,DB05393,Phenytoin,DB00252
Racepinephrine may decrease the vasoconstricting activities of Amibegron.,DB05395,Racepinephrine,DB11124
The risk or severity of adverse effects can be increased when Albinterferon Alfa-2B is combined with Zidovudine.,DB05396,Zidovudine,DB00495
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with ME-609.,DB05402,Corticorelin ovine triflutate,DB09067
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with XTL-001.,DB05405,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with NCX 1022.,DB05410,Corticorelin ovine triflutate,DB09067
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Canertinib.,DB05424,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of motexafin gadolinium.,DB05428,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with RIGScan CR49.,DB05437,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with SRP 299.,DB05440,Dimethyl fumarate,DB08908
Trastuzumab may increase the neutropenic activities of Briakinumab.,DB05459,Trastuzumab,DB00072
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tandutinib.,DB05465,Vemurafenib,DB08881
Technetium Tc-99m ciprofloxacin may increase the QTc-prolonging activities of Delamanid.,DB05488,Delamanid,DB11637
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Otelixizumab.,DB05496,Hepatitis B Vaccine (Recombinant),DB11627
Telaprevir may increase the QTc-prolonging activities of Delamanid.,DB05521,Delamanid,DB11637
Acetaminophen may increase the hepatotoxic activities of Mipomersen.,DB05528,Acetaminophen,DB00316
Cyclophosphamide may increase the cardiotoxic activities of Alanosine.,DB05540,Cyclophosphamide,DB00531
The serum concentration of Brivaracetam can be increased when it is combined with Dasatinib.,DB05541,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Iratumumab.,DB05550,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Enokizumab.,DB05555,Hepatitis B Vaccine (Recombinant),DB11627
Naluzotan may increase the hypertensive activities of Droxidopa.,DB05562,Droxidopa,DB06262
Cyclophosphamide may increase the cardiotoxic activities of Ramucirumab.,DB05578,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Farletuzumab.,DB05595,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Sodium stibogluconate can be decreased when it is combined with Tafenoquine.,DB05630,Tafenoquine,DB06608
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Veltuzumab.,DB05656,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Palifosfamide.,DB05668,Cyclophosphamide,DB00531
The serum concentration of Apremilast can be increased when it is combined with Dasatinib.,DB05676,Dasatinib,DB01254
Trastuzumab may increase the neutropenic activities of Ustekinumab.,DB05679,Trastuzumab,DB00072
BL-1020 may increase the hypotensive activities of Nicomorphine.,DB05687,Nicomorphine,DB13454
GTS-21 may decrease the anticholinergic activities of Cimetropium.,DB05708,Cimetropium,DB09271
The risk or severity of adverse effects can be increased when Andrographolide is combined with Pitolisant.,DB05767,Pitolisant,DB11642
The serum concentration of Trastuzumab emtansine can be increased when it is combined with Dasatinib.,DB05773,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Oglufanide.,DB05779,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Irofulven.,DB11733,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with PRO-542.,DB05793,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with TNX-901.,DB05797,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prasterone sulfate.,DB05804,Corticorelin ovine triflutate,DB09067
The therapeutic efficacy of Abiraterone can be decreased when used in combination with Spironolactone.,DB05812,Spironolactone,DB00421
The risk or severity of rhabdomyolysis can be increased when GPI-1485 is combined with Mevastatin.,DB05814,Mevastatin,DB06693
The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digoxin Immune Fab (Ovine).,DB05829,Digoxin Immune Fab (Ovine),DB00076
The therapeutic efficacy of Trestolone can be decreased when used in combination with Tipiracil.,DB05830,Tipiracil,DB09343
The risk or severity of hypotension can be increased when Racepinephrine is combined with Seletracetam.,DB12175,Racepinephrine,DB11124
The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Apalutamide.,DB05889,Apalutamide,DB11901
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with RI 624.,DB05892,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of KOS-1584.,DB05903,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with MYO-029.,DB05915,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Transcrocetinate.,DB05974,Cyclophosphamide,DB00531
The serum concentration of Tizanidine can be increased when it is combined with Obeticholic acid.,DB05990,Tizanidine,DB00697
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Glembatumumab vedotin.,DB05996,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Cariprazine can be increased when it is combined with Dasatinib.,DB06016,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Olaratumab.,DB06043,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with IPH 2101.,DB06049,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Rotigotine can be decreased when used in combination with Lumateperone.,DB06077,Rotigotine,DB05271
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Treprostinil.,DB06081,Treprostinil,DB00374
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with IMC-1C11.,DB06101,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Eldelumab.,DB06116,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Sertindole can be increased when it is combined with Dasatinib.,DB06144,Dasatinib,DB01254
The serum concentration of Spiramycin can be increased when it is combined with Dasatinib.,DB06145,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfathiazole.,DB06147,Dexketoprofen,DB09214
The serum concentration of Mianserin can be increased when it is combined with Dasatinib.,DB06148,Dasatinib,DB01254
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Teicoplanin.,DB06149,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfadimethoxine.,DB06150,Dexketoprofen,DB09214
Nabilone may increase the tachycardic activities of Nylidrin.,DB06152,Nabilone,DB00486
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.,DB06153,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Pentaerythritol Tetranitrate is combined with Azficel-T.,DB06154,Azficel-T,DB11051
The serum concentration of Rimonabant can be increased when it is combined with Dasatinib.,DB06155,Dasatinib,DB01254
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Istaroxime.,DB06157,Corticorelin ovine triflutate,DB09067
Cyclophosphamide may increase the cardiotoxic activities of Rubitecan.,DB06159,Cyclophosphamide,DB00531
Garenoxacin may increase the QTc-prolonging activities of Delamanid.,DB06160,Delamanid,DB11637
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lumiliximab.,DB06162,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Plevitrexed.,DB06163,Cyclophosphamide,DB00531
Trastuzumab may increase the neutropenic activities of Canakinumab.,DB06168,Trastuzumab,DB00072
The serum concentration of Rilpivirine can be increased when it is combined with Noscapine.,DB06174,Rilpivirine,DB08864
The serum concentration of Romidepsin can be increased when it is combined with Dasatinib.,DB06176,Dasatinib,DB01254
The risk or severity of increased transaminases can be increased when Vemurafenib is combined with Ipilimumab.,DB06186,Vemurafenib,DB08881
Racepinephrine may decrease the vasoconstricting activities of Solabegron.,DB06190,Racepinephrine,DB11124
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Nimotuzumab.,DB06192,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Pixantrone.,DB06193,Cyclophosphamide,DB00531
The risk or severity of hyperkalemia can be increased when Elocalcitol is combined with Benzthiazide.,DB06194,Benzthiazide,DB00562
The risk or severity of adverse effects can be increased when Fluticasone is combined with Seliciclib.,DB06195,Fluticasone,DB13867
The risk or severity of adverse effects can be increased when Icatibant is combined with Pitolisant.,DB06196,Pitolisant,DB11642
Lidocaine may increase the arrhythmogenic activities of Tedisamil.,DB06200,Lidocaine,DB00281
The serum concentration of Phenytoin can be increased when it is combined with Rufinamide.,DB06201,Phenytoin,DB00252
The risk or severity of adverse effects can be increased when Lasofoxifene is combined with Ospemifene.,DB06202,Ospemifene,DB04938
The serum concentration of Alogliptin can be increased when it is combined with Dasatinib.,DB06203,Dasatinib,DB01254
Tapentadol may increase the constipating activities of Ramosetron.,DB06204,Ramosetron,DB09290
Sugammadex may increase the anticoagulant activities of Lepirudin.,DB06206,Lepirudin,DB00001
The risk or severity of hypotension can be increased when Silodosin is combined with Menthol.,DB06207,Menthol,DB00825
The serum concentration of Prasugrel can be increased when it is combined with Aprepitant.,DB06209,Aprepitant,DB00673
The serum concentration of Fostamatinib can be increased when it is combined with Eltrombopag.,DB06210,Fostamatinib,DB12010
The serum concentration of Valproic Acid can be decreased when it is combined with Doripenem.,DB06211,Valproic Acid,DB00313
Tolvaptan may increase the hyperkalemic activities of Candoxatril.,DB06212,Candoxatril,DB00616
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Regadenoson.,DB06213,Dipyridamole,DB00975
Ferumoxytol can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB06215,Technetium Tc-99m oxidronate,DB09139
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.,DB06216,Doxylamine,DB00366
The serum concentration of Vernakalant can be decreased when it is combined with Peginterferon alfa-2b.,DB06217,Peginterferon alfa-2b,DB00022
The serum concentration of Lacosamide can be decreased when it is combined with Phenytoin.,DB06218,Phenytoin,DB00252
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dalbavancin.,DB06219,Picosulfuric acid,DB09268
Trastuzumab may increase the neutropenic activities of Alicaforsen.,DB06224,Trastuzumab,DB00072
The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Azficel-T.,DB08477,Azficel-T,DB11051
The risk or severity of adverse effects can be increased when Nalmefene is combined with Naloxegol.,DB06230,Naloxegol,DB09049
Cyclophosphamide may increase the cardiotoxic activities of Ridaforolimus.,DB06233,Cyclophosphamide,DB00531
The serum concentration of Vadimezan can be decreased when it is combined with Osimertinib.,DB13081,Osimertinib,DB09330
The serum concentration of Avanafil can be increased when it is combined with Dasatinib.,DB06237,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Clenoliximab.,DB06241,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Eflornithine.,DB06243,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Exisulind is combined with Pitolisant.,DB06246,Pitolisant,DB11642
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluasterone.,DB06250,Corticorelin ovine triflutate,DB09067
The risk or severity of adverse effects can be increased when Dersalazine is combined with Fluticasone.,DB06251,Fluticasone,DB13867
Hexaminolevulinate may increase the photosensitizing activities of Verteporfin.,DB06261,Verteporfin,DB00460
Ephedra may increase the hypertensive activities of Droxidopa.,DB06262,Ephedra,DB01363
Cyclophosphamide may increase the cardiotoxic activities of Amrubicin.,DB06263,Cyclophosphamide,DB00531
The serum concentration of Tolperisone can be decreased when it is combined with Osimertinib.,DB06264,Osimertinib,DB09330
Cyclophosphamide may increase the cardiotoxic activities of Lonidamine.,DB03762,Cyclophosphamide,DB00531
The serum concentration of Udenafil can be increased when it is combined with Dasatinib.,DB06267,Dasatinib,DB01254
The serum concentration of Sitaxentan can be decreased when it is combined with Apalutamide.,DB06268,Apalutamide,DB11901
The risk or severity of adverse effects can be increased when Sulodexide is combined with Azficel-T.,DB06271,Azficel-T,DB11051
Cyclophosphamide may increase the cardiotoxic activities of Maxacalcitol.,DB06272,Cyclophosphamide,DB00531
Trastuzumab may increase the neutropenic activities of Tocilizumab.,DB06273,Trastuzumab,DB00072
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Alvimopan.,DB06274,Nicomorphine,DB13454
Torcetrapib may increase the myelosuppressive activities of Lipegfilgrastim.,DB06281,Lipegfilgrastim,DB13200
The serum concentration of Levocetirizine can be increased when it is combined with Dasatinib.,DB06282,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.,DB06283,Doxylamine,DB00366
The serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.,DB06287,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.,DB06288,Doxylamine,DB00366
The serum concentration of Agomelatine can be increased when it is combined with Simeprevir.,DB06290,Agomelatine,DB06594
The serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.,DB06292,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Motavizumab.,DB06310,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Elotuzumab.,DB06317,Cyclophosphamide,DB00531
The serum concentration of Saxagliptin can be increased when it is combined with Dasatinib.,DB06335,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Coltuximab ravtansine.,DB06342,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lucatumumab.,DB06360,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Pertuzumab.,DB06366,Cyclophosphamide,DB00531
The serum concentration of Indisulam can be decreased when it is combined with Apalutamide.,DB06370,Apalutamide,DB11901
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Siplizumab.,DB06371,Hepatitis B Vaccine (Recombinant),DB11627
Trastuzumab may increase the neutropenic activities of Rilonacept.,DB06372,Trastuzumab,DB00072
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Abafungin.,DB06395,Vemurafenib,DB08881
Bazedoxifene may increase the thrombogenic activities of Conestat alfa.,DB06401,Conestat alfa,DB09228
Vilanterol may increase the QTc-prolonging activities of Telavancin.,DB06402,Vilanterol,DB09082
The serum concentration of Ambrisentan can be increased when it is combined with Dasatinib.,DB06403,Dasatinib,DB01254
Bazedoxifene may increase the thrombogenic activities of Human C1-esterase inhibitor.,DB06404,Bazedoxifene,DB06401
The risk or severity of adverse effects can be increased when Idraparinux is combined with Azficel-T.,DB06406,Azficel-T,DB11051
Doxercalciferol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).,DB06410,Digoxin Immune Fab (Ovine),DB00076
Fluticasone may increase the fluid retaining activities of Oxymetholone.,DB06412,Fluticasone,DB13867
The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.,DB06413,Cyclosporine,DB00091
The serum concentration of Etravirine can be increased when it is combined with Dasatinib.,DB07191,Dasatinib,DB01254
Calfactant may increase the bradycardic activities of Poractant alfa.,DB06415,Poractant alfa,DB09113
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cethromycin.,DB06419,Picosulfuric acid,DB09268
Cyclophosphamide may increase the cardiotoxic activities of Annamycin.,DB06420,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Declopramide is combined with Sulpiride.,DB06421,Sulpiride,DB00391
Cyclophosphamide may increase the cardiotoxic activities of Tezacitabine.,DB06433,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Semaxanib.,DB06436,Cyclophosphamide,DB00531
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ravuconazole.,DB06440,Vemurafenib,DB08881
Vitamin E may increase the antiplatelet activities of Cangrelor.,DB06441,Vitamin E,DB00163
The serum concentration of Saxagliptin can be decreased when it is combined with Avasimibe.,DB06442,Saxagliptin,DB06335
Iloprost may increase the hypotensive activities of Diethylnorspermine.,DB06445,Iloprost,DB01088
The risk or severity of hypotension can be increased when Racepinephrine is combined with Dotarizine.,DB06446,Racepinephrine,DB11124
The serum concentration of Remacemide can be decreased when it is combined with Orlistat.,DB06458,Orlistat,DB01083
Cyclophosphamide may increase the cardiotoxic activities of Squalamine.,DB06461,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Apolizumab.,DB06467,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of clomethiazole can be increased when it is combined with Dasatinib.,DB06470,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Porfiromycin.,DB06478,Cyclophosphamide,DB00531
The serum concentration of Prucalopride can be increased when it is combined with Curcumin.,DB06480,Curcumin,DB11672
The serum concentration of Repinotan can be decreased when it is combined with Peginterferon alfa-2b.,DB06506,Peginterferon alfa-2b,DB00022
The serum concentration of Muraglitazar can be decreased when it is combined with Osimertinib.,DB06510,Osimertinib,DB09330
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.,DB06512,Doxylamine,DB00366
The serum concentration of Tramiprosate can be decreased when it is combined with Orlistat.,DB06527,Orlistat,DB01083
The therapeutic efficacy of Pafuramidine can be increased when used in combination with Menthol.,DB06532,Menthol,DB00825
The risk or severity of adverse effects can be increased when Astaxanthin is combined with Treprostinil.,DB06543,Treprostinil,DB00374
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bivatuzumab.,DB06550,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Gaboxadol can be decreased when it is combined with Orlistat.,DB06554,Orlistat,DB01083
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lerdelimumab.,DB06557,Hepatitis B Vaccine (Recombinant),DB11627
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.,DB06579,Doxylamine,DB00366
The therapeutic efficacy of Dextofisopam can be increased when used in combination with Isocarboxazid.,DB06582,Isocarboxazid,DB01247
The risk or severity of rhabdomyolysis can be increased when Mitemcinal is combined with Mevastatin.,DB06587,Mevastatin,DB06693
The serum concentration of Pazopanib can be increased when it is combined with Eltrombopag.,DB06589,Eltrombopag,DB06210
The serum concentration of Ceftaroline fosamil can be increased when it is combined with Probenecid.,DB06590,Probenecid,DB01032
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.,DB06594,Doxylamine,DB00366
The serum concentration of Midostaurin can be increased when it is combined with Dasatinib.,DB06595,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lexatumumab.,DB06599,Hepatitis B Vaccine (Recombinant),DB11627
Nemonoxacin may increase the hypoglycemic activities of Sulfisoxazole.,DB06600,Sulfisoxazole,DB00263
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Reslizumab.,DB06602,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Panobinostat can be increased when it is combined with Dasatinib.,DB06603,Dasatinib,DB01254
The serum concentration of Apixaban can be increased when it is combined with Eltrombopag.,DB07828,Eltrombopag,DB06210
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Teplizumab.,DB06606,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Catumaxomab.,DB06607,Cyclophosphamide,DB00531
The serum concentration of Ivermectin can be decreased when it is combined with Tafenoquine.,DB06608,Ivermectin,DB00602
Trastuzumab may increase the neutropenic activities of Mepolizumab.,DB06612,Trastuzumab,DB00072
The excretion of Vincristine can be decreased when combined with Bosutinib.,DB06616,Vincristine,DB00541
The serum concentration of Axitinib can be increased when it is combined with Dasatinib.,DB06626,Dasatinib,DB01254
Anacetrapib may increase the myelosuppressive activities of Lipegfilgrastim.,DB06630,Lipegfilgrastim,DB13200
The risk or severity of adverse effects can be increased when Otamixaban is combined with Azficel-T.,DB06635,Azficel-T,DB11051
The serum concentration of Isavuconazonium can be increased when it is combined with Dasatinib.,DB06636,Dasatinib,DB01254
The metabolism of Dalfampridine can be decreased when combined with Ticlopidine.,DB06637,Ticlopidine,DB00208
The risk or severity of adverse effects can be increased when Denosumab is combined with Wortmannin.,DB06643,Wortmannin,DB08059
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Volociximab.,DB06647,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Ofatumumab.,DB06650,Cyclophosphamide,DB00531
The serum concentration of Vicriviroc can be increased when it is combined with Dasatinib.,DB06652,Dasatinib,DB01254
The serum concentration of Safinamide can be increased when it is combined with Dasatinib.,DB06654,Dasatinib,DB01254
Trolamine salicylate may increase the hypoglycemic activities of Liraglutide.,DB06655,Trolamine salicylate,DB11079
Rostaporfin may increase the photosensitizing activities of Verteporfin.,DB06659,Verteporfin,DB00460
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Saredutant.,DB06660,Vemurafenib,DB08881
Trastuzumab may increase the neutropenic activities of Abetimus.,DB06662,Trastuzumab,DB00072
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Pasireotide.",DB06663,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The serum concentration of Odanacatib can be increased when it is combined with Dasatinib.,DB06670,Dasatinib,DB01254
Trastuzumab may increase the neutropenic activities of Golimumab.,DB06674,Trastuzumab,DB00072
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Esmirtazapine.",DB06678,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Asoprisnil.,DB06680,Carboprost Tromethamine,DB00429
Trastuzumab may increase the neutropenic activities of Belatacept.,DB06681,Trastuzumab,DB00072
The serum concentration of Vilazodone can be increased when it is combined with Dasatinib.,DB06684,Dasatinib,DB01254
The serum concentration of Laquinimod can be increased when it is combined with Dasatinib.,DB06685,Dasatinib,DB01254
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Wortmannin.,DB06688,Wortmannin,DB08059
The metabolism of Ethanolamine Oleate can be decreased when combined with Ticlopidine.,DB06689,Ticlopidine,DB00208
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.,DB06690,Doxylamine,DB00366
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mepyramine.",DB06691,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Zidovudine can be decreased when it is combined with Aprotinin.,DB06692,Zidovudine,DB00495
The serum concentration of Mevastatin can be decreased when it is combined with Efavirenz.,DB06693,Efavirenz,DB00625
Iloprost may increase the hypotensive activities of Xylometazoline.,DB06694,Iloprost,DB01088
The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Azficel-T.,DB06695,Azficel-T,DB11051
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Arbekacin.,DB06696,Digoxin Immune Fab (Ovine),DB00076
The serum concentration of Artemether can be increased when it is combined with Dasatinib.,DB06697,Dasatinib,DB01254
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Betahistine.",DB06698,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Degarelix may increase the QTc-prolonging activities of Lenvatinib.,DB06699,Lenvatinib,DB09078
The serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.,DB06700,Dasatinib,DB01254
Dexmethylphenidate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.,DB06701,Ioflupane I-123,DB08824
The serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.,DB06702,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Iobenguane.,DB09497,Cyclophosphamide,DB00531
The serum concentration of Fentanyl can be decreased when it is combined with Isometheptene.,DB06706,Fentanyl,DB00813
Levomilnacipran may decrease the antihypertensive activities of Levonordefrin.,DB06707,Levomilnacipran,DB08918
The serum concentration of Lumefantrine can be increased when it is combined with Dasatinib.,DB06708,Dasatinib,DB01254
Methacholine may decrease the anticholinergic activities of Cimetropium.,DB06709,Cimetropium,DB09271
The serum concentration of Methyltestosterone can be increased when it is combined with Dasatinib.,DB06710,Dasatinib,DB01254
Urapidil may decrease the vasoconstricting activities of Naphazoline.,DB06711,Urapidil,DB12661
The serum concentration of Nilvadipine can be increased when it is combined with Dasatinib.,DB06712,Dasatinib,DB01254
Norelgestromin may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,DB06713,Lamotrigine,DB00555
The serum concentration of Aminophylline can be increased when it is combined with Potassium Iodide.,DB06715,Aminophylline,DB01223
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.,DB05279,Doxylamine,DB00366
The serum concentration of Tolbutamide can be decreased when it is combined with Fosaprepitant.,DB06717,Tolbutamide,DB01124
Fluticasone may increase the fluid retaining activities of Stanozolol.,DB06718,Fluticasone,DB13867
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Buserelin.",DB06719,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The serum concentration of Gimatecan can be decreased when it is combined with Apalutamide.,DB06721,Apalutamide,DB11901
The serum concentration of Mevastatin can be decreased when it is combined with Aluminum hydroxide.,DB06723,Mevastatin,DB06693
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Carbonate.,DB06724,Menthol,DB00825
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Pitolisant.,DB06725,Pitolisant,DB11642
Bufuralol may increase the hypoglycemic activities of Metahexamide.,DB06726,Metahexamide,DB13675
The serum concentration of Sparteine can be decreased when it is combined with Peginterferon alfa-2b.,DB06727,Peginterferon alfa-2b,DB00022
The metabolism of Aniline can be decreased when combined with Ticlopidine.,DB06728,Ticlopidine,DB00208
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfaphenazole.,DB06729,Dexketoprofen,DB09214
Gestodene may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,DB06730,Lamotrigine,DB00555
The serum concentration of Rilpivirine can be increased when it is combined with Seproxetine.,DB06731,Rilpivirine,DB08864
The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Menthol.,DB06733,Menthol,DB00825
The serum concentration of Enclomiphene can be decreased when it is combined with Peginterferon alfa-2b.,DB06735,Peginterferon alfa-2b,DB00022
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Pitolisant.,DB06736,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pitolisant.,DB06737,Pitolisant,DB11642
Ketobemidone may increase the constipating activities of Ramosetron.,DB06738,Ramosetron,DB09290
The serum concentration of Seratrodast can be increased when it is combined with Dasatinib.,DB06739,Dasatinib,DB01254
The serum concentration of Gavestinel can be decreased when it is combined with Apalutamide.,DB06741,Apalutamide,DB11901
The serum concentration of Ambroxol can be increased when it is combined with Dasatinib.,DB06742,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Ginsenoside C.,DB06748,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Danaparoid is combined with Azficel-T.,DB06754,Azficel-T,DB11051
Glycine betaine may increase the myelosuppressive activities of Lipegfilgrastim.,DB06756,Lipegfilgrastim,DB13200
Beractant may increase the bradycardic activities of Poractant alfa.,DB06761,Poractant alfa,DB09113
The serum concentration of Pinacidil can be increased when it is combined with Dasatinib.,DB06762,Dasatinib,DB01254
Trimethoprim may increase the hyperkalemic activities of Saralasin.,DB06763,Trimethoprim,DB00440
Nabilone may increase the tachycardic activities of Tetryzoline.,DB06764,Nabilone,DB00486
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Alcaftadine.",DB06766,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Mecamylamine can be decreased when it is combined with Ammonium chloride.,DB06767,Mecamylamine,DB00657
The serum concentration of Bendamustine can be decreased when it is combined with Osimertinib.,DB06769,Osimertinib,DB09330
The serum concentration of Benzyl alcohol can be increased when it is combined with Dasatinib.,DB06770,Dasatinib,DB01254
Besifloxacin may increase the QTc-prolonging activities of Delamanid.,DB05862,Delamanid,DB11637
The serum concentration of Cabazitaxel can be increased when it is combined with Dasatinib.,DB06772,Dasatinib,DB01254
The serum concentration of Lithium can be decreased when it is combined with Human calcitonin.,DB06773,Lithium,DB01356
The metabolism of Capsaicin can be decreased when combined with Ticlopidine.,DB05318,Ticlopidine,DB00208
The serum concentration of Chenodeoxycholic acid can be increased when it is combined with Dasatinib.,DB06777,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Dalteparin is combined with Azficel-T.,DB06779,Azficel-T,DB11051
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desoxycorticosterone acetate.,DB06780,Corticorelin ovine triflutate,DB09067
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Difluprednate.,DB06781,Corticorelin ovine triflutate,DB09067
Dimercaprol can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB06782,Technetium Tc-99m oxidronate,DB09139
Prussian blue can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB09538,Technetium Tc-99m oxidronate,DB09139
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Halcinonide.,DB06786,Corticorelin ovine triflutate,DB09067
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Histrelin.",DB06788,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Dasatinib.,DB06789,Dasatinib,DB01254
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Lanreotide.",DB06791,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The serum concentration of Mevastatin can be decreased when it is combined with Lanthanum carbonate.,DB06792,Mevastatin,DB06693
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lodoxamide.",DB06794,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The risk or severity of adverse effects can be increased when Mafenide is combined with Nitrous acid.,DB06795,Nitrous acid,DB09112
The therapeutic efficacy of Mebutamate can be decreased when used in combination with Yohimbine.,DB06797,Yohimbine,DB01392
The serum concentration of Mecamylamine can be decreased when it is combined with Methenamine.,DB06146,Mecamylamine,DB00657
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylnaltrexone.,DB06800,Fesoterodine,DB06702
The risk or severity of adverse effects can be increased when Nepafenac is combined with Pitolisant.,DB06802,Pitolisant,DB11642
The serum concentration of Niclosamide can be decreased when it is combined with Tafenoquine.,DB06803,Tafenoquine,DB06608
The therapeutic efficacy of Nonoxynol-9 can be decreased when used in combination with Tipiracil.,DB06804,Tipiracil,DB09343
The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluticasone.,DB06807,Fluticasone,DB13867
Cyclophosphamide may increase the cardiotoxic activities of Plicamycin.,DB06810,Cyclophosphamide,DB00531
The serum concentration of Pralatrexate can be increased when it is combined with Sulfamethoxazole.,DB05527,Sulfamethoxazole,DB01015
Racepinephrine may decrease the vasoconstricting activities of Protokylol.,DB06814,Racepinephrine,DB11124
The serum concentration of Pyrvinium can be decreased when it is combined with Tafenoquine.,DB06816,Tafenoquine,DB06608
The serum concentration of Raltegravir can be decreased when it is combined with Tipranavir.,DB05355,Tipranavir,DB00932
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Haloperidol.,DB12600,Haloperidol,DB00502
The therapeutic efficacy of Sulconazole can be increased when used in combination with Menthol.,DB06820,Menthol,DB00825
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfameter.,DB06821,Dexketoprofen,DB09214
The risk or severity of adverse effects can be increased when Tinzaparin is combined with Treprostinil.,DB06822,Treprostinil,DB00374
The serum concentration of Ferric pyrophosphate can be decreased when it is combined with Triethylenetetramine.,DB06824,Ferric pyrophosphate,DB09147
"The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Triptorelin.",DB06825,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
Iloprost may increase the hypotensive activities of Unoprostone.,DB06826,Iloprost,DB01088
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Viomycin.,DB06827,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when 3-Hydroxyhippuric acid is combined with Sulpiride.,DB07069,Sulpiride,DB00391
Cyclophosphamide may increase the cardiotoxic activities of Veliparib.,DB07232,Cyclophosphamide,DB00531
The serum concentration of Zidovudine can be decreased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.,DB07347,Zidovudine,DB00495
The therapeutic efficacy of Brefeldin A can be increased when used in combination with Menthol.,DB07348,Menthol,DB00825
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Anisomycin.,DB07374,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when Azapropazone is combined with Pitolisant.,DB07402,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Felbinac is combined with Pitolisant.,DB07477,Pitolisant,DB11642
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Chloramphenicol succinate.,DB07565,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when Tranilast is combined with Pitolisant.,DB07615,Pitolisant,DB11642
Epibatidine may decrease the anticholinergic activities of Cimetropium.,DB07720,Cimetropium,DB09271
The serum concentration of Zidovudine can be decreased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.,DB07744,Zidovudine,DB00495
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Pitolisant.,DB07767,Pitolisant,DB11642
Hexestrol may increase the thrombogenic activities of Conestat alfa.,DB08959,Conestat alfa,DB09228
The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Dosulepin.,DB07954,Dosulepin,DB09167
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.,DB07996,Dexketoprofen,DB09214
"The serum concentration of Zidovudine can be decreased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.",DB08044,Zidovudine,DB00495
The therapeutic efficacy of Wortmannin can be increased when used in combination with Menthol.,DB08059,Menthol,DB00825
Cyclophosphamide may increase the cardiotoxic activities of nocodazole.,DB08313,Cyclophosphamide,DB00531
The serum concentration of Sulthiame can be decreased when it is combined with Orlistat.,DB08329,Orlistat,DB01083
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PICEATANNOL.,DB08399,Vemurafenib,DB08881
Puromycin may increase the respiratory depressant activities of Alcuronium.,DB08437,Alcuronium,DB13648
The serum concentration of Parecoxib can be increased when it is combined with Dasatinib.,DB08439,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Efaproxiral.,DB06459,Cyclophosphamide,DB00531
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Norepinephrine.",DB08550,Norepinephrine,DB00368
Triclosan may increase the myelosuppressive activities of Lipegfilgrastim.,DB08604,Lipegfilgrastim,DB13200
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thiamphenicol.,DB08621,Picosulfuric acid,DB09268
The serum concentration of Zidovudine can be decreased when it is combined with Thiorphan.,DB01654,Zidovudine,DB00495
The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Azficel-T.,DB08794,Azficel-T,DB11051
The serum concentration of Methotrexate can be increased when it is combined with Azidocillin.,DB08795,Methotrexate,DB00563
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pipazethate.,DB08796,Dexketoprofen,DB09214
The risk or severity of adverse effects can be increased when Salicylamide is combined with Pitolisant.,DB08797,Pitolisant,DB11642
The serum concentration of Sulfamoxole can be decreased when it is combined with Apalutamide.,DB08798,Apalutamide,DB11901
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Antazoline.",DB08799,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chloropyramine.",DB07523,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dimetindene.",DB08801,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Isothipendyl.",DB08802,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Fluticasone may increase the fluid retaining activities of Nandrolone decanoate.,DB08804,Fluticasone,DB13867
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Metiamide.",DB08805,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Roxatidine acetate.",DB08806,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Bopindolol may increase the hypoglycemic activities of Metahexamide.,DB08807,Metahexamide,DB13675
Bupranolol may increase the hypoglycemic activities of Metahexamide.,DB08808,Metahexamide,DB13675
Cinitapride may increase the hypertensive activities of Droxidopa.,DB08810,Droxidopa,DB06262
The serum concentration of Rilpivirine can be increased when it is combined with Tofisopam.,DB08811,Rilpivirine,DB08864
The risk or severity of adverse effects can be increased when Nadroparin is combined with Azficel-T.,DB08813,Azficel-T,DB11051
Vitamin E may increase the antiplatelet activities of Triflusal.,DB08814,Vitamin E,DB00163
The serum concentration of Lurasidone can be increased when it is combined with Dasatinib.,DB08815,Dasatinib,DB01254
The serum concentration of Ticagrelor can be increased when it is combined with Dasatinib.,DB04902,Dasatinib,DB01254
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Palmidrol.,DB08819,Palmidrol,DB14043
The excretion of Vincristine can be decreased when combined with Ivacaftor.,DB05989,Vincristine,DB00541
Trimethoprim may increase the hyperkalemic activities of Azilsartan medoxomil.,DB05358,Trimethoprim,DB00440
Dexmethylphenidate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.,DB09548,Dexmethylphenidate,DB06701
The serum concentration of Deferiprone can be increased when it is combined with Troglitazone.,DB08826,Troglitazone,DB00197
The serum concentration of Lomitapide can be increased when it is combined with Dasatinib.,DB08827,Dasatinib,DB01254
The serum concentration of Vismodegib can be increased when it is combined with Dasatinib.,DB08828,Dasatinib,DB01254
2-deoxyglucose may increase the myelosuppressive activities of Lipegfilgrastim.,DB08831,Lipegfilgrastim,DB13200
Trimethoprim may increase the hyperkalemic activities of Temocapril.,DB08836,Trimethoprim,DB00440
The risk or severity of adverse effects can be increased when Agmatine is combined with Memantine.,DB08838,Memantine,DB01043
Nabilone may increase the tachycardic activities of Tyramine.,DB08841,Nabilone,DB00486
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with GS 0573.,DB08843,Sipuleucel-T,DB06688
The serum concentration of Pitavastatin can be decreased when it is combined with Efavirenz.,DB06514,Efavirenz,DB00625
DPDPE may increase the constipating activities of Ramosetron.,DB08861,Ramosetron,DB09290
The serum concentration of Rilpivirine can be increased when it is combined with Dasatinib.,DB05083,Dasatinib,DB01254
The serum concentration of Bupropion can be increased when it is combined with Crizotinib.,DB08700,Bupropion,DB01156
The serum concentration of Ulipristal can be increased when it is combined with Dasatinib.,DB05366,Dasatinib,DB01254
The serum concentration of Fingolimod can be increased when it is combined with Aprepitant.,DB08868,Aprepitant,DB00673
The serum concentration of the active metabolites of Cortisone acetate can be reduced when Cortisone acetate is used in combination with Tesamorelin resulting in a loss in efficacy.,DB08869,Cortisone acetate,DB01380
The serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone undecanoate.,DB08870,Testosterone undecanoate,DB13946
Eribulin may increase the QTc-prolonging activities of Lenvatinib.,DB04940,Lenvatinib,DB09078
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.,DB04922,Doxylamine,DB00366
Boceprevir may increase the QTc-prolonging activities of Delamanid.,DB05665,Delamanid,DB11637
The serum concentration of Fidaxomicin can be decreased when it is combined with Apalutamide.,DB08874,Apalutamide,DB11901
The serum concentration of Cabozantinib can be increased when it is combined with Dasatinib.,DB05153,Dasatinib,DB01254
The serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib.,DB08877,Dasatinib,DB01254
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Belimumab.,DB08879,Sipuleucel-T,DB06688
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Pitolisant.,DB03805,Pitolisant,DB11642
The serum concentration of Vemurafenib can be increased when it is combined with Teriflunomide.,DB05238,Teriflunomide,DB08880
The serum concentration of Zidovudine can be decreased when it is combined with Linagliptin.,DB08882,Zidovudine,DB00495
The serum concentration of Perampanel can be increased when it is combined with Dasatinib.,DB08883,Dasatinib,DB01254
The serum concentration of Gadoxetic acid can be decreased when it is combined with Apalutamide.,DB08884,Apalutamide,DB11901
Cyclophosphamide may increase the cardiotoxic activities of Aflibercept.,DB08885,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Asparaginase Erwinia chrysanthemi.,DB08886,Cyclophosphamide,DB00531
Icosapent ethyl may increase the antiplatelet activities of Relcovaptan.,DB06291,Relcovaptan,DB13929
The serum concentration of Carfilzomib can be decreased when it is combined with Apalutamide.,DB08889,Apalutamide,DB11901
The serum concentration of Mirabegron can be increased when it is combined with Dasatinib.,DB05702,Dasatinib,DB01254
The serum concentration of Tofacitinib can be increased when it is combined with Aprepitant.,DB08183,Aprepitant,DB00673
The serum concentration of Regorafenib can be increased when it is combined with Dasatinib.,DB08896,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Aclidinium is combined with Nicomorphine.,DB08897,Nicomorphine,DB13454
The serum concentration of the active metabolites of Levoleucovorin can be reduced when Levoleucovorin is used in combination with Glucarpidase resulting in a loss in efficacy.,DB08898,Levoleucovorin,DB11596
The metabolism of Enzalutamide can be decreased when combined with Nabilone.,DB05094,Nabilone,DB00486
The serum concentration of Quazepam can be increased when it is combined with Teduglutide.,DB08900,Quazepam,DB01589
The serum concentration of Ponatinib can be increased when it is combined with Dasatinib.,DB06300,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Raxibacumab.,DB05872,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Bedaquiline can be increased when it is combined with Dasatinib.,DB08903,Dasatinib,DB01254
Trastuzumab may increase the neutropenic activities of Certolizumab pegol.,DB08904,Trastuzumab,DB00072
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Formestane.,DB08905,Corticorelin ovine triflutate,DB09067
The serum concentration of Fluticasone furoate can be increased when it is combined with Dasatinib.,DB08906,Dasatinib,DB01254
The serum concentration of Canagliflozin can be increased when it is combined with Dasatinib.,DB08907,Dasatinib,DB01254
Trastuzumab may increase the neutropenic activities of Dimethyl fumarate.,DB08908,Trastuzumab,DB00072
The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Haloperidol.,DB06170,Haloperidol,DB00502
The serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.,DB08910,Dasatinib,DB01254
The serum concentration of Saxagliptin can be decreased when it is combined with Trametinib.,DB08911,Saxagliptin,DB06335
The serum concentration of Dabrafenib can be increased when it is combined with Teriflunomide.,DB08912,Teriflunomide,DB08880
Cyclophosphamide may increase the cardiotoxic activities of Radium Ra 223 Dichloride.,DB09566,Cyclophosphamide,DB00531
The serum concentration of Afatinib can be increased when it is combined with Teriflunomide.,DB08916,Teriflunomide,DB08880
Promethazine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB08917,Promethazine,DB01069
The serum concentration of Levomilnacipran can be increased when it is combined with Dasatinib.,DB08918,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pitolisant.,DB08921,Pitolisant,DB11642
The serum concentration of Perospirone can be increased when it is combined with Dasatinib.,DB08922,Dasatinib,DB01254
Racepinephrine may decrease the vasoconstricting activities of Adrafinil.,DB08925,Racepinephrine,DB11124
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.,DB08927,Doxylamine,DB00366
The serum concentration of Dolutegravir can be increased when it is combined with Teriflunomide.,DB08930,Teriflunomide,DB08880
The serum concentration of Riociguat can be increased when it is combined with Dasatinib.,DB08931,Dasatinib,DB01254
The serum concentration of Macitentan can be increased when it is combined with Dasatinib.,DB08932,Dasatinib,DB01254
The serum concentration of Zuclopenthixol can be increased when it is combined with Luliconazole.,DB08933,Zuclopenthixol,DB01624
The serum concentration of Sofosbuvir can be increased when it is combined with Teriflunomide.,DB08934,Teriflunomide,DB08880
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Obinutuzumab.,DB08935,Ticagrelor,DB08816
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chlorcyclizine.",DB08936,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Mevastatin can be decreased when it is combined with Magaldrate.,DB08938,Mevastatin,DB06693
The risk or severity of adverse effects can be increased when Kebuzone is combined with Pitolisant.,DB08940,Pitolisant,DB11642
Dronabinol may increase the tachycardic activities of Isoxsuprine.,DB08941,Dronabinol,DB00470
The risk or severity of adverse effects can be increased when Isoxicam is combined with Pitolisant.,DB08942,Pitolisant,DB11642
The therapeutic efficacy of Isoconazole can be increased when used in combination with Menthol.,DB08943,Menthol,DB00825
The risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.,DB08947,Aldesleukin,DB00041
The risk or severity of hypotension can be increased when Indoramin is combined with Menthol.,DB08950,Menthol,DB00825
The risk or severity of adverse effects can be increased when Indoprofen is combined with Pitolisant.,DB08951,Pitolisant,DB11642
Indenolol may increase the hypoglycemic activities of Metahexamide.,DB08952,Metahexamide,DB13675
The risk or severity of adverse effects can be increased when Nordazepam is combined with Indalpine.,DB08953,Nordazepam,DB14028
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Memantine.,DB08954,Memantine,DB01043
The risk or severity of adverse effects can be increased when Ibuproxam is combined with Pitolisant.,DB08955,Pitolisant,DB11642
Racepinephrine may decrease the vasoconstricting activities of Hexoprenaline.,DB08957,Racepinephrine,DB11124
The therapeutic efficacy of Hexetidine can be increased when used in combination with Menthol.,DB08958,Menthol,DB00825
Iloprost may increase the hypotensive activities of Hexamethonium.,DB08960,Iloprost,DB01088
The therapeutic efficacy of Azosemide can be decreased when used in combination with Trolamine salicylate.,DB08961,Trolamine salicylate,DB11079
The serum concentration of Glibornuride can be increased when it is combined with Voriconazole.,DB08962,Voriconazole,DB00582
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Palmidrol.,DB08964,Palmidrol,DB14043
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fusafungine.,DB08965,Picosulfuric acid,DB09268
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dimetotiazine.",DB08967,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluprednidene.,DB08970,Corticorelin ovine triflutate,DB09067
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocortolone.,DB08971,Corticorelin ovine triflutate,DB09067
Flumequine may increase the hypoglycemic activities of Sulfisoxazole.,DB08972,Sulfisoxazole,DB00263
The serum concentration of Flubendazole can be decreased when it is combined with Tafenoquine.,DB08974,Tafenoquine,DB06608
The risk or severity of adverse effects can be increased when Floctafenine is combined with Pitolisant.,DB08976,Pitolisant,DB11642
The risk or severity of hypotension can be increased when Racepinephrine is combined with Fendiline.,DB08980,Racepinephrine,DB11124
The risk or severity of adverse effects can be increased when Fenbufen is combined with Pitolisant.,DB08981,Pitolisant,DB11642
The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Etofibrate.,DB08983,Ursodeoxycholic acid,DB01586
The risk or severity of adverse effects can be increased when Etofenamate is combined with Pitolisant.,DB08984,Pitolisant,DB11642
Nabilone may increase the tachycardic activities of Etilefrine.,DB08985,Nabilone,DB00486
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.,DB08986,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.,DB08987,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Epirizole is combined with Pitolisant.,DB08991,Pitolisant,DB11642
The risk or severity of hypotension can be increased when Racepinephrine is combined with Eperisone.,DB08992,Racepinephrine,DB11124
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Enviomycin.,DB08993,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when Ditazole is combined with Treprostinil.,DB08994,Treprostinil,DB00374
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Dimetacrine.,DB08996,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Dexetimide is combined with Nicomorphine.,DB08997,Nicomorphine,DB13454
"Cyamemazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.",DB09000,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The metabolism of Barbexaclone can be increased when combined with Rifaximin.,DB09001,Rifaximin,DB01220
The risk or severity of adverse effects can be increased when Batroxobin is combined with Treprostinil.,DB09005,Treprostinil,DB00374
The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Nicomorphine.,DB09007,Nicomorphine,DB13454
The serum concentration of Cephaloridine can be increased when it is combined with Probenecid.,DB09008,Probenecid,DB01032
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Articaine.,DB09009,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Carmofur.,DB09010,Cyclophosphamide,DB00531
The serum concentration of Beclamide can be decreased when it is combined with Orlistat.,DB09011,Orlistat,DB01083
Befunolol may increase the hypoglycemic activities of Metahexamide.,DB09013,Metahexamide,DB13675
The therapeutic efficacy of Captodiame can be decreased when used in combination with Yohimbine.,DB09014,Yohimbine,DB01392
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Canrenoic acid.,DB09015,Nicomorphine,DB13454
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Butriptyline.,DB09016,Pitolisant,DB11642
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.,DB09017,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Bromopride is combined with Sulpiride.,DB09018,Sulpiride,DB00391
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium carbonate.,DB09020,Magnesium carbonate,DB09481
The therapeutic efficacy of Benzoctamine can be decreased when used in combination with Yohimbine.,DB09021,Yohimbine,DB01392
Benfluorex may increase the myelosuppressive activities of Lipegfilgrastim.,DB09022,Lipegfilgrastim,DB13200
The risk or severity of adverse effects can be increased when Benactyzine is combined with Nicomorphine.,DB09023,Nicomorphine,DB13454
The serum concentration of Aliskiren can be increased when it is combined with Dasatinib.,DB01258,Dasatinib,DB01254
The serum concentration of Ledipasvir can be increased when it is combined with Curcumin.,DB09027,Curcumin,DB11672
Trastuzumab may increase the neutropenic activities of Secukinumab.,DB09029,Trastuzumab,DB00072
Vitamin E may increase the antiplatelet activities of Vorapaxar.,DB05692,Vitamin E,DB00163
The therapeutic efficacy of Miltefosine can be increased when used in combination with Menthol.,DB09031,Menthol,DB00825
Trastuzumab may increase the neutropenic activities of Vedolizumab.,DB05802,Trastuzumab,DB00072
The risk or severity of adverse effects can be increased when Suvorexant is combined with Alaproclate.,DB09034,Alaproclate,DB13233
Cyclophosphamide may increase the cardiotoxic activities of Nivolumab.,DB06132,Cyclophosphamide,DB00531
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Siltuximab.,DB09036,Sipuleucel-T,DB06688
Cyclophosphamide may increase the cardiotoxic activities of Pembrolizumab.,DB09037,Cyclophosphamide,DB00531
The risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Candoxatril.,DB09038,Candoxatril,DB00616
The serum concentration of Eliglustat can be increased when it is combined with Dasatinib.,DB05715,Dasatinib,DB01254
The therapeutic efficacy of Efinaconazole can be increased when used in combination with Menthol.,DB09040,Menthol,DB00825
The therapeutic efficacy of Tavaborole can be increased when used in combination with Menthol.,DB05058,Menthol,DB00825
The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Mosapramine.,DB09042,Mosapramine,DB13676
Trolamine salicylate may increase the hypoglycemic activities of Albiglutide.,DB05162,Trolamine salicylate,DB11079
Trolamine salicylate may increase the hypoglycemic activities of Dulaglutide.,DB09045,Trolamine salicylate,DB11079
The serum concentration of Quingestanol can be decreased when it is combined with Metreleptin.,DB09046,Quingestanol,DB13685
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Finafloxacin.,DB09047,Picosulfuric acid,DB09268
The serum concentration of Netupitant can be decreased when it is combined with Peginterferon alfa-2b.,DB09048,Peginterferon alfa-2b,DB00022
The serum concentration of Naloxegol can be decreased when it is combined with Bosentan.,DB09049,Bosentan,DB00559
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Blinatumomab.,DB09052,Sipuleucel-T,DB06688
Linseed oil may increase the antiplatelet activities of Ibrutinib.,DB09053,Linseed oil,DB11357
The serum concentration of Idelalisib can be increased when it is combined with Teriflunomide.,DB09054,Teriflunomide,DB08880
Acipimox may increase the myopathic rhabdomyolysis activities of Aluminium clofibrate.,DB09055,Aluminium clofibrate,DB13780
The therapeutic efficacy of Amorolfine can be increased when used in combination with Menthol.,DB09056,Menthol,DB00825
Bazedoxifene may increase the thrombogenic activities of Anthrax immune globulin human.,DB09057,Bazedoxifene,DB06401
The risk or severity of adverse effects can be increased when PF-00610355 is combined with Atosiban.,DB09059,PF-00610355,DB11871
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Avibactam.,DB09060,Picosulfuric acid,DB09268
The serum concentration of Cannabidiol can be increased when it is combined with Dasatinib.,DB09061,Dasatinib,DB01254
The serum concentration of Cefminox can be increased when it is combined with Probenecid.,DB09062,Probenecid,DB01032
Fluticasone may increase the hyperglycemic activities of Ceritinib.,DB09063,Fluticasone,DB13867
The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Ciprofibrate.,DB09064,Ursodeoxycholic acid,DB01586
Cobicistat may increase the QTc-prolonging activities of Delamanid.,DB09065,Delamanid,DB11637
The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Nafarelin.,DB09066,Nafarelin,DB00666
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluticasone.,DB09067,Fluticasone,DB13867
The serum concentration of Vortioxetine can be increased when it is combined with Dasatinib.,DB05700,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimetazidine.,DB09069,Metoclopramide,DB01233
Iloprost may increase the hypotensive activities of Tibolone.,DB09070,Iloprost,DB01088
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.,DB05359,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Alaproclate.,DB09072,Alaproclate,DB13233
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib.,DB09073,Sipuleucel-T,DB06688
The serum concentration of Olaparib can be increased when it is combined with Dasatinib.,DB05940,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Edoxaban is combined with Azficel-T.,DB09075,Azficel-T,DB11051
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Nicomorphine.,DB09076,Nicomorphine,DB13454
Dinutuximab may increase the hypotensive activities of Risperidone.,DB09077,Risperidone,DB00734
The serum concentration of Lenvatinib can be increased when it is combined with Dasatinib.,DB09078,Dasatinib,DB01254
The serum concentration of Nintedanib can be increased when it is combined with Curcumin.,DB09079,Curcumin,DB11672
The serum concentration of Olodaterol can be decreased when it is combined with Apalutamide.,DB09080,Apalutamide,DB11901
The serum concentration of Vilanterol can be increased when it is combined with Dasatinib.,DB06577,Dasatinib,DB01254
The serum concentration of Ivabradine can be increased when it is combined with Dasatinib.,DB09083,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Benzydamine is combined with Pitolisant.,DB09084,Pitolisant,DB11642
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.,DB09085,Doxylamine,DB00366
The serum concentration of Dolutegravir can be decreased when it is combined with Potassium alum.,DB09087,Dolutegravir,DB08930
The risk or severity of hypotension can be increased when Racepinephrine is combined with Trimebutine.,DB09089,Racepinephrine,DB11124
The risk or severity of hypotension can be increased when Racepinephrine is combined with Pinaverium.,DB09090,Racepinephrine,DB11124
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Tixocortol.,DB09091,Corticorelin ovine triflutate,DB09067
The serum concentration of Xanthinol can be increased when it is combined with Dosulepin.,DB09092,Dosulepin,DB09167
Chlortetracycline may increase the anticoagulant activities of Tioclomarol.,DB09093,Tioclomarol,DB13451
Cyclophosphamide may increase the cardiotoxic activities of Podophyllin.,DB09094,Cyclophosphamide,DB00531
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Difluocortolone.,DB09095,Corticorelin ovine triflutate,DB09067
The risk or severity of adverse effects can be increased when Benzoyl peroxide is combined with Dapsone.,DB09096,Dapsone,DB00250
The therapeutic efficacy of Quinagolide can be decreased when used in combination with Mosapramine.,DB09097,Mosapramine,DB13676
The serum concentration of Somatostatin can be decreased when it is combined with Apalutamide.,DB09099,Apalutamide,DB11901
"The metabolism of Aminophylline can be increased when combined with Thyroid, porcine.",DB09100,Aminophylline,DB01223
The serum concentration of Elvitegravir can be increased when it is combined with Dasatinib.,DB05618,Dasatinib,DB01254
The serum concentration of Daclatasvir can be increased when it is combined with Dasatinib.,DB09102,Dasatinib,DB01254
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Celecoxib.,DB09103,Celecoxib,DB00482
The serum concentration of Mevastatin can be decreased when it is combined with Magnesium hydroxide.,DB09104,Mevastatin,DB06693
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Asfotase Alfa.,DB09105,Hepatitis B Vaccine (Recombinant),DB11627
Methoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Thalidomide.,DB06279,Thalidomide,DB01041
Nitrous acid may increase the hypotensive activities of Risperidone.,DB09112,Risperidone,DB00734
Fingolimod may increase the bradycardic activities of Poractant alfa.,DB09113,Fingolimod,DB08868
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Ethanol.,DB09116,Ethanol,DB00898
The risk or severity of adverse effects can be increased when Paraldehyde is combined with Alaproclate.,DB09117,Alaproclate,DB13233
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.,DB09118,Doxylamine,DB00366
The metabolism of Lofexidine can be decreased when combined with Eslicarbazepine acetate.,DB09119,Lofexidine,DB04948
The serum concentration of Agomelatine can be increased when it is combined with Zucapsaicin.,DB09120,Agomelatine,DB06594
Sarilumab may increase the immunosuppressive activities of Aurothioglucose.,DB09121,Sarilumab,DB11767
The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Zidovudine.,DB09122,Zidovudine,DB00495
The serum concentration of Dienogest can be increased when it is combined with Dasatinib.,DB09123,Dasatinib,DB01254
Medrogestone may increase the thrombogenic activities of Conestat alfa.,DB09124,Conestat alfa,DB09228
The risk or severity of adverse effects can be increased when Potassium Citrate is combined with Azficel-T.,DB09125,Azficel-T,DB11051
The serum concentration of Brexpiprazole can be increased when it is combined with Dasatinib.,DB09128,Dasatinib,DB01254
The serum concentration of Vitamin C can be decreased when it is combined with Copper.,DB09130,Vitamin C,DB00126
Gadoteric acid can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB09132,Technetium Tc-99m oxidronate,DB09139
The risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.,DB09134,Aldesleukin,DB00041
The risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.,DB09135,Aldesleukin,DB00041
The serum concentration of Technetium Tc-99m mebrofenin can be decreased when it is combined with Apalutamide.,DB09137,Apalutamide,DB11901
The risk or severity of adverse effects can be increased when Palmidrol is combined with Technetium Tc-99m medronate.,DB09138,Palmidrol,DB14043
The serum concentration of Technetium Tc-99m oxidronate can be increased when it is combined with Aloglutamol.,DB09139,Aloglutamol,DB13650
The serum concentration of Sonidegib can be increased when it is combined with Dasatinib.,DB09143,Dasatinib,DB01254
Promethazine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB06790,Promethazine,DB01069
Promethazine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB09147,Promethazine,DB01069
Sodium Chloride may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.,DB09153,Lithium,DB01356
The risk or severity of adverse effects can be increased when Sodium Citrate is combined with Azficel-T.,DB09159,Azficel-T,DB11051
The risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.,DB09156,Aldesleukin,DB00041
The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Apalutamide.,DB09161,Apalutamide,DB11901
The serum concentration of Etizolam can be increased when it is combined with Dasatinib.,DB09166,Dasatinib,DB01254
"Dosulepin may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.",DB09167,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Lofentanil may increase the constipating activities of Ramosetron.,DB09174,Ramosetron,DB09290
The serum concentration of Dasabuvir can be increased when it is combined with Dasatinib.,DB09183,Dasatinib,DB01254
The therapeutic efficacy of Viloxazine can be increased when used in combination with Isocarboxazid.,DB09185,Isocarboxazid,DB01247
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Etoperidone.",DB09194,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lorpiprazole.",DB09195,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Agomelatine can be increased when it is combined with Lobeglitazone.,DB09198,Agomelatine,DB06594
The metabolism of Netoglitazone can be decreased when combined with Trimethoprim.,DB09199,Trimethoprim,DB00440
The metabolism of Rivoglitazone can be decreased when combined with Trimethoprim.,DB09200,Trimethoprim,DB00440
Ciglitazone may increase the hypoglycemic activities of Insulin Glulisine.,DB09201,Insulin Glulisine,DB01309
The serum concentration of Fentanyl can be decreased when it is combined with Cirazoline.,DB09202,Fentanyl,DB00813
Nabilone may increase the tachycardic activities of Synephrine.,DB09203,Nabilone,DB00486
Arotinolol may increase the hypoglycemic activities of Metahexamide.,DB09204,Metahexamide,DB13675
The risk or severity of hypotension can be increased when Trimazosin is combined with Menthol.,DB09206,Menthol,DB00825
The risk or severity of adverse effects can be increased when AS-8112 is combined with Deutetrabenazine.,DB09207,Deutetrabenazine,DB12161
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegloticase.,DB09208,Pegvisomant,DB00082
The risk or severity of adverse effects can be increased when Pholcodine is combined with Naloxegol.,DB09209,Naloxegol,DB09049
"The risk or severity of adverse effects can be increased when Piracetam is combined with Thyroid, porcine.",DB09210,"Thyroid, porcine",DB09100
Limaprost may increase the antiplatelet activities of Relcovaptan.,DB09211,Relcovaptan,DB13929
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Pitolisant.,DB09212,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Fluticasone is combined with Dexibuprofen.,DB09213,Fluticasone,DB13867
The serum concentration of Dexketoprofen can be increased when it is combined with Probenecid.,DB09214,Probenecid,DB01032
The risk or severity of adverse effects can be increased when Droxicam is combined with Pitolisant.,DB09215,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pitolisant.,DB09216,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Clonixin is combined with Pitolisant.,DB09218,Pitolisant,DB11642
Nicorandil may increase the hyperkalemic activities of Amiloride.,DB09220,Amiloride,DB00594
The serum concentration of Penicillamine can be decreased when it is combined with Polaprezinc.,DB09221,Penicillamine,DB00859
The risk or severity of adverse effects can be increased when Camostat is combined with Fibrinogen Human.,DB09222,Camostat,DB13729
The serum concentration of Blonanserin can be increased when it is combined with Dasatinib.,DB09223,Dasatinib,DB01254
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Melperone.,DB09224,Doxylamine,DB00366
The serum concentration of Zotepine can be increased when it is combined with Dasatinib.,DB09225,Dasatinib,DB01254
The therapeutic efficacy of Rotigotine can be decreased when used in combination with RP5063.,DB09226,Rotigotine,DB05271
The risk or severity of hypotension can be increased when Racepinephrine is combined with Barnidipine.,DB09227,Racepinephrine,DB11124
Bazedoxifene may increase the thrombogenic activities of Conestat alfa.,DB09228,Bazedoxifene,DB06401
The risk or severity of hypotension can be increased when Racepinephrine is combined with Aranidipine.,DB09229,Racepinephrine,DB11124
The risk or severity of hypotension can be increased when Racepinephrine is combined with Azelnidipine.,DB09230,Racepinephrine,DB11124
The serum concentration of Benidipine can be increased when it is combined with Dasatinib.,DB09231,Dasatinib,DB01254
The risk or severity of hypotension can be increased when Racepinephrine is combined with Cilnidipine.,DB09232,Racepinephrine,DB11124
The risk or severity of hypotension can be increased when Racepinephrine is combined with Darodipine.,DB09234,Racepinephrine,DB11124
The risk or severity of hypotension can be increased when Racepinephrine is combined with Efonidipine.,DB09235,Racepinephrine,DB11124
The serum concentration of Lacidipine can be increased when it is combined with Dasatinib.,DB09236,Dasatinib,DB01254
The serum concentration of Brexpiprazole can be increased when it is combined with Manidipine.,DB09238,Brexpiprazole,DB09128
The risk or severity of hypotension can be increased when Niguldipine is combined with Menthol.,DB09239,Menthol,DB00825
The risk or severity of hypotension can be increased when Racepinephrine is combined with Niludipine.,DB09240,Racepinephrine,DB11124
Methylene blue may increase the hypertensive activities of Norepinephrine.,DB09241,Norepinephrine,DB00368
Yohimbine may decrease the antihypertensive activities of Moxonidine.,DB09242,Yohimbine,DB01392
Hydracarbazine may increase the hypertensive activities of Norepinephrine.,DB09243,Norepinephrine,DB00368
Pirlindole may increase the hypertensive activities of Norepinephrine.,DB09244,Norepinephrine,DB00368
Toloxatone may increase the hypertensive activities of Norepinephrine.,DB09245,Norepinephrine,DB00368
Benmoxin may increase the hypertensive activities of Norepinephrine.,DB09246,Norepinephrine,DB00368
Iproclozide may increase the hypertensive activities of Norepinephrine.,DB09247,Norepinephrine,DB00368
Mebanazine may increase the hypertensive activities of Norepinephrine.,DB09248,Norepinephrine,DB00368
Octamoxin may increase the hypertensive activities of Norepinephrine.,DB09249,Norepinephrine,DB00368
Pheniprazine may increase the hypertensive activities of Norepinephrine.,DB09250,Norepinephrine,DB00368
Phenoxypropazine may increase the hypertensive activities of Norepinephrine.,DB09251,Norepinephrine,DB00368
Pivhydrazine may increase the hypertensive activities of Norepinephrine.,DB09252,Norepinephrine,DB00368
Safrazine may increase the hypertensive activities of Norepinephrine.,DB09253,Norepinephrine,DB00368
Caroxazone may increase the hypertensive activities of Norepinephrine.,DB09254,Norepinephrine,DB00368
The risk or severity of adverse effects can be increased when Dextran is combined with Azficel-T.,DB09255,Azficel-T,DB11051
The serum concentration of the active metabolites of Tegafur can be increased when Tegafur is used in combination with Metronidazole.,DB09256,Metronidazole,DB00916
The serum concentration of the active metabolites of Floxuridine can be increased when Floxuridine is used in combination with Gimeracil.,DB09257,Floxuridine,DB00322
The risk or severity of adverse effects can be increased when Bemiparin is combined with Treprostinil.,DB09258,Treprostinil,DB00374
The risk or severity of adverse effects can be increased when Reviparin is combined with Azficel-T.,DB09259,Azficel-T,DB11051
The risk or severity of adverse effects can be increased when Parnaparin is combined with Treprostinil.,DB09260,Treprostinil,DB00374
The risk or severity of adverse effects can be increased when Certoparin is combined with Azficel-T.,DB09261,Azficel-T,DB11051
The serum concentration of Imidafenacin can be increased when it is combined with Dasatinib.,DB09262,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Idarucizumab.,DB09264,Hepatitis B Vaccine (Recombinant),DB11627
Lixisenatide can cause a decrease in the absorption of Tioclomarol resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB09265,Tioclomarol,DB13451
Metabutethamine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.,DB09266,Metabutethamine,DB13578
The serum concentration of Strontium ranelate can be decreased when it is combined with Magnesium hydroxide.,DB09267,Magnesium hydroxide,DB09104
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Griseofulvin.,DB09268,Griseofulvin,DB00400
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Haloperidol.,DB09269,Haloperidol,DB00502
The serum concentration of Ubidecarenone can be decreased when it is combined with Apalutamide.,DB09270,Apalutamide,DB11901
Epibatidine may decrease the anticholinergic activities of Cimetropium.,DB09271,Epibatidine,DB07720
The serum concentration of Eluxadoline can be decreased when it is combined with Apalutamide.,DB09272,Apalutamide,DB11901
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Doxofylline.,DB09273,Pseudoephedrine,DB00852
The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nevirapine resulting in a loss in efficacy.,DB09274,Nevirapine,DB00238
The serum concentration of Mevastatin can be decreased when it is combined with Bismuth Subcitrate.,DB09275,Mevastatin,DB06693
"The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Candoxatril is combined with Sodium aurothiomalate.",DB09276,Candoxatril,DB00616
The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Estradiol.,DB09277,Estradiol,DB00783
The serum concentration of Teriflunomide can be decreased when it is combined with Activated charcoal.,DB05269,Teriflunomide,DB08880
The serum concentration of Fimasartan can be increased when it is combined with Ketoconazole.,DB09279,Ketoconazole,DB01026
The serum concentration of Propafenone can be decreased when it is combined with Lumacaftor.,DB09280,Propafenone,DB01182
The serum concentration of Mevastatin can be decreased when it is combined with Magnesium Trisilicate.,DB09281,Mevastatin,DB06693
Molsidomine may increase the hypotensive activities of Guanoclor.,DB09282,Guanoclor,DB13779
Trapidil may increase the antiplatelet activities of Relcovaptan.,DB09283,Relcovaptan,DB13929
The risk or severity of adverse effects can be increased when Fluticasone is combined with Morniflumate.,DB09285,Fluticasone,DB13867
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.,DB09286,Doxylamine,DB00366
The serum concentration of Digoxin can be decreased when it is combined with Polyethylene glycol.,DB09287,Digoxin,DB00390
The risk or severity of adverse effects can be increased when Propacetamol is combined with Pitolisant.,DB09288,Pitolisant,DB11642
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Tianeptine.,DB09289,Pitolisant,DB11642
Nicomorphine may increase the constipating activities of Ramosetron.,DB09290,Nicomorphine,DB13454
The serum concentration of Brexpiprazole can be increased when it is combined with Rolapitant.,DB09291,Brexpiprazole,DB09128
Trimethoprim may increase the hyperkalemic activities of Sacubitril.,DB09292,Trimethoprim,DB00440
"The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Thyroid, porcine.",DB12217,"Thyroid, porcine",DB09100
The risk or severity of adverse effects can be increased when Fluticasone is combined with Talniflumate.,DB09295,Fluticasone,DB13867
The serum concentration of Ombitasvir can be increased when it is combined with Teriflunomide.,DB09296,Teriflunomide,DB08880
The serum concentration of Paritaprevir can be increased when it is combined with Dasatinib.,DB09297,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Nicomorphine.,DB11535,Nicomorphine,DB13454
Chondroitin sulfate may increase the anticoagulant activities of Warfarin.,DB11339,Warfarin,DB00682
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alirocumab.,DB09302,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Evolocumab.,DB09303,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Oxaprotiline can be increased when used in combination with Isocarboxazid.,DB09307,Isocarboxazid,DB01247
The serum concentration of Repaglinide can be increased when it is combined with Solithromycin.,DB09308,Repaglinide,DB00912
The serum concentration of Repaglinide can be increased when it is combined with Kitasamycin.,DB09309,Repaglinide,DB00912
Trastuzumab may increase the neutropenic activities of Antilymphocyte immunoglobulin (horse).,DB09312,Trastuzumab,DB00072
"The serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Dasatinib.",DB09317,Dasatinib,DB01254
"The serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Dasatinib.",DB09318,Dasatinib,DB01254
The serum concentration of Methotrexate can be increased when it is combined with Carbenicillin indanyl.,DB09319,Methotrexate,DB00563
The serum concentration of Methotrexate can be increased when it is combined with Procaine benzylpenicillin.,DB09320,Methotrexate,DB00563
The serum concentration of Dolutegravir can be decreased when it is combined with Zinc oxide.,DB09321,Dolutegravir,DB08930
The serum concentration of Dolutegravir can be decreased when it is combined with Zinc sulfate.,DB09322,Dolutegravir,DB08930
The serum concentration of Methotrexate can be increased when it is combined with Benzathine benzylpenicillin.,DB09323,Methotrexate,DB00563
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulbactam.,DB09324,Picosulfuric acid,DB09268
The metabolism of Tegafur-uracil can be decreased when combined with Clotrimazole.,DB09327,Clotrimazole,DB00257
The serum concentration of Osimertinib can be increased when it is combined with Teriflunomide.,DB09330,Teriflunomide,DB08880
Cyclophosphamide may increase the cardiotoxic activities of Daratumumab.,DB09331,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Alatrofloxacin.,DB09335,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Mersalyl.,DB09338,Nicomorphine,DB13454
The serum concentration of Glucose can be decreased when it is combined with Testosterone undecanoate.,DB09341,Testosterone undecanoate,DB13946
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.,DB09342,Doxylamine,DB00366
The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Tipiracil.,DB09343,Diethylstilbestrol,DB00255
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.,DB09345,Doxylamine,DB00366
Levobetaxolol may increase the hypoglycemic activities of Metahexamide.,DB09351,Metahexamide,DB13675
Amoxapine may increase the stimulatory activities of Hydroxyamphetamine.,DB09352,Amoxapine,DB00543
Polyestradiol phosphate may increase the thrombogenic activities of Conestat alfa.,DB09369,Conestat alfa,DB09228
Norethynodrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,DB09371,Lamotrigine,DB00555
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluprednisolone.,DB09378,Corticorelin ovine triflutate,DB09067
"The serum concentration of Estrogens, esterified can be increased when it is combined with Dasatinib.",DB09381,Dasatinib,DB01254
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Meprednisone.,DB09383,Mifamurtide,DB13615
The serum concentration of Norgestrel can be increased when it is combined with Dasatinib.,DB09389,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Isosorbide.,DB05707,Cyclophosphamide,DB00531
Ferric pyrophosphate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB09414,Ferric pyrophosphate,DB09147
The risk or severity of adverse effects can be increased when Amoxapine is combined with Sodium phosphate.,DB09525,Amoxapine,DB00543
Tartaric acid can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB09459,Technetium Tc-99m oxidronate,DB09139
The serum concentration of Brentuximab vedotin can be increased when it is combined with Glycerin.,DB04077,Brentuximab vedotin,DB08870
Trimethoprim may increase the hyperkalemic activities of Enalaprilat.,DB09477,Trimethoprim,DB00440
The serum concentration of Mevastatin can be decreased when it is combined with Magnesium carbonate.,DB09481,Mevastatin,DB06693
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Acrivastine.",DB09488,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thiosulfuric acid.,DB09499,Picosulfuric acid,DB09268
Cyclophosphamide may increase the cardiotoxic activities of Mequinol.,DB09516,Cyclophosphamide,DB00531
The therapeutic efficacy of Human secretin can be decreased when used in combination with Methscopolamine.,DB06369,Methscopolamine,DB11315
Titanium dioxide may increase the photosensitizing activities of Verteporfin.,DB09536,Verteporfin,DB00460
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone.,DB09543,Fluticasone,DB13867
The serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Dasatinib.,DB09555,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Necitumumab.,DB05774,Cyclophosphamide,DB00531
Ferric pyrophosphate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DBSALT001586,Ferric pyrophosphate,DB09147
The therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids.,DB09568,Lepirudin,DB00001
The serum concentration of Ixazomib can be increased when it is combined with Dasatinib.,DB09570,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Rotavirus Vaccine.,DB10307,Dimethyl fumarate,DB08908
"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Chloroquine.",DB10283,Chloroquine,DB00608
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Rubella virus vaccine.,DB10317,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Varicella Zoster Vaccine (Live/Attenuated).,DB10318,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Bacillus calmette-guerin substrain tice live antigen.,DB10343,Dimethyl fumarate,DB08908
The therapeutic efficacy of Menthol can be decreased when used in combination with Casein.,DB10516,Menthol,DB00825
"The serum concentration of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when it is combined with Garlic.",DB10532,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).,DB10583,Dimethyl fumarate,DB08908
Cranberry may increase the anticoagulant activities of Tioclomarol.,DB10631,Tioclomarol,DB13451
The risk or severity of adverse effects can be increased when Licorice is combined with Digoxin Immune Fab (Ovine).,DB10675,Digoxin Immune Fab (Ovine),DB00076
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Salmonella typhi ty2 vi polysaccharide antigen.,DB10803,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Bacillus calmette-guerin substrain connaught live antigen.,DB10804,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Yellow Fever Vaccine.,DB10805,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Hepatitis A Vaccine.,DB10309,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Salmonella typhi ty21a live antigen.,DB11050,Dimethyl fumarate,DB08908
The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.,DB05348,Lepirudin,DB00001
The serum concentration of Phylloquinone can be decreased when it is combined with Mineral oil.,DB11057,Phylloquinone,DB01022
The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Deflazacort.,DB11079,Deflazacort,DB11921
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Citrate.,DB11093,Menthol,DB00825
The risk or severity of hyperkalemia can be increased when Vitamin D is combined with Benzthiazide.,DB11094,Benzthiazide,DB00562
The risk or severity of adverse effects can be increased when Desirudin is combined with Azficel-T.,DB11095,Azficel-T,DB11051
Potassium bicarbonate may increase the hyperkalemic activities of Candoxatril.,DB11098,Candoxatril,DB00616
The serum concentration of Dolutegravir can be decreased when it is combined with Aluminum sesquichlorohydrate.,DB11108,Dolutegravir,DB08930
The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Tolevamer.,DB11110,Tolevamer,DB01344
The serum concentration of Chloroxylenol can be decreased when it is combined with Tafenoquine.,DB11121,Tafenoquine,DB06608
Nabilone may increase the tachycardic activities of Racepinephrine.,DB11124,Nabilone,DB00486
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium gluconate.,DB11126,Menthol,DB00825
Opium may increase the constipating activities of Ramosetron.,DB11130,Ramosetron,DB09290
Omega-3 fatty acids may increase the antiplatelet activities of Ticagrelor.,DB11133,Ticagrelor,DB08816
The serum concentration of Dolutegravir can be decreased when it is combined with Selenium.,DB11135,Dolutegravir,DB08930
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butamben.,DB11148,Doxylamine,DB00366
The serum concentration of Pyrantel can be decreased when it is combined with Tafenoquine.,DB11156,Tafenoquine,DB06608
Ferric sulfate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB11171,Technetium Tc-99m oxidronate,DB09139
Zinc picolinate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB11175,Technetium Tc-99m oxidronate,DB09139
The risk or severity of adverse effects can be increased when Homatropine is combined with Nicomorphine.,DB11181,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Pentoxyverine is combined with Naloxegol.,DB11186,Naloxegol,DB09049
The serum concentration of Rilpivirine can be increased when it is combined with Peppermint oil.,DB11198,Rilpivirine,DB08864
Ferrous bisglycinate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB11210,Technetium Tc-99m oxidronate,DB09139
Cyclophosphamide may increase the cardiotoxic activities of Lycopene.,DB11231,Cyclophosphamide,DB00531
Poliglusam can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB11234,Technetium Tc-99m oxidronate,DB09139
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Thonzylamine.",DB11235,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Sarilumab may increase the immunosuppressive activities of Borage oil.,DB11238,Sarilumab,DB11767
The serum concentration of Dolutegravir can be decreased when it is combined with Aluminum sulfate.,DB11239,Dolutegravir,DB08930
The serum concentration of Tocopherol can be increased when it is combined with Dasatinib.,DB11251,Dasatinib,DB01254
The serum concentration of Hexylresorcinol can be decreased when it is combined with Tafenoquine.,DB11254,Tafenoquine,DB06608
Chromium picolinate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB11255,Technetium Tc-99m oxidronate,DB09139
The serum concentration of the active metabolites of Primidone can be reduced when Primidone is used in combination with Levomefolic acid resulting in a loss in efficacy.,DB11256,Primidone,DB00794
The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Azficel-T.,DB11268,Azficel-T,DB11051
Dihydroergocornine may increase the hypertensive activities of Lofexidine.,DB11273,Lofexidine,DB04948
The serum concentration of Dihydro-alpha-ergocryptine can be increased when it is combined with Dasatinib.,DB11274,Dasatinib,DB01254
Racepinephrine may decrease the vasoconstricting activities of DL-Methylephedrine.,DB11278,Racepinephrine,DB11124
The risk or severity of adverse effects can be increased when Diethyltoluamide is combined with Sulpiride.,DB11282,Sulpiride,DB00391
Rice bran oil may increase the myelosuppressive activities of Lipegfilgrastim.,DB11293,Lipegfilgrastim,DB13200
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.,DB11304,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Protein C is combined with Azficel-T.,DB11312,Azficel-T,DB11051
The risk or severity of adverse effects can be increased when Methscopolamine is combined with Nicomorphine.,DB11315,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Factor IX Complex (Human).,DB14047,Aminocaproic Acid,DB00513
The serum concentration of Dolutegravir can be decreased when it is combined with Aluminum oxide.,DB11342,Dolutegravir,DB08930
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Phosphate.,DB11053,Menthol,DB00825
Linseed oil may increase the antiplatelet activities of Ibrutinib.,DB11357,Ibrutinib,DB09053
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pitolisant.,DB11358,Pitolisant,DB11642
The serum concentration of Selexipag can be increased when it is combined with Dasatinib.,DB11362,Dasatinib,DB01254
The serum concentration of Brentuximab vedotin can be increased when it is combined with Alectinib.,DB11363,Brentuximab vedotin,DB08870
Cyclophosphamide may increase the cardiotoxic activities of Roquinimex.,DB11366,Cyclophosphamide,DB00531
The serum concentration of Cefroxadine can be increased when it is combined with Probenecid.,DB11367,Probenecid,DB01032
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.,DB11371,Doxylamine,DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.,DB11376,Doxylamine,DB00366
The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Palmidrol.,DB11411,Palmidrol,DB14043
The serum concentration of Moxidectin can be decreased when it is combined with Tafenoquine.,DB11431,Tafenoquine,DB06608
The serum concentration of Oxfendazole can be decreased when it is combined with Tafenoquine.,DB11446,Tafenoquine,DB06608
The therapeutic efficacy of Prostalene can be decreased when used in combination with Palmidrol.,DB11454,Palmidrol,DB14043
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tilmicosin.,DB11471,Picosulfuric acid,DB09268
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Xylazine.,DB11477,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Nalorphine is combined with Naloxegol.,DB11490,Naloxegol,DB09049
Sarafloxacin may increase the QTc-prolonging activities of Delamanid.,DB11491,Delamanid,DB11637
The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Deslorelin.,DB11510,Choline C 11,DB09277
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Dihydrostreptomycin.,DB11512,Digoxin Immune Fab (Ovine),DB00076
Cyclophosphamide may increase the cardiotoxic activities of Masitinib.,DB11526,Cyclophosphamide,DB00531
The serum concentration of Lesinurad can be decreased when it is combined with Apalutamide.,DB11560,Apalutamide,DB11901
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ixekizumab.,DB11569,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Elbasvir can be increased when it is combined with Dasatinib.,DB11574,Dasatinib,DB01254
The serum concentration of Grazoprevir can be increased when it is combined with Dasatinib.,DB11575,Dasatinib,DB01254
The serum concentration of Venetoclax can be increased when it is combined with Dasatinib.,DB11581,Dasatinib,DB01254
The therapeutic efficacy of Thiocolchicoside can be increased when used in combination with Lorpiprazole.,DB11582,Lorpiprazole,DB09195
The serum concentration of Zidovudine can be decreased when it is combined with Asunaprevir.,DB11586,Zidovudine,DB00495
Racepinephrine may decrease the vasoconstricting activities of Etafedrine.,DB11587,Racepinephrine,DB11124
Carbon monoxide may increase the myelosuppressive activities of Lipegfilgrastim.,DB11588,Lipegfilgrastim,DB13200
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Bilastine.",DB11591,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Isatoic anhydride.,DB11593,Picosulfuric acid,DB09268
Cyclophosphamide may increase the cardiotoxic activities of Atezolizumab.,DB11595,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Tegafur.,DB11596,Tegafur,DB09256
The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Azficel-T.,DB11598,Azficel-T,DB11051
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Human rabies virus immune globulin.,DB11603,Dimethyl fumarate,DB08908
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tetanus Immune Globulin.,DB11604,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Saxagliptin can be decreased when it is combined with Myrrh.,DB11605,Saxagliptin,DB06335
Normethadone may increase the constipating activities of Ramosetron.,DB11609,Ramosetron,DB09290
The serum concentration of Velpatasvir can be increased when it is combined with Dasatinib.,DB11613,Dasatinib,DB01254
The serum concentration of Rupatadine can be increased when it is combined with Dasatinib.,DB11614,Dasatinib,DB01254
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirarubicin.,DB11616,Sipuleucel-T,DB06688
Cyclophosphamide may increase the cardiotoxic activities of Aclarubicin.,DB11617,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Zorubicin.,DB11618,Cyclophosphamide,DB00531
Gestrinone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,DB11619,Lamotrigine,DB00555
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.,DB11621,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Zidovudine can be decreased when it is combined with Candoxatrilat.,DB11623,Zidovudine,DB00495
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Hepatitis B Vaccine (Recombinant).,DB10993,Dimethyl fumarate,DB08908
Cyclophosphamide may increase the cardiotoxic activities of Temoporfin.,DB11630,Cyclophosphamide,DB00531
The serum concentration of Cilostazol can be increased when it is combined with Opicapone.,DB11632,Cilostazol,DB01166
The excretion of Vincristine can be decreased when combined with Isavuconazole.,DB11633,Vincristine,DB00541
The serum concentration of Tocofersolan can be increased when it is combined with Dasatinib.,DB11635,Dasatinib,DB01254
Nomegestrol may increase the thrombogenic activities of Conestat alfa.,DB11636,Conestat alfa,DB09228
The serum concentration of Delamanid can be increased when it is combined with Dasatinib.,DB11637,Dasatinib,DB01254
The serum concentration of Thioproperazine can be increased when it is combined with Artenimol.,DB11638,Thioproperazine,DB01622
The risk or severity of adverse effects can be increased when Palmidrol is combined with Dibotermin alfa.,DB11639,Palmidrol,DB14043
The serum concentration of Vinflunine can be increased when it is combined with Dasatinib.,DB11641,Dasatinib,DB01254
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Amoxapine.,DB11642,Amoxapine,DB00543
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Conatumumab.,DB11646,Hepatitis B Vaccine (Recombinant),DB11627
Evacetrapib may increase the myelosuppressive activities of Lipegfilgrastim.,DB11655,Lipegfilgrastim,DB13200
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tabalumab.,DB11657,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Palmidrol.,DB11660,Palmidrol,DB14043
Cyclophosphamide may increase the cardiotoxic activities of Rabusertib.,DB11662,Cyclophosphamide,DB00531
The therapeutic efficacy of Psilocybine can be increased when used in combination with Isocarboxazid.,DB11664,Isocarboxazid,DB01247
The serum concentration of Bupropion can be increased when it is combined with Curcumin.,DB11672,Bupropion,DB01156
Equol may increase the thrombogenic activities of Conestat alfa.,DB11674,Conestat alfa,DB09228
Cyclophosphamide may increase the cardiotoxic activities of Treosulfan.,DB11678,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ficlatuzumab.,DB11680,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Figitumumab.,DB11685,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when E-6201 is combined with Pitolisant.,DB11687,Pitolisant,DB11642
Cyclophosphamide may increase the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.,DB11688,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Naldemedine is combined with Naloxegol.,DB11691,Naloxegol,DB09049
Trastuzumab may increase the neutropenic activities of Voclosporin.,DB04906,Trastuzumab,DB00072
The serum concentration of Zidovudine can be decreased when it is combined with Racecadotril.,DB11696,Zidovudine,DB00495
Tropisetron may decrease the analgesic activities of Tramadol.,DB11699,Tramadol,DB00193
The serum concentration of Tezacaftor can be increased when it is combined with Dasatinib.,DB11712,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Durvalumab.,DB11714,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bapineuzumab.,DB11715,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Misonidazole.,DB11716,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Ribociclib.,DB11730,Cyclophosphamide,DB00531
The serum concentration of Icotinib can be increased when it is combined with Dasatinib.,DB11737,Dasatinib,DB01254
Iloprost may increase the hypotensive activities of Rilmenidine.,DB11738,Iloprost,DB01088
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ebastine.",DB11742,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Epetraborole.,DB11744,Picosulfuric acid,DB09268
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Onartuzumab.,DB11746,Hepatitis B Vaccine (Recombinant),DB11627
Benfotiamine can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB11748,Technetium Tc-99m oxidronate,DB09139
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clobetasol.,DB11750,Corticorelin ovine triflutate,DB09067
Cyclophosphamide may increase the cardiotoxic activities of Bryostatin 1.,DB11752,Cyclophosphamide,DB00531
Tetrahydrocannabivarin may increase the hypertensive activities of Droxidopa.,DB11755,Droxidopa,DB06262
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Solanezumab.,DB11756,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Talazoparib.,DB11760,Cyclophosphamide,DB00531
The therapeutic efficacy of Avatrombopag can be decreased when used in combination with Sarilumab.,DB11767,Avatrombopag,DB11995
Talinolol may increase the hypoglycemic activities of Metahexamide.,DB11770,Metahexamide,DB13675
Cyclophosphamide may increase the cardiotoxic activities of Tremelimumab.,DB11771,Cyclophosphamide,DB00531
Pazufloxacin may increase the QTc-prolonging activities of Delamanid.,DB11774,Delamanid,DB11637
Trastuzumab may increase the neutropenic activities of Brodalumab.,DB11776,Trastuzumab,DB00072
Allicin may increase the hypoglycemic activities of Insulin Glulisine.,DB11780,Insulin Glulisine,DB01309
Trimethoprim may increase the hyperkalemic activities of Imidapril.,DB11783,Trimethoprim,DB00440
The risk or severity of adverse effects can be increased when Anisodamine is combined with Pitolisant.,DB11785,Pitolisant,DB11642
The serum concentration of Mirodenafil can be increased when it is combined with Simeprevir.,DB11792,Simeprevir,DB06290
Cyclophosphamide may increase the cardiotoxic activities of Niraparib.,DB11793,Cyclophosphamide,DB00531
The serum concentration of Bictegravir can be increased when it is combined with Dasatinib.,DB11799,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Tivozanib.,DB11800,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sirukumab.,DB11803,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Saracatinib.,DB11805,Cyclophosphamide,DB00531
The serum concentration of Zidovudine can be decreased when it is combined with Faldaprevir.,DB11808,Zidovudine,DB00495
Cyclophosphamide may increase the cardiotoxic activities of Talaporfin.,DB11812,Cyclophosphamide,DB00531
The serum concentration of Baricitinib can be increased when it is combined with Dasatinib.,DB11817,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lampalizumab.,DB11826,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Ertugliflozin can be increased when it is combined with Teriflunomide.,DB11827,Teriflunomide,DB08880
The serum concentration of Neratinib can be increased when it is combined with Dasatinib.,DB11828,Dasatinib,DB01254
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mocetinostat.,DB05651,Vemurafenib,DB08881
Cyclophosphamide may increase the cardiotoxic activities of Crenolanib.,DB11832,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Guselkumab.,DB11834,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dalotuzumab.,DB11840,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Entinostat.,DB11841,Cyclophosphamide,DB00531
The therapeutic efficacy of Angiotensin II can be decreased when used in combination with Patent Blue.,DB11842,Patent Blue,DB13967
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Emibetuzumab.,DB11849,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ligelizumab.,DB11856,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Seribantumab.,DB11857,Hepatitis B Vaccine (Recombinant),DB11627
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.,DB11859,Doxylamine,DB00366
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Landogrozumab.,DB11862,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Romosozumab.,DB11866,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Etiracetam can be decreased when it is combined with Orlistat.,DB11868,Orlistat,DB01083
The risk or severity of adverse effects can be increased when Amoxapine is combined with PF-00610355.,DB11871,Amoxapine,DB00543
"Cyclophosphamide may increase the cardiotoxic activities of 3,3'-diindolylmethane.",DB11875,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Acridine Carboxamide.,DB11880,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Infigratinib.,DB11886,Cyclophosphamide,DB00531
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lanicemine.,DB11889,Vemurafenib,DB08881
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with CUDC-907.,DB11891,Vemurafenib,DB08881
Prulifloxacin may increase the QTc-prolonging activities of Delamanid.,DB11892,Delamanid,DB11637
Cyclophosphamide may increase the cardiotoxic activities of Efatutazone.,DB11894,Cyclophosphamide,DB00531
"2,4-thiazolidinedione may increase the hypoglycemic activities of Insulin Glulisine.",DB11898,Insulin Glulisine,DB01309
The serum concentration of Levomenol can be decreased when it is combined with Apalutamide.,DB11901,Levomenol,DB13153
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flumatinib.,DB11904,Vemurafenib,DB08881
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lanopepden.,DB11912,Picosulfuric acid,DB09268
The serum concentration of Valbenazine can be increased when it is combined with Dasatinib.,DB11915,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of 6-O-benzylguanine.,DB11919,Cyclophosphamide,DB00531
The serum concentration of Deflazacort can be increased when it is combined with Dasatinib.,DB11921,Dasatinib,DB01254
Flomoxef may increase the nephrotoxic activities of Bekanamycin.,DB11935,Bekanamycin,DB13673
Bempedoic acid may increase the hypoglycemic activities of Insulin Glulisine.,DB11936,Insulin Glulisine,DB01309
The serum concentration of Delafloxacin can be increased when it is combined with Teriflunomide.,DB11943,Teriflunomide,DB08880
Cyclophosphamide may increase the cardiotoxic activities of Avelumab.,DB11945,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Duvelisib is combined with Pitolisant.,DB11952,Pitolisant,DB11642
The serum concentration of Zidovudine can be decreased when it is combined with Delanzomib.,DB11956,Zidovudine,DB00495
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Crenezumab.,DB11959,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of hypotension can be increased when Racepinephrine is combined with Carboxyamidotriazole.,DB11960,Racepinephrine,DB11124
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rilotumumab.,DB11972,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Anifrolumab.,DB11976,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Letaxaban is combined with Azficel-T.,DB11984,Azficel-T,DB11051
The therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Hepatitis B Vaccine (Recombinant).,DB11988,Hepatitis B Vaccine (Recombinant),DB11627
Trastuzumab may increase the neutropenic activities of Benznidazole.,DB11989,Trastuzumab,DB00072
The serum concentration of Rilpivirine can be increased when it is combined with Diacerein.,DB11994,Rilpivirine,DB08864
The serum concentration of Avatrombopag can be increased when it is combined with Dasatinib.,DB11995,Dasatinib,DB01254
The serum concentration of Abemaciclib can be increased when it is combined with Dasatinib.,DB12001,Dasatinib,DB01254
The serum concentration of Fostamatinib can be increased when it is combined with Dasatinib.,DB12010,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Axelopran is combined with Naloxegol.,DB12013,Naloxegol,DB09049
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ozagrel.",DB12017,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The risk or severity of adverse effects can be increased when Triptolide is combined with Pitolisant.,DB12025,Pitolisant,DB11642
The serum concentration of Voxilaprevir can be increased when it is combined with Dasatinib.,DB12026,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Broxuridine.,DB12028,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gantenerumab.,DB12034,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Zidovudine can be decreased when it is combined with Ulinastatin.,DB12038,Zidovudine,DB00495
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Setrobuvir.,DB12051,Dexketoprofen,DB09214
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Visilizumab.,DB12053,Hepatitis B Vaccine (Recombinant),DB11627
Iloprost may increase the hypotensive activities of BQ-123.,DB12054,Iloprost,DB01088
Cyclophosphamide may increase the cardiotoxic activities of Trebananib.,DB12056,Cyclophosphamide,DB00531
The serum concentration of Letermovir can be decreased when it is combined with Apalutamide.,DB12070,Apalutamide,DB11901
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Albaconazole.,DB12073,Vemurafenib,DB08881
Amoxapine may increase the stimulatory activities of Ritobegron.,DB12080,Amoxapine,DB00543
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Anecortave.,DB12081,Corticorelin ovine triflutate,DB09067
Cyclophosphamide may increase the cardiotoxic activities of Vesnarinone.,DB12082,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Mafosfamide.,DB12083,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of LCL-161.,DB12085,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Oxitropium is combined with Nicomorphine.,DB12086,Nicomorphine,DB13454
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lorvotuzumab mertansine.,DB12089,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Patritumab.,DB12090,Hepatitis B Vaccine (Recombinant),DB11627
Naftopidil may increase the antiplatelet activities of Relcovaptan.,DB12092,Relcovaptan,DB13929
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.,DB12093,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Semapimod is combined with Pitolisant.,DB12094,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Amoxapine is combined with Abediterol.,DB12100,Amoxapine,DB00543
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fulranumab.,DB12102,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tarextumab.,DB12104,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Imagabalin can be decreased when used in combination with Yohimbine.,DB12105,Yohimbine,DB01392
Cyclophosphamide may increase the cardiotoxic activities of Taselisib.,DB12108,Cyclophosphamide,DB00531
The serum concentration of MK-212 can be decreased when it is combined with Orlistat.,DB12111,Orlistat,DB01083
Cyclophosphamide may increase the cardiotoxic activities of Zuretinol acetate.,DB12112,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Epigallocatechin Gallate.,DB12116,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gevokizumab.,DB06062,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Namitecan.,DB12124,Cyclophosphamide,DB00531
The serum concentration of Methotrexate can be increased when it is combined with Sultamicillin.,DB12127,Methotrexate,DB00563
The risk or severity of hypotension can be increased when Racepinephrine is combined with Vinpocetine.,DB12131,Racepinephrine,DB11124
The serum concentration of Barnidipine can be increased when it is combined with Alisporivir.,DB12139,Barnidipine,DB09227
Cyclophosphamide may increase the cardiotoxic activities of Duligotuzumab.,DB12142,Cyclophosphamide,DB00531
The serum concentration of Zidovudine can be decreased when it is combined with S-3304.,DB12149,Zidovudine,DB00495
The therapeutic efficacy of Cordycepin can be increased when used in combination with Menthol.,DB12156,Menthol,DB00825
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dupilumab.,DB12159,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Bucillamine is combined with Pitolisant.,DB12160,Pitolisant,DB11642
The serum concentration of Deutetrabenazine can be increased when it is combined with Dasatinib.,DB12161,Dasatinib,DB01254
Tipranavir may increase the antiplatelet activities of Sarpogrelate.,DB12163,Tipranavir,DB00932
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tralokinumab.,DB05556,Hepatitis B Vaccine (Recombinant),DB11627
Tipranavir may increase the antiplatelet activities of Eplivanserin.,DB12177,Tipranavir,DB00932
Secoisolariciresinol may increase the thrombogenic activities of Conestat alfa.,DB12179,Conestat alfa,DB09228
Dalcetrapib may increase the myelosuppressive activities of Lipegfilgrastim.,DB12181,Lipegfilgrastim,DB13200
Cyclophosphamide may increase the cardiotoxic activities of Binetrakin.,DB12182,Cyclophosphamide,DB00531
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gepirone.,DB12184,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Exatecan.,DB12185,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etrolizumab.,DB12189,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Atamestane.,DB12194,Corticorelin ovine triflutate,DB09067
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ganitumab.,DB12205,Hepatitis B Vaccine (Recombinant),DB11627
Iron isomaltoside 1000 can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB12208,Technetium Tc-99m oxidronate,DB09139
Landiolol may increase the hypoglycemic activities of Metahexamide.,DB12212,Metahexamide,DB13675
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etaracizumab.,DB12213,Hepatitis B Vaccine (Recombinant),DB11627
Bergapten may increase the photosensitizing activities of Verteporfin.,DB12216,Verteporfin,DB00460
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Canrenone.,DB12221,Nicomorphine,DB13454
Cyclophosphamide may increase the cardiotoxic activities of Lurtotecan.,DB12222,Cyclophosphamide,DB00531
The risk or severity of hypotension can be increased when Bunazosin is combined with Menthol.,DB12230,Menthol,DB00825
Cyclophosphamide may increase the cardiotoxic activities of KRN-7000.,DB12232,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Polatuzumab Vedotin.,DB12240,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Triclabendazole can be decreased when it is combined with Tafenoquine.,DB12245,Tafenoquine,DB06608
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Inclacumab.,DB12246,Hepatitis B Vaccine (Recombinant),DB11627
Racepinephrine may decrease the vasoconstricting activities of Tulobuterol.,DB12248,Racepinephrine,DB11124
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cixutumumab.,DB05759,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with CG-200745.,DB12259,Vemurafenib,DB08881
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ascrinvacumab.,DB12261,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Epofolate.,DB12266,Cyclophosphamide,DB00531
The serum concentration of Brigatinib can be increased when it is combined with Teriflunomide.,DB12267,Teriflunomide,DB08880
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.,DB12273,Doxylamine,DB00366
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Aducanumab.,DB12274,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Propiverine can be increased when it is combined with Dasatinib.,DB12278,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of OBP-801.,DB12279,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Darexaban is combined with Azficel-T.,DB12289,Azficel-T,DB11051
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.,DB12308,Doxylamine,DB00366
Racepinephrine may decrease the vasoconstricting activities of Dopexamine.,DB12313,Racepinephrine,DB11124
The serum concentration of Thioproperazine can be increased when it is combined with Chlorproguanil.,DB12314,Thioproperazine,DB01622
The serum concentration of Cilostazol can be increased when it is combined with Benzbromarone.,DB12319,Cilostazol,DB01166
Ifetroban may increase the antiplatelet activities of Relcovaptan.,DB12321,Relcovaptan,DB13929
The serum concentration of Rucaparib can be increased when it is combined with Dasatinib.,DB12332,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tanezumab.,DB12335,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Carisbamate can be decreased when it is combined with Orlistat.,DB12338,Orlistat,DB01083
Cyclophosphamide may increase the cardiotoxic activities of Navitoclax.,DB05764,Cyclophosphamide,DB00531
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Temocillin.,DB12343,Picosulfuric acid,DB09268
Cyclophosphamide may increase the cardiotoxic activities of Bizelesin.,DB12352,Cyclophosphamide,DB00531
Piclozotan may increase the hypertensive activities of Droxidopa.,DB12361,Droxidopa,DB06262
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dusigitumab.,DB12363,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of bleeding can be increased when Betrixaban is combined with Alaproclate.,DB06601,Alaproclate,DB13233
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ricolinostat.,DB12376,Vemurafenib,DB08881
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Relebactam.,DB12377,Picosulfuric acid,DB09268
Cyclophosphamide may increase the cardiotoxic activities of Indirubin.,DB12379,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Merestinib.,DB12381,Cyclophosphamide,DB00531
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with R-306465.,DB12382,Vemurafenib,DB08881
Cyclophosphamide may increase the cardiotoxic activities of 10-hydroxycamptothecin.,DB12385,Cyclophosphamide,DB00531
The risk or severity of rhabdomyolysis can be increased when Sagopilone is combined with Mevastatin.,DB05654,Mevastatin,DB06693
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fresolimumab.,DB12396,Hepatitis B Vaccine (Recombinant),DB11627
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.,DB12401,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Lisofylline is combined with Pitolisant.,DB12406,Pitolisant,DB11642
Cyclophosphamide may increase the cardiotoxic activities of Sulforaphane.,DB12422,Cyclophosphamide,DB00531
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Orvepitant.,DB12427,Vemurafenib,DB08881
The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pitolisant.,DB05822,Pitolisant,DB11642
Cyclophosphamide may increase the cardiotoxic activities of Nadifloxacin.,DB12447,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bococizumab.,DB12456,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Belotecan.,DB12459,Cyclophosphamide,DB00531
Fluticasone may increase the fluid retaining activities of GLPG-0492.,DB12461,Fluticasone,DB13867
Ketanserin may increase the antiplatelet activities of Relcovaptan.,DB12465,Relcovaptan,DB13929
Cyclophosphamide may increase the cardiotoxic activities of Taurolidine.,DB12473,Cyclophosphamide,DB00531
Lynestrenol may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,DB12474,Lamotrigine,DB00555
The therapeutic efficacy of Piribedil can be decreased when used in combination with Metoclopramide.,DB12478,Metoclopramide,DB01233
The serum concentration of Copanlisib can be increased when it is combined with Dasatinib.,DB12483,Dasatinib,DB01254
Tetrahydrouridine may increase the myelosuppressive activities of Lipegfilgrastim.,DB12484,Lipegfilgrastim,DB13200
Promestriene may increase the thrombogenic activities of Conestat alfa.,DB12487,Conestat alfa,DB09228
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mirvetuximab Soravtansine.,DB12489,Hepatitis B Vaccine (Recombinant),DB11627
Piritramide may increase the constipating activities of Ramosetron.,DB12492,Ramosetron,DB09290
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mogamulizumab.,DB12498,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Cortexolone 17-propionate.,DB12499,Corticorelin ovine triflutate,DB09067
Cyclophosphamide may increase the cardiotoxic activities of 9-aminocamptothecin.,DB12515,Cyclophosphamide,DB00531
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Raclopride.,DB12518,Doxylamine,DB00366
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mizolastine.",DB12523,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Cyclophosphamide may increase the cardiotoxic activities of Molgramostim.,DB12525,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Inebilizumab.,DB12530,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Rilpivirine can be increased when it is combined with Oxetacaine.,DB12532,Rilpivirine,DB08864
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mavrilimumab.,DB12534,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Oltipraz can be decreased when it is combined with Tafenoquine.,DB12539,Tafenoquine,DB06608
The risk or severity of adverse effects can be increased when Samidorphan is combined with Naloxegol.,DB12543,Naloxegol,DB09049
The risk or severity of adverse effects can be increased when Indobufen is combined with Pitolisant.,DB12545,Pitolisant,DB11642
Cyclophosphamide may increase the cardiotoxic activities of Pyrazoloacridine.,DB12549,Cyclophosphamide,DB00531
The serum concentration of Mebeverine can be decreased when it is combined with Orlistat.,DB12554,Orlistat,DB01083
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Blosozumab.,DB12560,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Abexinostat.,DB05921,Vemurafenib,DB08881
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Tecemotide.,DB12568,Dimethyl fumarate,DB08908
The risk or severity of sedation and somnolence can be increased when AZD-3043 is combined with Deutetrabenazine.,DB12576,Deutetrabenazine,DB12161
Cyclophosphamide may increase the cardiotoxic activities of Fosbretabulin.,DB12577,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when JNJ-37822681 is combined with Deutetrabenazine.,DB12579,Deutetrabenazine,DB12161
The serum concentration of Ubidecarenone can be increased when it is combined with Piperine.,DB12582,Ubidecarenone,DB09270
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bimagrumab.,DB12584,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Ondelopran is combined with Naloxegol.,DB12585,Naloxegol,DB09049
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dacetuzumab.,DB05539,Hepatitis B Vaccine (Recombinant),DB11627
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Indiplon.,DB12590,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Apaziquone.,DB12593,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Combretastatin.,DB12596,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Nafamostat is combined with Pitolisant.,DB12598,Pitolisant,DB11642
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Sisomicin.,DB12604,Digoxin Immune Fab (Ovine),DB00076
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tovetumab.,DB12609,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Plazomicin.,DB12615,Digoxin Immune Fab (Ovine),DB00076
The risk or severity of adverse effects can be increased when Mizoribine is combined with Pitolisant.,DB12617,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Apocynin is combined with Pitolisant.,DB12618,Pitolisant,DB11642
"The risk or severity of adverse effects can be increased when 3,5-diiodothyropropionic acid is combined with Piracetam.",DB12629,Piracetam,DB09210
Cyclophosphamide may increase the cardiotoxic activities of Onapristone.,DB12637,Cyclophosphamide,DB00531
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Givinostat.,DB12645,Vemurafenib,DB08881
The risk or severity of hypotension can be increased when Urapidil is combined with Menthol.,DB12661,Menthol,DB00825
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Protionamide.,DB12667,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Rolofylline.,DB05360,Nicomorphine,DB13454
Cyclophosphamide may increase the cardiotoxic activities of Soblidotin.,DB12677,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Salirasib.,DB12681,Cyclophosphamide,DB00531
Gusperimus may increase the hypoglycemic activities of Insulin Glulisine.,DB12692,Insulin Glulisine,DB01309
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.,DB12693,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Phenethyl Isothiocyanate.,DB12695,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Methylselenocysteine.,DB12697,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibalizumab.,DB05435,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Intetumumab.,DB12701,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Spiradoline.,DB12704,Nicomorphine,DB13454
The therapeutic efficacy of Sulprostone can be decreased when used in combination with Palmidrol.,DB12708,Palmidrol,DB14043
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perazine.,DB12710,Doxylamine,DB00366
Sotagliflozin may increase the hypoglycemic activities of Insulin Glulisine.,DB12713,Insulin Glulisine,DB01309
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Carlumab.,DB12718,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Dolastatin 10.,DB12730,Cyclophosphamide,DB00531
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Firategrast.,DB12732,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Demcizumab.,DB12734,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Etanidazole.,DB12736,Cyclophosphamide,DB00531
Butylphthalide may increase the antiplatelet activities of Relcovaptan.,DB12749,Relcovaptan,DB13929
Bucindolol may increase the hypoglycemic activities of Metahexamide.,DB12752,Metahexamide,DB13675
Iloprost may increase the hypotensive activities of Cicletanine.,DB12766,Iloprost,DB01088
The therapeutic efficacy of Ocrelizumab can be decreased when used in combination with BCG vaccine.,DB12768,Ocrelizumab,DB11988
Cyclophosphamide may increase the cardiotoxic activities of Lometrexol.,DB12769,Cyclophosphamide,DB00531
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lafutidine.",DB12770,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Hydroxytyrosol may increase the antiplatelet activities of Relcovaptan.,DB12771,Relcovaptan,DB13929
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abituzumab.,DB12775,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Higenamine is combined with Pitolisant.,DB12779,Pitolisant,DB11642
Balaglitazone may increase the hypoglycemic activities of Insulin Glulisine.,DB12781,Insulin Glulisine,DB01309
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Palmidrol.,DB12789,Palmidrol,DB14043
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Naptumomab Estafenatox.,DB12807,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Cepeginterferon alfa-2B is combined with Zidovudine.,DB12814,Zidovudine,DB00495
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Crotedumab.,DB12815,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Concizumab.,DB12820,Hepatitis B Vaccine (Recombinant),DB11627
Perflubutane can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB05392,Technetium Tc-99m oxidronate,DB09139
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Depatuxizumab.,DB12826,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amithiozone.,DB12829,Picosulfuric acid,DB09268
The risk or severity of adverse effects can be increased when Gabexate is combined with Azficel-T.,DB12831,Azficel-T,DB11051
Cyclophosphamide may increase the cardiotoxic activities of Prednimustine.,DB12832,Cyclophosphamide,DB00531
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.,DB12833,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Licorice is combined with Oleandrin.,DB12843,Licorice,DB10675
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rontalizumab.,DB12844,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Amatuximab.,DB06122,Hepatitis B Vaccine (Recombinant),DB11627
Racepinephrine may decrease the vasoconstricting activities of Reproterol.,DB12846,Racepinephrine,DB11124
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Clazakizumab.,DB12849,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Zidovudine can be decreased when it is combined with Sivelestat.,DB12863,Zidovudine,DB00495
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benperidol.,DB12867,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Buthionine Sulfoximine.,DB12870,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Dianhydrogalactitol.,DB12873,Cyclophosphamide,DB00531
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Oxatomide.",DB12877,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Cyclophosphamide may increase the cardiotoxic activities of Indole-3-carbinol.,DB12881,Cyclophosphamide,DB00531
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lavoltidine.",DB12884,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ozanezumab.,DB12891,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sacituzumab govitecan.,DB12893,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Fiacitabine.,DB12901,Cyclophosphamide,DB00531
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trofosfamide.,DB12902,Sipuleucel-T,DB06688
Cyclophosphamide may increase the cardiotoxic activities of Nolatrexed.,DB12912,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Mitolactol.,DB12916,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Pinometostat.,DB12920,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorsulfaquinoxaline.,DB12921,Dexketoprofen,DB09214
The risk or severity of hypotension can be increased when Racepinephrine is combined with Gallopamil.,DB12923,Racepinephrine,DB11124
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ozenoxacin.,DB12924,Picosulfuric acid,DB09268
Iloprost may increase the hypotensive activities of Cafedrine.,DB12926,Iloprost,DB01088
Iloprost may increase the hypotensive activities of Theodrenaline.,DB12927,Iloprost,DB01088
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Opipramol.,DB12930,Pitolisant,DB11642
The therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Menthol.,DB12939,Menthol,DB00825
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Milatuzumab.,DB12943,Hepatitis B Vaccine (Recombinant),DB11627
Iloprost may increase the hypotensive activities of Dihydralazine.,DB12945,Iloprost,DB01088
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxifluridine.,DB12947,Sipuleucel-T,DB06688
Cyclophosphamide may increase the cardiotoxic activities of Didox.,DB12948,Cyclophosphamide,DB00531
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pivagabine.,DB12951,Vemurafenib,DB08881
"Prothipendyl may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.",DB12958,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
Cyclophosphamide may increase the cardiotoxic activities of Mitoguazone.,DB12967,Cyclophosphamide,DB00531
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.,DB12972,Doxylamine,DB00366
The serum concentration of Thioproperazine can be increased when it is combined with Pyronaridine.,DB12975,Thioproperazine,DB01622
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Robatumumab.,DB12976,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Penclomedine.,DB12987,Cyclophosphamide,DB00531
Vancomycin may increase the neuromuscular blocking activities of Neosaxitoxin.,DB12989,Vancomycin,DB00512
Deoxyspergualin may increase the hypoglycemic activities of Insulin Glulisine.,DB12991,Insulin Glulisine,DB01309
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Acteoside.,DB12996,Sipuleucel-T,DB06688
The risk or severity of adverse effects can be increased when Tinoridine is combined with Pitolisant.,DB13001,Pitolisant,DB11642
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cortivazol.,DB13003,Mifamurtide,DB13615
The serum concentration of Carbendazim can be decreased when it is combined with Tafenoquine.,DB13009,Tafenoquine,DB06608
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hypericin.,DB13014,Sipuleucel-T,DB06688
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.,DB13025,Doxylamine,DB00366
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Tucaresol.,DB13027,Calcium carbimide,DB09116
The serum concentration of Valproic Acid can be decreased when it is combined with Biapenem.,DB13028,Valproic Acid,DB00313
Ramatroban may increase the antiplatelet activities of Relcovaptan.,DB13036,Relcovaptan,DB13929
The therapeutic efficacy of Gossypol can be decreased when used in combination with Tipiracil.,DB13044,Tipiracil,DB09343
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Racotumomab.,DB13045,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Irsogladine.,DB13056,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Epibatidine.,DB13058,Epibatidine,DB07720
The risk or severity of adverse effects can be increased when Parthenolide is combined with Pitolisant.,DB13063,Pitolisant,DB11642
Nabilone may increase the tachycardic activities of Tramazoline.,DB13064,Nabilone,DB00486
The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Liarozole.,DB13066,Choline C 11,DB09277
The serum concentration of Barnidipine can be increased when it is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,DB13068,Barnidipine,DB09227
Cyclophosphamide may increase the cardiotoxic activities of Nimustine.,DB13069,Cyclophosphamide,DB00531
The serum concentration of Macimorelin can be increased when it is combined with Dasatinib.,DB05917,Dasatinib,DB01254
The therapeutic efficacy of Nefiracetam can be increased when used in combination with Isocarboxazid.,DB13082,Isocarboxazid,DB01247
The risk or severity of hyperkalemia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Benzthiazide.,DB13097,Benzthiazide,DB00562
The risk or severity of sedation and somnolence can be increased when Valnoctamide is combined with Deutetrabenazine.,DB13099,Deutetrabenazine,DB12161
Amoxapine may increase the stimulatory activities of Mephedrone.,DB13108,Amoxapine,DB00543
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Amitriptylinoxide.,DB13114,Pitolisant,DB11642
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Norflurane.,DB13116,Doxylamine,DB00366
Trastuzumab may increase the neutropenic activities of Paquinimod.,DB05901,Trastuzumab,DB00072
The risk or severity of adverse effects can be increased when Troxerutin is combined with Azficel-T.,DB13124,Azficel-T,DB11051
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Olokizumab.,DB13127,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Sizofiran.,DB13128,Cyclophosphamide,DB00531
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Pitolisant.,DB13131,Pitolisant,DB11642
The serum concentration of Thioproperazine can be increased when it is combined with Artemisinin.,DB13132,Thioproperazine,DB01622
The risk or severity of adverse effects can be increased when Fluindione is combined with Azficel-T.,DB13136,Azficel-T,DB11051
The serum concentration of Levosalbutamol can be decreased when it is combined with Apalutamide.,DB05761,Apalutamide,DB11901
"The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.",DB13141,"(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE",DB08044
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium glubionate.,DB13142,Menthol,DB00825
Methallenestril may increase the thrombogenic activities of Conestat alfa.,DB13143,Conestat alfa,DB09228
The serum concentration of Phenytoin can be decreased when it is combined with Nedaplatin.,DB13145,Phenytoin,DB00252
The serum concentration of Fluciclovine (18F) can be decreased when it is combined with Apalutamide.,DB13146,Apalutamide,DB11901
The risk or severity of adverse effects can be increased when Protein S human is combined with Azficel-T.,DB13149,Azficel-T,DB11051
The risk or severity of thrombotic microangiopathy can be increased when Emicizumab is combined with Anti-inhibitor coagulant complex.,DB13151,Emicizumab,DB13923
The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Coagulation Factor IX Human.,DB13152,Aminocaproic Acid,DB00513
The serum concentration of Levomenol can be decreased when it is combined with Apalutamide.,DB13153,Apalutamide,DB11901
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clobetasone.,DB13158,Corticorelin ovine triflutate,DB09067
Alphaprodine may increase the constipating activities of Ramosetron.,DB13160,Ramosetron,DB09290
Trimethoprim may increase the hyperkalemic activities of Zofenopril.,DB13166,Trimethoprim,DB00440
The risk or severity of adverse effects can be increased when Alclofenac is combined with Pitolisant.,DB13167,Pitolisant,DB11642
Fluticasone may increase the fluid retaining activities of Nandrolone.,DB13169,Fluticasone,DB13867
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tunicamycin.,DB13172,Picosulfuric acid,DB09268
The serum concentration of Rilpivirine can be increased when it is combined with Rhein.,DB13174,Rilpivirine,DB08864
The serum concentration of Troleandomycin can be increased when it is combined with Dasatinib.,DB01361,Dasatinib,DB01254
Gluconic Acid can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB09408,Technetium Tc-99m oxidronate,DB09139
Daidzein may increase the thrombogenic activities of Conestat alfa.,DB13182,Conestat alfa,DB09228
The serum concentration of Lithium can be decreased when it is combined with Calcitonin porcine.,DB13189,Lithium,DB01356
The risk or severity of sedation and somnolence can be increased when Valerian is combined with Deutetrabenazine.,DB13196,Deutetrabenazine,DB12161
Dinutuximab may increase the myelosuppressive activities of Lipegfilgrastim.,DB13200,Dinutuximab,DB09077
The serum concentration of Mevastatin can be decreased when it is combined with Bismuth subnitrate.,DB13209,Mevastatin,DB06693
Iloprost may increase the hypotensive activities of Guanoxan.,DB13211,Iloprost,DB01088
The risk or severity of adverse effects can be increased when Fentiazac is combined with Pitolisant.,DB13217,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Tribenoside is combined with Pitolisant.,DB13227,Pitolisant,DB11642
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium lactate.,DB13231,Menthol,DB00825
The risk or severity of adverse effects can be increased when Nordazepam is combined with Alaproclate.,DB13233,Nordazepam,DB14028
Trastuzumab may increase the neutropenic activities of Begelomab.,DB13241,Trastuzumab,DB00072
The serum concentration of Mevastatin can be decreased when it is combined with Magnesium silicate.,DB13249,Mevastatin,DB06693
The risk or severity of adverse effects can be increased when Propatyl nitrate is combined with Rosiglitazone.,DB13255,Rosiglitazone,DB00412
Ferrous sulfate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB13257,Technetium Tc-99m oxidronate,DB09139
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.,DB13259,Doxylamine,DB00366
Sitafloxacin may increase the QTc-prolonging activities of Delamanid.,DB13261,Delamanid,DB11637
The serum concentration of Cefatrizine can be increased when it is combined with Probenecid.,DB13266,Probenecid,DB01032
The serum concentration of Ipecac can be increased when it is combined with Dasatinib.,DB13293,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Atracurium is combined with Nicomorphine.,DB13295,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Licorice is combined with Proscillaridin.,DB13307,Licorice,DB10675
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Pitolisant.,DB13314,Pitolisant,DB11642
The serum concentration of Mevastatin can be decreased when it is combined with Hydrotalcite.,DB13322,Mevastatin,DB06693
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.,DB13323,Doxylamine,DB00366
Dihydroergocristine may increase the hypertensive activities of Lofexidine.,DB13345,Lofexidine,DB04948
The risk or severity of adverse effects can be increased when Bufexamac is combined with Pitolisant.,DB13346,Pitolisant,DB11642
The therapeutic efficacy of Deanol can be increased when used in combination with Isocarboxazid.,DB13352,Isocarboxazid,DB01247
Iloprost may increase the hypotensive activities of Vincamine.,DB13374,Iloprost,DB01088
Cyclophosphamide may increase the cardiotoxic activities of Edrecolomab.,DB13375,Cyclophosphamide,DB00531
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Melitracen.,DB13384,Pitolisant,DB11642
Esatenolol may increase the hypoglycemic activities of Metahexamide.,DB13443,Metahexamide,DB13675
The serum concentration of Midecamycin can be increased when it is combined with Dasatinib.,DB13456,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Lentinan.,DB13480,Cyclophosphamide,DB00531
The risk or severity of hypotension can be increased when Racepinephrine is combined with Bencyclane.,DB13488,Racepinephrine,DB11124
The risk or severity of adverse effects can be increased when Otilonium is combined with Nicomorphine.,DB13500,Nicomorphine,DB13454
The risk or severity of adverse effects can be increased when Tyrothricin is combined with Epibatidine.,DB13503,Epibatidine,DB07720
Cloranolol may increase the hypoglycemic activities of Metahexamide.,DB13508,Metahexamide,DB13675
The risk or severity of adverse effects can be increased when Aloxiprin is combined with Fluticasone.,DB13509,Fluticasone,DB13867
The risk or severity of adverse effects can be increased when Pranoprofen is combined with Pitolisant.,DB13514,Pitolisant,DB11642
Metergoline may increase the hypertensive activities of Lofexidine.,DB13520,Lofexidine,DB04948
Mepindolol may increase the hypoglycemic activities of Metahexamide.,DB13530,Metahexamide,DB13675
Iloprost may increase the hypotensive activities of Cyclopenthiazide.,DB13532,Iloprost,DB01088
The therapeutic efficacy of Mephenesin can be increased when used in combination with Lorpiprazole.,DB13583,Lorpiprazole,DB09195
Fluticasone may increase the fluid retaining activities of Mesterolone.,DB13587,Fluticasone,DB13867
The serum concentration of Mevastatin can be decreased when it is combined with Almasilate.,DB13595,Mevastatin,DB06693
The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pitolisant.,DB13612,Pitolisant,DB11642
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fluocortolone.,DB13615,Fluocortolone,DB08971
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.,DB13643,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Semustine.,DB13647,Cyclophosphamide,DB00531
The serum concentration of Mevastatin can be decreased when it is combined with Aloglutamol.,DB13650,Mevastatin,DB06693
The serum concentration of Dolutegravir can be decreased when it is combined with Montmorillonite.,DB13654,Dolutegravir,DB08930
The serum concentration of Methotrexate can be increased when it is combined with Propicillin.,DB13660,Methotrexate,DB00563
The serum concentration of Cefozopran can be increased when it is combined with Probenecid.,DB13667,Probenecid,DB01032
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexchlorpheniramine.",DB13679,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Cefpirome can be increased when it is combined with Probenecid.,DB13682,Probenecid,DB01032
The risk or severity of hyperkalemia can be increased when Tacalcitol is combined with Benzthiazide.,DB13689,Benzthiazide,DB00562
The risk or severity of adverse effects can be increased when Distigmine is combined with Epibatidine.,DB13694,Epibatidine,DB07720
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pristinamycin.,DB13704,Picosulfuric acid,DB09268
"2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Tritoqualine.",DB13711,"2,5-Dimethoxy-4-ethylthioamphetamine",DB13940
The serum concentration of Bioallethrin can be increased when it is combined with Dasatinib.,DB13746,Dasatinib,DB01254
Epanolol may increase the hypoglycemic activities of Metahexamide.,DB13757,Metahexamide,DB13675
The serum concentration of Varenicline can be increased when it is combined with Niperotidine.,DB13760,Varenicline,DB01273
Rufloxacin may increase the QTc-prolonging activities of Delamanid.,DB13772,Delamanid,DB11637
Tertatolol may increase the hypoglycemic activities of Metahexamide.,DB13775,Metahexamide,DB13675
Racepinephrine may decrease the vasoconstricting activities of Xamoterol.,DB13781,Racepinephrine,DB11124
The risk or severity of adverse effects can be increased when Acemetacin is combined with Pitolisant.,DB13783,Pitolisant,DB11642
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Clopamide.,DB13792,Dexketoprofen,DB09214
The therapeutic efficacy of Menthol can be decreased when used in combination with Calcium levulinate.,DB13800,Menthol,DB00825
The risk or severity of sedation and somnolence can be increased when Reposal is combined with Deutetrabenazine.,DB13805,Deutetrabenazine,DB12161
Cyclophosphamide may increase the cardiotoxic activities of Paclitaxel poliglumex.,DB13809,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Oblimersen.,DB13811,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Ranimustine.,DB13832,Cyclophosphamide,DB00531
The risk or severity of hypotension can be increased when Racepinephrine is combined with Caroverine.,DB13835,Racepinephrine,DB11124
The serum concentration of Methotrexate can be increased when it is combined with Metampicillin.,DB13836,Methotrexate,DB00563
The risk or severity of sedation can be increased when Lorpiprazole is combined with Doxefazepam.,DB13837,Lorpiprazole,DB09195
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cloprednol.,DB13843,Mifamurtide,DB13615
The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Clofibride.,DB13849,Ursodeoxycholic acid,DB01586
The serum concentration of Artemotil can be decreased when it is combined with Tafenoquine.,DB13851,Tafenoquine,DB06608
Demegestone may increase the thrombogenic activities of Conestat alfa.,DB13857,Conestat alfa,DB09228
The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluticasone.,DB13864,Fluticasone,DB13867
Ethynodiol may increase the thrombogenic activities of Conestat alfa.,DB13866,Conestat alfa,DB09228
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluticasone.,DB13867,Corticorelin ovine triflutate,DB09067
Trastuzumab may increase the neutropenic activities of Adefovir.,DB13868,Trastuzumab,DB00072
The serum concentration of Albendazole oxide can be decreased when it is combined with Tafenoquine.,DB13871,Tafenoquine,DB06608
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.,DB13872,Doxylamine,DB00366
The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibric acid.,DB13873,Ursodeoxycholic acid,DB01586
The serum concentration of Enasidenib can be increased when it is combined with Dasatinib.,DB13874,Dasatinib,DB01254
Harmaline may increase the hypertensive activities of Norepinephrine.,DB13875,Norepinephrine,DB00368
Brofaromine may increase the hypertensive activities of Norepinephrine.,DB13876,Norepinephrine,DB00368
Cyclophosphamide may increase the cardiotoxic activities of Iniparib.,DB05975,Cyclophosphamide,DB00531
The serum concentration of Pibrentasvir can be increased when it is combined with Teriflunomide.,DB13878,Teriflunomide,DB08880
The serum concentration of Glecaprevir can be decreased when it is combined with Apalutamide.,DB13879,Apalutamide,DB11901
Ferric subsulfate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB13885,Technetium Tc-99m oxidronate,DB09139
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Human cytomegalovirus immune globulin.,DB13886,Hepatitis B Vaccine (Recombinant),DB11627
Cyclophosphamide may increase the cardiotoxic activities of Coumermycin A1.,DB13912,Cyclophosphamide,DB00531
Cyclophosphamide may increase the cardiotoxic activities of Toyocamycin.,DB13916,Cyclophosphamide,DB00531
The serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan.,DB13919,Brentuximab vedotin,DB08870
The risk or severity of thrombotic microangiopathy can be increased when Emicizumab is combined with Anti-inhibitor coagulant complex.,DB13923,Anti-inhibitor coagulant complex,DB13151
The therapeutic efficacy of Dotatate gallium Ga-68 can be decreased when used in combination with Somatostatin.,DB13925,Somatostatin,DB09099
Semaglutide may increase the hypoglycemic activities of Insulin Human.,DB13928,Insulin Human,DB00030
Buflomedil may increase the antiplatelet activities of Relcovaptan.,DB13929,Buflomedil,DB13510
"Amoxapine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.",DB13940,Amoxapine,DB00543
The serum concentration of Piperaquine can be increased when it is combined with Dasatinib.,DB13941,Dasatinib,DB01254
The serum concentration of Testosterone cypionate can be increased when it is combined with Dasatinib.,DBSALT001298,Dasatinib,DB01254
The serum concentration of Testosterone enanthate can be increased when it is combined with Dasatinib.,DB13945,Dasatinib,DB01254
The serum concentration of Testosterone undecanoate can be increased when it is combined with Dasatinib.,DBSALT001033,Dasatinib,DB01254
Ferric cation can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB13949,Technetium Tc-99m oxidronate,DB09139
The risk or severity of hypotension can be increased when Racepinephrine is combined with WIN 55212-2.,DB13950,Racepinephrine,DB11124
The serum concentration of Stanolone acetate can be decreased when it is combined with Apalutamide.,DBSALT002357,Apalutamide,DB11901
The serum concentration of Estradiol acetate can be increased when it is combined with Dasatinib.,DBSALT000065,Dasatinib,DB01254
The serum concentration of Estradiol benzoate can be increased when it is combined with Dasatinib.,DBSALT000066,Dasatinib,DB01254
The serum concentration of Estradiol cypionate can be increased when it is combined with Dasatinib.,DBSALT000067,Dasatinib,DB01254
The serum concentration of Estradiol dienanthate can be increased when it is combined with Dasatinib.,DBSALT002570,Dasatinib,DB01254
The serum concentration of Estradiol valerate can be increased when it is combined with Dasatinib.,DBSALT000068,Dasatinib,DB01254
The risk or severity of hypotension can be increased when Racepinephrine is combined with Fish oil.,DB13961,Racepinephrine,DB11124
The therapeutic efficacy of Fimasartan can be decreased when used in combination with Patent Blue.,DB13967,Fimasartan,DB09279
The serum concentration of Rilpivirine can be increased when it is combined with Cimicifuga racemosa.,DB13975,Rilpivirine,DB08864
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sulesomab.,DB13976,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Besilesomab.,DB13979,Hepatitis B Vaccine (Recombinant),DB11627
Nomegestrol acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.,DB13981,Lamotrigine,DB00555
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclopropane.,DB13984,Doxylamine,DB00366
The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Somatostatin.,DB13985,Somatostatin,DB09099
Alaproclate may increase the hyponatremic activities of Epitizide.,DB13989,Alaproclate,DB13233
The serum concentration of Pipequaline can be decreased when it is combined with Orlistat.,DB13991,Orlistat,DB01083
The therapeutic efficacy of MRK-409 can be decreased when used in combination with Yohimbine.,DB13993,Yohimbine,DB01392
The serum concentration of alpha-Tocopherol acetate can be increased when it is combined with Dasatinib.,DB14003,Dasatinib,DB01254
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tildrakizumab.,DB14004,Hepatitis B Vaccine (Recombinant),DB11627
The serum concentration of Choline salicylate can be increased when it is combined with Bupropion.,DBSALT001576,Bupropion,DB01156
Pentetic acid can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.,DB14007,Technetium Tc-99m oxidronate,DB09139
The serum concentration of Medical Cannabis can be increased when it is combined with Dasatinib.,DB14009,Dasatinib,DB01254
"5-methoxy-N,N-dimethyltryptamine may increase the hypertensive activities of Droxidopa.",DB14010,Droxidopa,DB06262
The serum concentration of Nabiximols can be increased when it is combined with Dasatinib.,DB14011,Dasatinib,DB01254
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Bromotheophylline.,DB14018,Nicomorphine,DB13454
The serum concentration of Fosnetupitant can be increased when it is combined with Dasatinib.,DB14019,Dasatinib,DB01254
Cyclophosphamide may increase the cardiotoxic activities of Clinafloxacin.,DB14025,Cyclophosphamide,DB00531
Taspoglutide may increase the hypoglycemic activities of Insulin Human.,DB14027,Insulin Human,DB00030
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nordazepam.,DB14028,Doxylamine,DB00366
Cyclophosphamide may increase the cardiotoxic activities of Tretamine.,DB14031,Cyclophosphamide,DB00531
The serum concentration of Acetyl sulfisoxazole can be decreased when it is combined with Apalutamide.,DBSALT000856,Apalutamide,DB11901
Englitazone may increase the hypoglycemic activities of Insulin Glulisine.,DB14035,Insulin Glulisine,DB01309
beta-Sitosterol may increase the myelosuppressive activities of Lipegfilgrastim.,DB14038,Lipegfilgrastim,DB13200
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Erenumab.,DB14039,Hepatitis B Vaccine (Recombinant),DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fremanezumab.,DB14041,Hepatitis B Vaccine (Recombinant),DB11627
The risk or severity of adverse effects can be increased when Palmidrol is combined with Pitolisant.,DB14043,Pitolisant,DB11642
